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ABSTRACT 
Medulloblastoma (MB) is the commonest intracranial childhood malignancy and 
despite recent advances, current therapeutic approaches are still associated with 
high morbidity and mortality. A novel molecular classification has recently been 
proposed for these tumours – WNT Group (best prognosis), SHH Group 
(intermediate prognosis), Group 3 (worst prognosis) and Group 4 (intermediate 
prognosis). BMI1, a transcriptional repressor of the Polycomb group genes, is 
overexpressed in MB, most significantly in those of Group 4 MBs. Bone 
Morphogenetic Proteins (BMPs) are morphogens belonging to TGF-β superfamily of 
growth factors, and are known to inhibit MB cell proliferation and induce apoptosis in 
vitro, and to inhibit tumour growth in vivo. Our team have recently demonstrated that 
Bmi1 regulates cell adhesion properties during cerebellar development through 
repression of the BMP pathway. The aim of this project is to assess whether BMI1 
overexpression may contribute to MB pathogenesis through repression of the BMP 
pathway. 
Here we demonstrate that BMI1 knock down derepresses BMP pathway, and using 
a novel xenograft model of human MB of Group 4, we show that BMI1 controls 
tumour volume and intraparenchymal invasion. In in vitro assays on MB cell lines we 
show that cell adhesion and motility is controlled by BMI1 in a BMP dependent 
manner and that deregulation of extracellular matrix proteins are key mediators of 
this effect. Furthermore, we demonstrate that BMP treatment to BMI1 
overexpressing MB cells reduces cell proliferation and invasion, suggesting BMI1 as 
a possible biomarker for those tumours that could benefit from treatment with BMP 
agonist small molecules.   
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CHAPTER 1 Introduction        
   
1.1 Development of the cerebellum  
 
1.1.1 Overview of the normal cerebellum: 
   
Cerebellum (Latin: ‘little brain’), contains more than half of the total neurons of the 
brain, and plays an important role in our daily living (Wang and Zoghbi 2001). It 
primarily controls motor activity, regulating movements, co-ordination, muscle tone 
and balance; and integrates sensory and motor data from brain stem, spinal cord 
and cerebral cortex. Grossly, the cerebellum is divided along the medial-lateral axis 
into vermis (located along the midsagittal plane), intermediate zones (directly lateral 
to vermis), and the two lateral hemispheres (located lateral to intermediate zones) 
[Fig 1.1 A]. The two fissures namely posterolateral fissure and primary fissure, divide 
the cerebellar cortex along the anterior-posterior axis into flocculonodular lobe, 
posterior lobe and anterior lobe respectively (Fig 1.1 A). These lobes are further 
divided along the anterior-posterior axis into ten lobules at the vermis and eight 
lobules at the heimspheres (Fig 1.1 B). All the above divisions of the cerebellum bear 
functional relevance. Histologically, the mature cerebellar cortex has three layers – 
1) the Molecular Layer (ML), containing Stellate and Basket neurons, 2) the Purkinje 
Layer (PL) containing Purkinje cells and Bergman glia (a type of radial glial cells), 
and 3) the Internal Granular Layer (IGL), containing granule neurons, Golgi cells and 
glial cells (Fig 1.1 C). The Purkinje cells, Golgi cells, Stellate cells and Basket cells 
are inhibitory neurons (GABAergic, releasing γ-aminobutyric acid) and the granule 
neurons are excitatory (glutamatergic, releasing glutamate). While Golgi cells 
provide inhibitory feedback to granule neurons, Stellate and Basket cells modulate 
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Purkinje cells which provide the primary output from the cerebellar cortex to the deep 
cerebellar nuclei. The axons of the granule cells are projected to the ML where they 
bifurcate in opposite directions to form Parallel fibres, which make excitatory 
synapses with Purkinje cells (Fig 1.1 C). In addition to the above cells, the cerebellar 
cortex contains Mossy fibres and Climbing fibres (Fig 1.1 C). The former originate 
from the spinocerebellar, pontocerebellar and vestibulocerebellar pathways and 
make excitatory synapses onto the granule cells (and the cerebellar nuclei).  The 
latter originate in the inferior olive and make excitatory synapses onto the Purkinje 
cells (and the cerebellar nuclei).  
 
Fig. 1.1 Morphology of normal cerebellum. 
(A) Gross anatomy of the cerebellum. (B) Diagrammatic representation of sagittal section at the 
vermis, showing division of cerebellar cortex into 10 lobules, I – X (there would be 8 lobules in the 
lateral hemispheres). Approximate locations of the deep cerebellar nuclei are represented in the white 
matter (WM). (C) Diagram representing the cells of the cerebellar cortex. Outer molecular layer (ML) 
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containing interneurons Basket and Stellate cells, middle Purkinje cell layer (PL) with Purkinje cells 
which has extensive dendritic arborisations, and the inner granule cell layer (IGL), containing granule 
neurons which send their axons to the molecular layer. In addition, there are Mossy and Climbing 
fibres entering into the cortex, and their connections are shown in brown and purple respectively. The 
glial cells are present in the WM and in the PL. The glial cells in the PL are called Bergmann glia. The 
excitatory synapses are marked with +, and inhibitory with -. 
 
The cerebellar white matter contains fibre tracts, along with astrocytes, 
oligodendrocytes and neurons of the deep cerebellar nuclei (Altman J 1997; Behesti 
and Marino 2009). The deep cerebellar nuclei are - the fastigial nucleus (most 
medially located), the interposed nuclei (situated lateral to the fastigial nucleus), the 
dentate nucleus (largest nucleus, located lateral to the interposed nuclei) and 
functionally connected vestibular nuclei (actually located in the medulla). Three fibre 
bundles carry the cerebellar inputs and outputs, connecting the cerebellum to other 
parts of the brain and spinal cord, namely - the inferior cerebellar peduncle, the 
middle cerebellar peduncle and the superior cerebellar peduncle.  
 
Although historically the cerebellum has been known to mainly coordinate motor 
functions,  its role in cognition, memory and language functions has been postulated 
based on neuropsychiatric manifestations in patients with cerebellar disorders 
(Timmann and Daum 2007). However despite several study models, no concrete 
circuitry evidence has been established so far, and the consensus is that the role of 
cerebellum in the above functions are inferential (Koziol, Budding et al. 2013).  
1.1.2 Cerebellar development 
 
The development of the cerebellum begins in humans from an early embryonic stage 
and extends until the first postnatal years. Due to this protracted period of 
development, the cerebellum is susceptible to a spectrum of complex developmental 
disorders including genetic/sporadic syndromes (hypoplasia of cerebellar vermis in 
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Dandy-Walker syndrome), non-genetic abnormalities (cerebellar hypoplasia 
secondary to congenital cytomegalovirus infection), metabolic abnormalities 
(cerebellar atrophy secondary to pyruvate dehydrogenase deficiency) and neoplasia 
(Ramaekers, Heimann et al. 1997). There is considerable evidence that the origin of 
medulloblastoma is intimately related to the development of the cerebellum 
(reviewed in (ten Donkelaar, Lammens et al. 2003; Marino 2005; Gilbertson and 
Ellison 2008). Therefore it is relevant to first discuss the normal cerebellar 
developmental process in order to understand the pathogenesis of medulloblastoma.    
The mouse has been extensively used as a model of human CNS development 
because it has close anatomic, physiologic and genetic similarity to humans. 
Moreover the ease of genetic manipulation of gene expression which can be 
achieved in mouse models is also very appealing. Hence, mouse models to study 
the molecular mechanisms of cerebellar development and medulloblastoma 
pathogenesis have been extensively used due to the high degree of conservation of 
cerebellar anatomy and function between mouse and human (Chizhikov and Millen 
2003; Kho, Zhao et al. 2004). A word of caution is however warranted because of the 
inherent limitations of any experimental models.  In the following cerebellum 
development sections, the process of mouse development is mainly discussed, and 
where available, processes and time points in human development is mentioned.   
1.1.2.1 Early embryogenesis   
 
In vertebrates, the central nervous system (CNS) is derived from the neural plate 
(epithelial structure arising from the dorsal ectoderm of the gastrula) during 
embryogenesis. The neural plate subsequently closes to form the neural tube; and 
the brain develops from the rostral (head end) part of the neural tube. The neural 
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tube soon forms flexures giving rise to three primary brain vesicles – the 
prosencephalon (forebrain), the mesencephalon (midbrain) and the 
rhombencephalon (hind-brain). The prosencephalon acquires further lateral 
extensions to form the telencephalon which is connected at the midline with the 
diencephalon. The mesencephalon remains as a single structure. The 
rhombencephalon is separated from the mesencephalon by the cephalic flexure and 
the cervical flexure separates it from the spinal cord. The pontine flexure divides the 
rhombencephalon into the metencephalon and the myelencephalon at embryonic 
day 9 (E9) in mouse. In vertebrates the rhombencephalon is known to arise from 
seven segments of the neural tube called rhombomeres 1-7 (Garel, Fallet-Bianco et 
al. 2011).  
The cerebellum develops from the roof of metencephalon (dorsal rhombomere 1), 
with contributions from the mesencephalon (Hatten and Heintz 1995). The cerebellar 
development occurs in several interconnected stages, controlled by multiple genetic 
events which can be categorized into four categories – 1) establishing cerebellar 
territory, 2) specification of cerebellar cell types, 3) proliferation, differentiation and 
migration of the cells and, 4) formation of the cerebellar circuitry.  
1.1.2.2 Establishment of the cerebellar territory (cerebellar anlage):  
 
The anterior-posterior boundaries of the developing cerebellum are determined by 
Fgf8 (fibroblast growth factor 8) and Wnt1 (wingless homologue 1) signals from the 
Isthmic Organizer (IO), which is located at the junction of mesencephalon and 
metencephalon (Sato, Joyner et al. 2004). In turn IO is formed as a result of 
expression of two main genes - Otx2 (mouse homologue of Drosophilia gene 
orthodenticle) and Gbx2 (mouse homologues of the Drosophilia gene and 
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unplugged) which are expressed at E8, in mesencephalon and in metencephalon 
respectively  
Some of the other genes that are important for establishing IO include En1 and En2 
(homeobox genes engrailed 1 & 2), Pax2 and Pax5 (paired box genes), Hoxa2 
(homeobox A2) and Lmx1b (Lim homeobox 1b). The mechanisms controlling the 
dorsal – ventral patterning of the developing cerebellum are not well established, but 
there is suggestion that it may be controlled by Bone morphogenetic proteins 
(BMPs), Sonic Hedgehog (Shh) and the expression of Lmx1a (Lim homeobox 1a) 
(Chizhikov and Millen 2003). The cerebellar anlage is formed between E10 and E11. 
Further to this, the cerebellum continues to develop for the rest of the embryonic 
period undergoing extensive morphological changes. Subsequently, from the alar 
plates two germinal centers are formed – 1) the Ventricular zone – a mouth-like 
structure at the roof (dorsal) of the 4th ventricle, adjacent to cerebellar anlage, and 2) 
the Rhombic lip – a specialised region of ventricular zone, adjacent to the roof of the 
4th ventricle (Fig 1.3 A). In contrast to most other brain regions, the cells of the 
cerebellum originate from these two distinct germinal zones (Fig 1.3 B). 
 
1.1.2.3 Morphogenesis of the cerebellum: 
 
Under this subheading, the next two stages of cerebellar development, namely the 
specification of the cerebellar cell types, and the proliferation/differentiation/migration 
of the cells, will be discussed. By fate mapping it is known that the cerebellar cell 
types arise at different developmental stages and from different locations (Hatten 
and Heintz 1995) and their development will be discussed below. 
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1.1.2.3.1 Purkinje cells and interneurons originate from the ventricular 
neuroepithelium: 
 
The cells of the deep cerebellar nuclei, Purkinje cells, and later Golgi cells, Stellate 
cell, Basket cells develop from multipotent precursor cells called the ventricular 
neuroepithelium (Hallonet and Le Douarin 1993) which express bHLH (basic helix 
loop helix) factor Ptf1a (pancreas specific transcription factor 1a). The ventricular 
neuroepithelium is located in the ventricular zone in the roof of the 4th ventricle as 
discussed above, which is also known as the primary germinal zone. Purkinje cells 
are specified at E13, when they exit the cell cycle and start to migrate along the 
radial glial cells towards the cerebellar primordium. From E14-E17 they migrate over 
the already formed deep cerebellar nuclei. In humans, the generation of the deep 
cerebellar nuclei and Purkinje cells are estimated to occur at around 5th – 6th week of 
gestation (ten Donkelaar, Lammens et al. 2003). These cells then arrest and await 
the inward migration of the granule neurons. This timely arrest of migration is driven 
by the reelin pathway (Hatten 1999). Purkinje cells rely on signalling from granule 
neuronal precursors for their migration, but their differentiation is thought to be 
independent of them. Towards late embryogenesis, the Climbing fibres from the 
inferior olive begin to connect to the Purkinje cells, which are thought to promote 
their development. At this stage, they express markers such as NST-1 (Hsp70-4, 
heat shock protein). Purkinje cells develop extensive arborisation towards their final 
maturation phase and start to establish synapses with granule neurons. Wnt3 is 
thought to influence this phase of development (Salinas, Fletcher et al. 1994).  
Earlier we learnt the role of Wnt1 signals from IO in the development of the 
cerebellar anlage. Furthemore, Wnt signaling is implicated in early CNS 
development (Salinas and Zou 2008) and in the regulation of growth and 
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differentiation of the developing cerebellum both in the embryonic and early 
postnatal stages (Schuller and Rowitch 2007). Mutations in the WNT pathway have a 
well-established role in human medulloblastoma development (discussed later in 
section 1.2.4). Therefore it is relevant to discuss Wnt signalling pathway briefly at 
this stage (other molecular pathways of relevance are discussed in the sections 
below).  
In the absence of Wnt signalling, intracellular β-catenin is phosphorylated by casein 
kinase Iα (CK1α) and/or CKIε at Ser45. In turn this enables glycogen synthase 
kinase 3β (GSK3β) to phosphorylate serine/threonine kinase residues 41, 37 and 33, 
which triggers ubiquitylation and proteasomal degradation of β-catenin. 
Phosphorylation and eventual degradation of β-catenin takes place in a multiprotein 
complex containing the axin (the scaffold protein), adenomatous polyposis coli (APC, 
the tumour suppressor gene product) and GSK3β. Wnt signalling is activated by the 
binding of Wnt ligands (which are secreted glycoproteins) to the transmembrane 
receptor Frizzled (Frz). In the presence of Wnts, dishevelled (Dsh, the activity of 
which is modulated by the kinase PAR1) blocks β-catenin phosphorylation by 
inhibiting GSK3 (α- and β-isoforms). The exact mechanism of GSK3 inhibition by 
Wnts is unclear and has been the focus of intensive research (Metcalfe and Bienz 
2011). Recently, a cell-biological model was proposed (Taelman, Dobrowolski et al. 
2010): Wnt proteins induce the uptake of GSK3 into multivesicular bodies (MVBs), 
an event that sequesters the enzyme away from newly synthesised β-catenin 
substrate in the cytoplasm, thus blocking its phosphorylation. The unphosphorylated 
(stabilised) β-catenin enters the nucleus and associates with LEF/TCF transcription 
factors, which leads to the transcription of Wnt-target genes. Some of the Wnt-target 
genes are c-MYC, CCND1 (cyclin D1), and NRSF/REST (RE1-silencing transcription 
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factor), which are involved in the proliferation, inhibition of apoptosis, and 
differentiation of cells (Huelsken and Behrens 2002; Ille and Sommer 2005; Rossi, 
Caracciolo et al. 2008). An overview of the Wnt signalling pathway is represented in 
Fig. 1.2A. 
 
In addition to the above, various growth factors are thought to influence the 
development of the Purkinje cells such as Ngf (nerve growth factor), acetylcholine, 
BDNF (brain-derived neurotrophic factor) and ciliary neurotrophic factor. Similarly, 
Rorα (RAR-related orphan receptor α) and Bcl2 (B-cell leukemia/lymphoma 2) genes 
are thought to play a role in this process (Wang and Zoghbi 2001).  
 
1.1.2.3.2 Granule neurons originate from the rhombic lip: 
 
In contrast to other cells of the cerebellum, which are derived from the ventricular 
zone, the granule neurons are derived from the rhombic lip, also known as second 
germinal zone. As mentioned before, the rhombic lip is the dorsolateral part of the 
alar plate formed at E9 – E10, between the 4th ventricle and the roof plate in the 
metencephalon, which forms the proliferative zone along the hindbrain (Wingate 
2001). Granule neurone progenitor cells (GNPs) from the rostral (upper or head end) 
part of the rhombic lip cells start to migrate outwards at about E13. Three members 
of TGF-β family, namely Bmp6, Bmp7 and Gdf7 expressed in the roof plate are 
known to play an important role in GNP specification (Alder, Lee et al. 1999). These 
cells populate the cerebellar anlage, reaching the superficial part, which form the 
external granular (or germinal) layer [EGL] by the end of embryonic period, which is 
known as secondary germinal zone. In humans, the EGL persists from several post 
natal months up to 1 or 2 years of age (Lemire RJ 1975). Math1 (atonal homologue 1 
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or Atoh1), which is expressed in the mid to hind brain region at about E9 – E10, is 
considered essential for the genesis of cerebellar GNPs (Ben-Arie, Bellen et al. 
1997) and its expression persists in the rhombic lip and its derivatives. At this stage 
the GNPs also express Nestin and other markers such as zinc finger proteins 
RU49/Zipro1, Zic1 and Zic 3.  
The Notch1 activity is known to prevent the induction of Math1 by antagonising the 
BMP signalling pathway at the level of Msx2 expression, thereby balancing between 
neural induction and maintenance of neural progenitors in the embryonic 
development of the rhombic lip (Machold, Kittell et al. 2007). Furthermore, 
postnatally Notch 2 is shown to inhibit differentiation and maintain cerebellar granule 
cell precursor proliferation (Solecki, Liu et al. 2001). As Notch signalling pathway 
mutations are associated with medulloblastoma development (reviewed in (Hatten 
and Roussel 2011)), it is  briefly discussed at this stage. Notch receptor acts as a 
membrane-tethered transcription factor, which is activated by Jagged (JAG) or Delta-
like (DDL) family members, cleaving the extracellular domain and releasing 
intracellular domain of Notch, which translocates to the nucleus (Fig 1.2 B), where it 
interacts with CBF1 [or other CSL family members such as Su(H) or Lag-1] of 
transcriptional regulators, leading to activation of target genes namely, Myc, p21, 
and the HES-family members (Ehebauer, Hayward et al. 2006).  
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Fig. 1.2 Diagrammatic representation of Wnt and Notch signalling pathways. 
 
(A) Wnt pathway. (B) Notch pathway.   
 
Once the GNPs form the EGL, they continue to proliferate in the outer EGL, driven 
by RU49/Zipro1, Zic1 and Math1. Cell proliferation in the outer EGL at this stage also 
requires input from Purkinje cells through secretion of Shh (Wechsler-Reya and 
Scott 1999). As Shh pathway mutations are associated with medulloblastoma 
development (discussed later in section 1.2.4), due to its effects on GNP 
proliferation, this pathway is briefly discussed here.  
The Shh pathway (Fig 1.6) is maintained in an ‘off’ state by Ptch (patched 
transmembrane protein) which inhibits smoothened protein (Smo). Upon ligand 
binding of Shh (secreted by Purkinje cells), Ptch-mediated repression is alleviated 
and a signal is transduced to the nucleus to promote the proliferation of granule cells 
via Gli (GLI-Kruppel) 1 and Gli 2, and possibly N-Myc mediated signalling cascade 
[Fig 1.6] (Marino 2005). The evidence that Shh pathway plays a role in GNP 
proliferation is strengthened by the association of Ptch (patched) mutation [leading to 
activation of Shh pathway] with  Gorlin’s or naevoid basal cell carcinoma syndrome 
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and medulloblastoma (Wechsler-Reya and Scott 2001). Expression of Gli1 and Gli 2 
which mediate Shh pathway, is shown to be in turn modulated by Zic proteins, 
suggesting that Zic proteins control GNP proliferation by affecting Shh pathway 
(Mizugishi, Aruga et al. 2001). Furthermore, Bmi1 (a Polycomb gene) is shown to be 
expressed in EGL precursor cells (at E16.5 & P8 in mouse and 26th gestational week 
and post natal 8 months in humans) and it is  thought to promote clonal expansion of 
GNPs (Leung, Lingbeek et al. 2004). The role of Bmi1 gene, which is thought to be a 
downstream target of Shh pathway, in cerebellar development and in 
medulloblastoma pathogenesis is discussed in detail later (section 1.3.2).  In 
addition, GNP proliferation in the outer EGL is also dependent on genes involved in 
cell cycle such as Cyclin D2.  
 
The GNPs then cease to proliferate and migrate from outer EGL into the inner EGL. 
This change from a proliferative to a postmitotic phase involves cell-cycle inhibitors 
such as p27/Kip1 (cyclin dependent kinase inhibitor 1b), which is expressed in the 
inner EGL (Miyazawa, Himi et al. 2000). In the inner EGL, GNPs lose their Math1 
expression, and begin to express other bHLH transcription factors NeuroD1 (Miyata, 
Maeda et al. 1999) and NSCL1 (Duncan, Bordas et al. 1997). The cell number at this 
stage is controlled by trophic factors such as BDNF and IGF1 (insulin-like growth 
factor 1) which modulate apoptosis (Goldowitz and Hamre 1998). 
Next, the GNPs differentiate (forming axons, the Parallel fibres) and migrate inwards 
along the Bergmann glia at around 16 – 25 weeks of postnatal age in humans. They 
migrate into their definitive site, the internal granular layer (IGL), under a single layer 
of Purkinje cells (Fig 1.3 C) separated by a transient layer, lamina dissecans. The 
cells at this stage mainly express Tag1 (tubulin-associated glycoprotein 1) and Tuj1 
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(class 3 β-tubulin), which are mature neuronal markers. They also express Dcc 
(deleted in colorectal carcinoma) and components of Dcc/netrin pathway, Unc5h2 
and Unc5h3, which are involved in cell migration and axonal projection. Several 
other genes have been implicated in the migration and differentiation of GNPs such 
as Pax6 (paired box homeotic gene 6) expressed in EGL, Girk2 (encoding inward-
rectifying K+ channel) and Grid2 (encoding δ2 glutamate receptor subunit). Several 
extracellular proteins that are known to be important at this stage are – astrotactin, 
thrombospondin, tenascin and neuregulin.  
 
The final stages of GNP cells maturation to form the granule neurons take place in 
the IGL, at which point they express mature markers such as GC5 (golgin candidate 
5) and GABA receptors (Raetzman and Siegel 1999). At this stage, the Mossy fibres 
(from the precerebellar nuclei) develop contact with the granule neurons, which is 
partly mediated by Wnt7a released by granule neurons (Hall, Lucas et al. 2000), and 
the granule neurons extend connections to the Golgi cells, which is mediated by a 
protein, called contactin (Stoeckli 2010).  
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Fig. 1.3 Schematic representation of cerebellar development*  
 
(A) & (B) Embryonal development of the cerebellum. (A) The cerebellar anlage is formed in the roof 
of the metencephalon with contribution from the mesencephalon, subsequently giving rise to two 
germinal centres – the ventricular zone or primary germinal zone and the rhombic lip adjacent to 4
th
 
ventricle. (B) Represents the boxed germinal centres from (A) and depicts migration of the precursor 
cells. The cells originating from neuroepithelium of the ventricular zone (VZ) migrate radially to give 
rise to Purkinje cells, Golgi cells, Basket cells and Stellate neurons. Granule neuron progenitor cells 
(GNPs) located in rhombic lip (RL) migrate dorsally to populate the external germinal layer (EGL) or 
the secondary germinal zone. (C) Late embryonic and postnatal development, showing clonal 
expansion of GNPs in the EGL which will then become postmitotic, differentiate and migrate inwards 
to generate the internal granular layer (IGL) under the Purkinje cells (PC). On the right hand side, the 
putative sites of origin of medulloblastoma, namely EGL and Neuroepihelium (NE) of VZ is shown.   
* This picture is adapted from Marino S, Trends in Mol Med, 2005. 
 
Apart from the granule neurons, the rhombic lip also generates cells of the 
precerebellar nuclei, namely pontine nucleus, lateral reticular nucleus, external 
cuneate nucleus, reticulotegmental nucleus (origin of Mossy fibres) and inferior olive 
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nucleus (origin of Climbing fibres), as demonstrated by the expression of Math1 
during their development (Ben-Arie, Bellen et al. 1997).  
 
1.1.2.4 Formation of cerebellar circuitry and completion of morphological 
development.  
 
As a final step in cerebellar development, there is the formation of the intricate 
neuronal circuitry which is crucial for cerebellar functions. This process is associated 
with terminal differentiation of the cerebellar neurons (Hatten and Heintz 1995). The 
main aspects of the development of the cerebellar circuit have been discussed in the 
relevant sections above, and an overview of the circuitry is depicted in Fig 1 C. 
Although these connections are present across the cerebellum, it is important to note 
that cerebellum is functionally highly compartmentalised (term coined following cell 
lineage experiments in Drosophila) into distinct modules (Herrup and Kuemerle 
1997). The morphological development of the cerebellum is completed by about post 
natal day 15 (P15) in mice (Millen, Wurst et al. 1994) and second postnatal year in 
the human. The post natal proliferation of progenitor cells in the EGL and the 
subsequent migration of granule neurons and ingrowth of cerebellar afferents results 
in a significant growth and foliation of the cerebellum.  
 
The origins and fates of different precursor cells and the molecular mechanisms that 
regulate their development are summarised in Table 1.1.   
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Table 1.1 Summary of the main genes and pathways regulating the different stages of cerebellar 
development.  
Stage of 
development 
Genes/proteins/molecules implied* 
 
Cerebellum anlage Otx2, Gbx2, Fgf8, Wnt1, En1/2, Pax2/5, BMP and Smad pathway**, Shh**, 
Hoxa2 
 
Purkinje cell 
development 
Ngf, BDNF, Ciliary neurotropic factor, acetyl choline, Nt4/5, Rorα, Reelin 
pathway (migration) 
 
Granule neuron 
development 
For generation/proliferation - Math1, Shh pathway**, Bmi1**, Ccnd2, p27, 
NeuroD1, NSCL1, TGF-β pathway**, Notch pathway. 
 
For migration - Tag1, Tuj1, Pax6, Dcc/netrin pathway, Unc5h2/3, Girk2, 
astrotactin, Thrombospondin**, tenascin, neuregulin. 
 
* Ref: Wang and Zoghbi, Nature Reviews 2001; Tong and Kwan, Mol. Cell. Biol. 2013. 
**These genes/pathways/molecules are relevant for this current study.  
 
1.1.2.5 Cells of origin of medulloblastoma   
 
Medulloblastoma is traditionally thought to arise from the granule cell progenitors 
located in the EGL (Kadin, Rubinstein et al. 1970; Reddy and Packer 1999; Marino, 
Vooijs et al. 2000), and possibly from precursor cells located in the ventricular 
neuroepithelium (Marino 2005; Gilbertson and Ellison 2008). Stem cells have also 
been isolated from post natal cerebellar white matter by means of sorting for the 
stem cell marker CD133 (Lee, Kessler et al. 2005). There is a shifting paradigm from 
viewing medulloblastoma as a single entity to different distinct subtypes, based on 
their genetic profiles and cell of origin (discussed later in section 1.2.6). There is 
evidence that MB subtypes demonstrate distinct anatomical differences in their origin 
and development (Gibson, Tong et al. 2010); such as - WNT tumours are related to 
4th ventricle close to dorsal brain stem and SHH tumors within the cerebellar 
hemispheres. While the cellular origin for WNT and SHH Group have been 
implicated as dorsal brainstem progenitors and cerebellar GNPs respectively, the 
origin of more aggressive Group 3 is thought to be from cerebellar stem cells 
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(reviewed in (Eberhart 2012)). The exact cellular origin for Group 4 remains to be 
elucidated.   
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1.2 Medulloblastoma 
 
Medulloblastoma (MB, medulloblastoma cerebelli), was first described as a primitive 
neuroectodermal tumour (PNET) by Bailey and Cushing in 1925 (Bailey and Cushing 
1925). Prior to that, MB were theoretically grouped under divergent tumours such as 
sarcomas, neuroblastomas, spongioblastomas (poorly differentiated gliomas 
including astrocytic, ependymal and oligodendroglia) and primitive tumours with 
capacity for multi-lineage differentiation (Rorke 1994). The WHO (World Health 
Organisation), ICD-O (International Classification of Disease for Oncology), 
recognised MB as one of the PNET and classified them under embryonal tumours 
[ICD-O code 9470/3] (Louis, Ohgaki et al. 2007). Other tumours of the central 
nervous system that are merged under PNET umbrella, primarily due to their 
histological similarity, are ependymoblastoma and supratentorial PNET.  
Medulloblastoma is defined as a malignant, invasive embryonal tumour of the 
cerebellum, occurring preferentially in children, with predominantly neuronal 
differentiation, and tendency to metastasize via CSF pathways (Giangaspero, Binger 
et al. 2000).  
WHO working group recognise four escalating grades in CNS tumours depending on 
histological severity – grade I (low proliferative potential, predicting good outcome) to 
grade IV (highly malignant, predicting worst outcome). Medulloblastoma corresponds 
histologically to WHO grade IV.     
Medulloblastoma in children are known to commonly arise within the vermis (>75%), 
whereas in adults it is more common to originate in the cerebellar hemispheres 
(Bourgouin, Tampieri et al. 1992; Tortori-Donati, Fondelli et al. 1996).  
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1.2.1 Epidemiology  
 
Brain and CNS cancers are the second most common cancers in the childhood, 
following leukemia, accounting to >27% of all cancers in 0-14 years age, with 
approximately 410 cases diagnosed each year in the UK (CRUK 2008-2010). 
Medulloblastoma is the commonest solid tumour in children, and is also the 
commonest brain malignancy, accounting to approximately 19 – 22% of all brain 
tumours (CCRG 2010). Age adjusted annual incidence rates for MB are 0.5 - 0.7 per 
100,000 children (Stevens, Cameron et al. 1991; McKean-Cowdin, Razavi et al. 
2013). National Cancer Institute’s SEER (Surveillance, Epidemiology and End 
Results) data (1973 - 2009) analysis by McKean et al. predicts that the combined 
incidence of MB-PNET shows an increasing trend as compared to previous decades, 
although this may be due to the changes in the classification of these tumours 
(McKean-Cowdin, Razavi et al. 2013).  
 
The peak incidence of MB is between 4 – 9 years of age (41%), followed by 0 - 3 
years (32%), 10 – 14 years (18%) and 15 – 19 years [9%] (McNeil, Cote et al. 2002).  
In general, childhood MB show a bimodal distribution, peaking at 3-4 years of age 
and then at 8-9 years. Collins' law highlights the importance of age at diagnosis to 
predict the outcome which is based on the period of risk for recurrence (PRR), 
defined as age at diagnosis plus 9 (Brown, Tavare et al. 1995; Zhang and Zhou 
1999). More than 70% of medulloblastoma occur in patients younger than 16 years 
of age. It is rare in adults, accounting to less than 1% of all adult malignancies. In 
adults, the majority (80%) of medulloblastoma occurs before the age of 40 years, 
and is very rare beyond the fifth decade of life (Giordana, Schiffer et al. 1999).  
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This decrease in incidence with increasing age is well in agreement with the 
embryonal nature of MB and favours genetic factors as etiology rather than 
environmental factors.  Occasional reports attempting to associate parental 
exposure/contact with chemicals (such as pesticides, hydrocarbons, and N-nitroso 
compounds) and metals with development of MB have been published , although 
none of which is conclusive (Bunin, Kuijten et al. 1993; Colt and Blair 1998; Zahm 
and Ward 1998). A study has reported detection of low frequency simian virus 
(SV40)- like sequences in MB samples, without detection of large T antigen 
(Weggen, Bayer et al. 2000). Another study has shown detection of John 
Cunningham (JC) virus genome in significant proportion of MB samples, with 
presence of JC Virus T antigen in tumour cells (Krynska, Del Valle et al. 1999). 
However, an aetiological role of the above polyomaviruses in medulloblastoma 
pathogenesis has not been established (Huang, Reis et al. 1999; Giangaspero, 
Binger et al. 2000).   
MB has a higher predilection in males, with approximately 65% of patients being 
male and 35% female. SEER data showed an annual incidence of combined MB-
PNET of 0.84 and 0.58 per 100,000 for males and females respectively (McKean-
Cowdin, Razavi et al. 2013). Based on ethnic background, MB-PNET was noted to 
be common in Caucasian population (82%) compared to African-Caribbean (9%) or 
other backgrounds [9%] (McNeil, Cote et al. 2002).   
The prognosis of MB depends on several factors such as age at diagnosis, stage of 
the tumour/presence of metastasis, histological and/or molecular subtype, and 
treatment received. However, overall survival rate for MB is 50 – 60 % (Verlooy, 
Mosseri et al. 2006; Rutkowski, von Hoff et al. 2010) and the median survival rate is 
better in females compared to males  (McNeil, Cote et al. 2002). There are 
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conflicting evidence reported regarding survival figures in adults, but the overall data 
does not suggest a significant difference in survival outcomes in adults compared to 
children (Davis, Freels et al. 1998; Smoll 2012) 
1.2.2 Clinical features  
 
The presenting clinical symptoms are: 1) Cerebellar, due to the primary tumour, 
namely – ataxia and disturbed gait (in children where the majority of tumours are in 
the vermis) and ispilateral dysmetria (in adults where most of the tumours are in the 
hemisphere). 2) Secondary to hydrocephalus, such as headache, lethargy, vomiting 
and other symptoms of raised intracranial pressure. In younger children with no 
verbal communication, behavioral changes and decreased social interactions are 
noted. Visual disturbances may also occur due to cranial nerve compression. 3) 
Rarely related to leptomeningeal dissemination, such as weakness, due to spinal 
cord or nerve root compression [radiculopathy] (Giangaspero, Binger et al. 2000; 
Jallo and A. 2012). Spinal cord metastasis via leptomeningeal route at the time of 
presentation is seen in up to 33% of cases (Hsieh, Wu et al. 2008). In addition, there 
may be symptoms due to associated supratentorial metastases (14 - 15%), 
spontaneous haemorrhage (5-6%) or systemic metastases [9%] (Park, Hoffman et 
al. 1983).  
Common differential diagnoses based on clinical features include brain stem 
gliomas, cavernous sinus syndrome, cerebellar haemorrhage, cerebral aneurysms 
and craniopharyngioma. Clinical evaluation combined with radiological (CT/MRI 
scans) examination and CSF cytology aid in detection of the extent and spread of 
the disease, which helps stratify patients for appropriate treatment scheme, which 
may or may not include craniospinal irradiation (Jakacki, Burger et al. 2012).  
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Furthermore, the extent and dissemination of MB are classified based on Chang’s 
staging system (Table 1.2) which guides the treatment strategies and outcomes 
(Chang, Housepian et al. 1969; Dufour, Beaugrand et al. 2012).  
Table 1.2 Chang’s Staging System for Medulloblastoma* 
Variable 
 
Greatest tumour dimension and disease spread 
 
Tumour classification 
T1 <3 cm 
T2 >3 cm 
T3a >3 cm with spread into the aqueduct of Sylvius and/or foramen of 
Luschka, cerebral subarachnoid space, third or lateral ventricles 
T3b >3 cm with unequivocal spread into the brainstem; for T3b, surgical 
staging maybe used in the absence of involvement at imaging 
T4 >3 cm with spread beyond the aqueduct of Sylvius and/or the foramen 
magnum 
 
Metastasis classification 
M1 Microscopic tumour cells in CSF 
M2 Gross nodular seeding in cerebellum 
M3 Gross nodular seeding in spinal subarachnoid space 
M4 Metastasis beyond cerebrospinal axis 
*Ref. Chang et al. Radiology, 1969. 
 
Although the above clinical variables are essential for patient stratification, 
classification of MB based on histology must not be underestimated. Histological 
classification has been and still remains the mainstay in neuropathology diagnosis, 
and proves to be a useful combination tool to tailor the treatment and predict 
prognosis (Davis, Freels et al. 1998; Packer, Rood et al. 2003; von Hoff, Hartmann 
et al. 2010).  
 
1.2.3 Histological classification  
 
The latest morphological classification of medulloblastoma (WHO classification of 
tumors of the CNS, 2007) lists the following subtypes (Ellison, Love et al. 2004; 
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Louis, Ohgaki et al. 2007; Gilbertson and Ellison 2008): 1) Classic, 2) Desmoplastic, 
3) Medulloblastoma with extensive nodularity (MBEN), 4) Anaplastic, and 5) Large-
cell MB.   
Classic MB is the commonest type of histology observed in more than 70% of MB 
(Burger and Scheithauer 1994). They are composed of uniformly arranged, small 
round to oval tumour cells with hyperchromatic nuclei and indistinct cytoplasm (Fig 
1.4 A). Nuclear molding (denting the neighboring) may be a marked feature due to 
the dense population of tumour cells. Neuroblastic (Homer-Wright) rosettes, which 
are tumour cells arranged in a circular fashion tangled around cytoplasmic 
processes, are observed in about 40% of classic MB. A high proportion of tumours 
show nuclear polymorphism, high mitotic activity and individual cell apoptosis (in the 
form of nuclear pyknosis or karyorrhexis as opposed to generalised geographic 
necrosis). Mitoses are seen in about 25% of the cases (Burger, Grahmann et al. 
1987) in keeping with the notion that MB are predominantly proliferative tumours. 
Occasional features include nuclear gigantism, multinucleate giant cells and atypical 
mitosis. A minority of cases have pseudopalisading necrosis, vascular proliferation or 
neovascularisation, calcification and massive haemorrhage. MB with classic 
histology has an intermediate prognostic risk, i.e., the outcomes are shown to be 
better than that of anaplastic/large cell variants, but worse than that of 
desmoplastic/MBEN variants [Fig 1.4 E] (Rutkowski, von Hoff et al. 2010).   
Desmoplastic MB constitutes about 7% of MB, and are typically characterised by 
the presence of nodular architecture with desmoplasia (increased reticulin/collagen) 
within the inter-nodular areas (Fig 1.4 B). The cells outside the nodules (within the 
desmoplasia) often show increased pleomorphism while the cells within the nodules 
are less pleomorphic and usually have a neuronal (neurocytic) phenotype with 
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positivity for neuronal markers such as synaptophysin and NeuN (McManamy, Pears 
et al. 2007). Desmoplasia may also occur in other types of MB as reaction to 
leptomeningeal invasion, and hence should be interpreted with caution (Gilbertson 
and Ellison 2008). The molecular and cytogenetic abnormalities in 
nodular/desmoplastic MBs are distinct compared to other subtypes (McManamy, 
Pears et al. 2007), and have a significantly better outcome compared to other 
subtypes. In adults, desmoplastic MB is the commonest variant observed, compared 
to children (Abacioglu, Uzel et al. 2002).    
Medulloblastoma with extensive nodularity (MBEN) represent about 3% of MB, 
and as the name suggests, they are extremely nodular giving a ‘grape-like’ 
appearance on imaging. The uniformly round intranodal cells are arranged in a 
streaming fine fibrillary background and due to their resemblance to neurocytes of 
central neurocytoma, this subtype have been previously termed as cerebellar 
neuroblastoma (Pearl and Takei 1981). These tumour subtype predominantly occur 
in children less than 3 years of age, and have a favourable outcome (Giangaspero, 
Perilongo et al. 1999).  
Anaplastic MB represent upto 15% of all MB and are characterised by large cells, 
and more striking nuclear pleomorphism, mitoses (with a high Ki-67 labelling index) 
and nuclear molding as compared to the classic type. They also have increased 
atypical mitoses, apoptotic bodies and show a distinctive cell wrapping phenomenon 
[Fig 1.4 C, wrapping of one cell around another] (Ellison, Love et al. 2004).  
Large cell MB accounts for about 3-4% of all MB, and histologically resembles the 
anaplastic type. They are composed of large cells with prominent nucleoli and more 
abundant cytoplasm (Fig 1.4 D) and they contain large areas of necrosis and display 
a high mitotic count. They are thought to resemble rhabdoid/atypical teratoid (AT/RT) 
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tumours of cerebellar origin, although they differ from these tumours in their 
immunophenotype and cytogenetic features (Giangaspero, Rigobello et al. 1992).  
Anaplastic and large cell variants are thought to form a continuum, and they have 
been grouped together for prognostic purposes and referred to as large-
cell/anaplastic (LCA) MB. LCA is biologically very aggressive and have the worst 
prognosis compared to other subtypes [Fig 1.4 E] (Giangaspero, Rigobello et al. 
1992; Ellison 2002; McManamy, Lamont et al. 2003).    
Rare forms of MB, such as medullomyoblastoma and melanotic MB are recognised. 
Medullomyoblastoma show rhabdomyoblast (immature skeletal muscle cell) 
differentiation, which may show formation of crude skeletal muscle fibrils or scattered 
large globular cells with desmin immunoreactivity (Smith and Davidson 1984). 
Melanotic MB, which otherwise has the histological appearance of classic MB, 
contains melanin pigment in a proportion of the cells, occasionally forming 
epithelioid, tubular or papillary pattern (Dolman 1988).  The biological behavior of 
these rare variants have been thought to be similar to classic MB, however the rarity 
of these cases has limited a thorough assessment (Ellison 2002).  
The common features that any  of the subtypes may display are i) invasion of the 
tumour cells into the cortex, deep white matter or the deep cerebellar nuclei, ii) 
extension into the subarachaoid space (4th ventricle), iii) leptomeningeal tumour 
deposits iv) supratentorial dissemination and v) metastasis outside of neural axis. 
Although the morphological differentiation of MB can be diverse, it mainly tends 
to occur along the neuroepithelial lines with the neuronal differentiation being the 
commonest. In keeping with this, immunoreactivity for synaptophysin is a 
characteristic feature of medulloblastoma and it is the most prominent in the nodules 
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and in the centre of neuroblastic rosettes. Other neuronal lineage markers such as 
nestin and vimentin show variable expression. Glial differentiation is rare, and when 
present, may form small groups of cells with astrocytic phenotypes, with GFAP (glial 
fibrillary acidic protein) immunoreactivity. Other than synaptophysin and GFAP, other 
markers such as S100 (marker of neural crest derivatives including glial cells), MIB-1 
(a proliferation marker, similar to Ki-67), Bcl-2 (B-cell lymphoma 2) and TP53 
(tumour protein 53) have also been associated with a minority of MB, the clinical 
significance of which is yet to be established (McLendon, Friedman et al. 1999). 
Ependymal differentiation is extremely rare, and if present raises possibility of other 
tumour diagnosis. In about 5% of the cases, mature ganglion cells are present 
(Burger, Grahmann et al. 1987).  
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Fig. 1.4 Histological variants of medulloblastoma and their predicted prognosis  
 
(A) Classic type, showing densely arranged small round to oval cells with hyperchromatic nuclei and 
indistinct cytoplasm. Also seen is nuclear molding. Classic type is the commonest histological MB 
variant.  (B) Desmoplastic type, with nodular tumour architecture. (C) Anaplastic type, showing large 
cells with more striking nuclear pleomorphism and nuclear molding, Arrow pointing to an example of 
cell wrapping phenomenon. (D) Large cell type comprising large cells with prominent nucleoli and 
more abundant cytoplasm. (E) Kaplan-Meier plot showing overall survival for different subtypes. 
Classic histology (yellow line) is associated with intermediate prognosis as compared to 
desmoplastic/nodular type (blue interrupted line, best prognosis) and large cell anaplastic type (red 
dots, worst prognosis). This picture is reproduced with permission from Rutkowski et al. JCO 2010. 
JCO copyright clearance licence no. 3254311484547 
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1.2.4 Genetic abnormalities in the pathogenesis of MB: 
 
Chromosomal aberrations: 
Common cytogenetic abnormalities in MB include isochromosome 17q (i17q), 
deletions of 17p and aberrations of chromosome 1. The most common specific 
abnormality, associated with more than 50% of the cases, is i17q (Bigner, Mark et al. 
1988) which mainly has a dicentric (with two centromeres) structure, similar to i17q 
occurring in leukemia. Although i17q is the most common mechanism for loss of 17p 
in MB, in minority of cases, partial or complete loss of 17p can occur by interstitial 
deletion, unbalanced translocation or monosomy 17 (Biegel, Burk et al. 1992). The 
types of aberrations of chromosome 1 found in MB are variable, and include 
unbalanced translocations, deletions and duplications (Griffin, Hawkins et al. 1988). 
Using comparative genomic hybridisation (CGH), further genomic imbalances in MB 
such as loss of chromosome 10q, loss of chromosome 11, and gain of chromosome 
7 (Reardon, Michalkiewicz et al. 1997) were identified. Isolated examples of 
deletions of 6q, 9q, 10q and 16q and gain of 4p, 5p, 7q, 8q and 9p have also been 
reported (Avet-Loiseau, Venuat et al. 1999; Giangaspero, Binger et al. 2000).  
These alterations are not distributed equally among the histologic variants. Presence 
of i17q in tumours has been associated with a poor clinical outcome, suggesting that 
this cytogenetic alteration may contribute to the development of aggressive variants 
of medulloblastoma. In contrast, monosomy 6 has recently been shown to occur 
exclusively in tumour with favourable prognosis, mainly in classic medulloblastomas. 
(Thompson, Fuller et al. 2006). Recently, gain of 6q and 17q were shown to be 
associated with poor prognosis, raising the possibility that they could be used as 
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independent markers of disease progression and survival (Pfister, Remke et al. 
2009). 
Gene amplification 
MYC (c-Myc) amplification (detected by fluorescent in-situ hybridisation/FISH) is the 
most common gene amplification found in MB containing double minutes (fragments 
of extrachromosomal DNA), followed by MYCN (N-myc) amplification which is found 
less often, together occurring in 6-8% of all MB (Badiali, Pession et al. 1991; 
Tomlinson, Jenkins et al. 1994). In particular the large cell histological variant which 
is associated with poor prognosis, carries a high incidence of MYC amplification 
(Brown, Kepner et al. 2000), which renders the tumour resistant to chemotherapy, 
resulting in fatal outcomes (Scheurlen, Schwabe et al. 1998).  Further studies have 
confirmed the association of MYC and MYCN amplification with aggressive MB types 
(Aldosari, Bigner et al. 2002). Pfister et al. have shown that MYC/MYCN 
amplification is associated with poor outcome in MB (hazard ratio for death = 2.75, 
reference being 1.00), suggesting their possible use as independent prognostic 
markers (Pfister, Remke et al. 2009).  
Mutations of tumour suppressor genes: 
Mutations of TP53 (P53, located on 17p13) have been identified in a subset of 5-
10% of MB (Adesina, Nalbantoglu et al. 1994; Batra, McLendon et al. 1995). Some 
studies have reported high association of TP53 mutation with large cell/anaplastic 
type of MB carrying a poor prognosis, hence suggesting that alterations within the 
TP53-ARF tumour suppressor pathway contribute to the development of aggressive 
types of MB (Frank, Hernan et al. 2004). Marino et al. have shown that somatic 
inactivation of Rb (retinoblastoma) gene in the EGL precursor cells of the developing 
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cerebellum in the p53-null mouse, induced high incidence of medulloblastoma 
formation of large cell anaplastic type (Marino, Vooijs et al. 2000),  through 
acquisition of additional genetic mutations affecting N-Myc and Ptch2 (Shakhova, 
Leung et al. 2006).  
PTEN (phosphatase and tensin homolog, located on chromosome 10q) mutations 
although found to be common in high grade gliomas, are rare in MB (Rasheed, 
Stenzel et al. 1997). However, a recent study has shown PTEN homozygous 
deletion to be present in 33% of MB (Inda, Mercapide et al. 2004). Also, Castellino et 
al. have demonstrated that heterozygosity for Pten promotes tumorigenesis in a 
mouse model of medulloblastoma and that PTEN expression is a marker of 
favourable prognosis (Castellino, Barwick et al. 2010).  
DMBT1 [deleted in malignant brain tumour 1, a member of scavenger receptor 
cysteine-rich (SRCR) superfamily, located on chromosome 10q] deletion, first cloned 
in a MB cell line, was identified and implicated in pathogenesis of small subset of MB 
(Mollenhauer, Wiemann et al. 1997).  
Familial syndromes and their genetic pathway mutations: 
Of particular importance, loss/mutations of tumour suppressor genes associated with 
two familial syndromes (Huang, Mahler-Araujo et al. 2000; Zurawel, Allen et al. 
2000) have been shown to predispose to MB – 1) Gorlin’s syndrome, and 2) Turcot 
syndrome. These syndromes are caused by the deregulation of the SHH and WNT 
signalling pathway and they will be discussed in parallel, as this should be useful to 
understand the novel molecular classification of MB which will be discussed later.  
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Gorlin’s syndrome [or naevoid basal cell carcinoma syndrome (NBCCS)] is a rare 
autosomal dominant condition with skeletal abnormalities, facial dysmorphism, large 
body size, ectopic calcifications, multiple basal cell carcinoma (Lo Muzio 2008).  
Medulloblastoma arising in Gorlin’s syndrome are known to have desmoplastic 
histology (Ellison 2002). As mentioned previously (section 1.1.2.3.2), Gorlin’s 
syndrome is characterised by germ line mutations of the PTCH (Patched) gene. As 
MB are thought to originate from GNPs of the EGL in developing cerebellum, 
deletion of PTCH in these cells result in malignant transformation leading to 
medulloblastoma. PTCH1 mutations have also been identified in about 9% of 
sporadic medulloblastoma (Thompson, Fuller et al. 2006). The function of Ptch1 as 
tumour suppressor was proved when 15% of mice with heterozygous deletion for 
Ptch1 developed medulloblastoma (Goodrich, Milenkovic et al. 1997). Mutations or 
deletions of Suppressor of Fused (SUFU) locus, a downstream molecule in the SHH 
signalling (Fig 1.6), have also been associated with sporadic MB (Taylor, Liu et al. 
2002), indicating that SUFU also acts as a tumour suppressor gene. Mutations of 
SMO (Smoothened) have also been reported in a significant proportion of MB 
(Zurawel, Allen et al. 2000).   
Turcot’s syndrome (Turcot, Despres et al. 1959) is a rare heritable disorder, 
associated with colonic cancer and malignant neuroepithelial brain tumours such as 
gliomas, and medulloblastoma. The syndrome is characterised by mutations of the 
APC (Adenomatous Polyposis Coli, located on chromosome 5q) gene (Huang, 
Mahler-Araujo et al. 2000). Since its first description, this syndrome has been refined 
to also include brain tumour polyposis (BTP) syndrome type 2, with APC mutation, 
which mainly develop medulloblastoma as their brain tumour component (Paraf, 
Jothy et al. 1997). APC is a component of the wingless (WNT) pathway (Ille and 
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Sommer 2005), which regulates various developmental processes including the 
proliferation and the fate of neural progenitor cells (WNT pathway has been 
described in section 1.1.2.3.2, Fig 1.2 A). Mutations in a range of WNT pathway 
members have been identified in sporadic medulloblastoma. They include CTNNB1 
(β-catenin 1, 8%), APC (3%) and AXIN [2%] (Zurawel, Chiappa et al. 1998; Huang, 
Mahler-Araujo et al. 2000; Yokota, Nishizawa et al. 2002). Compared to SHH 
pathway mutations, WNT pathway mutations are less frequent. In an analysis of 
childhood MB (from children entered in the International Society of Pediatric 
Oncology/United Kingdom Children’s Cancer Study Group) PNET3 trial, those cases 
with positivity for nuclear CTNNB1 showed better survival [5 year event free survival 
(EFS) of 89%], compared to CTNNB1 nuclear negative cases [5year EFS of 60%] 
(Ellison, Onilude et al. 2005). Another study from St Jude MB trial showed similar 
results, but importantly this study also demonstrated that CTNNB1 nucleopositive 
tumours and those tumour with Gli and SFRP1 positivity (indicative of SHH pathway 
activation) are mutually exclusive, and have significantly different survival rates 
favouring CTNNB1 nucleopositive tumours (Gajjar, Chintagumpala et al. 2006). 
Although SHH and WNT mutations appear mutually exclusive, these are only found 
in 30-40% of the MB (Thompson, Fuller et al. 2006).   
In keeping with the notion that mutations in signalling pathways regulating cerebellar 
development lead to medulloblastoma, there is evidence that also mutations leading 
to activation of the NOTCH pathway  are involved in MB tumorigenesis (Gilbertson 
and Ellison 2008). Notch signalling, discussed before (in section 1.1.2.3.2, Fig 1.2 
B), is known to play a multifaceted role in the differentiation, morphogenesis and 
functioning of the vertebrate nervous system (Louvi and Artavanis-Tsakonas 2006)A 
study has shown that activation of NOTCH2 in embryonal brain tumour cell lines 
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accelerated their proliferation and in vivo growth; this study also observed NOTCH2 
to be expressed at high levels in some MBs  and to be occasionally amplified at DNA 
level (Fan, Mikolaenko et al. 2004). Other syndromes where MB may develop 
include i) Li Fraumeni syndrome, with germ-line TP53 mutation (Tabori, Baskin et al. 
2010), and ii) Ruenstein-Taybi syndrome, with germ-line CREBBP (CREB binding 
protein) deletion, which is the first syndrome identified for non-WNT/non-SHH MB. 
(Bourdeaut, Miquel et al. 2013).  
Mutations in RAS signalling pathway are known to be associated with certain 
syndromes such as Noonan syndrome with multiple lentigines [or Leopard 
syndrome, with skin, facial and cardiac defects] (Sarkozy, Digilio et al. 2008). 
Recently Rankin et al., have reported an adult patient with clinical and molecular 
features of Leopard syndrome with PTPN11 mutation to have had MB as a child, 
indicating that MB may be an association with RAS associated mutations (Rankin, 
Short et al. 2013).  
Alternative splicing: 
Alternative splicing is a controlled mechanism for generating protein diversity, and 
refers to a primary transcript being spliced in more than one pattern to generate 
multiple, distinct mRNAs (Koscielny, Le Texier et al. 2009). Previous studies have 
reported alternative splicing of individual genes in human MB (Ferretti, Di Marcotullio 
et al. 2006; Li, Shu et al. 2007). A more recent, genome wide analysis of alternative 
splicing in paediatric MB and normal cerebellum by Menghi et al., have identified 
eleven validated splicing events associated with MB (Menghi, Jacques et al. 2011). 
Three of the eleven genes (DAAM1, EHBP1 and TRRAP) were shown to have 
characteristics for Sonic Hedgehog-driven MBs. Furthermore, they demonstrate that 
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some of the tumour associated splicing patterns were observed in the GNP cell 
cultures, suggesting  that abnormal alternative splicing during cerebellar 
development may lead to failure of neuronal differentiation and MB development 
(Menghi, Jacques et al. 2011). The main genes  known to participate in 
medulloblastoma pathogenesis, are summarised in Table 1.3 (de Bont, Packer et al. 
2008).  
Table 1.3 Differentially expressed genes in medulloblastoma*  
Genes Change type Approximate % 
of tumour 
association 
(where known) 
 
 
Genes Change type Approximate % 
of tumour 
association 
(where known) 
SHH signalling  IGF signalling continued 
PTCH1 Mutation 4 – 13   IGF-1R Phosphorylation 80 
PTCH2 Overexpression   IRS-1 Overexpression  
SUFU Mutation 0 – 9   IGF-2 Overexpression  
Smo Mutation 0 – 10  AKT/PKB Phosphorylation  
Gli Overexpression 30  Erk-1 Phosphorylation  
BMI1** Overexpression 67  Erk-2 Phosphorylation  
RENKCTD 11 Deletion 39  IGFBP-2 Overexpression  
Wnt signalling  CXCR4 Overexpression 51 
Axin 1 Mutation 1 – 6  PDGFRB Overexpression  
Deletion 12 – 41  OTX2 Overexpression >70 
Axin 2 Mutation 3  Amplification 33 
APC Mutation 1 – 4  ATOH1 Expression  
β-catenin Mutation 1 – 63  P75 Expression  
Survivin  Overexpression  5 – 50   Overexpression  
SOX4 Overexpression    TrkA Overexpression 67 
SOX11 Overexpression   TrkC Overexpression 29 - 73 
Cyclin D1 Overexpression   Heparanase Expression 62 - 88 
Cyclin D2 Overexpression   NEUROG1 Expression 55 
Lef1 Overexpression   Calbindin Expression 41 
Notch signalling  P53 Mutation 0 - 11 
HES1 Overexpression  <46  PAX5 Overexpression 70 
HES5 Overexpression <71  MDM2 Overexpression 0 - 20 
JAG1 Overexpression   CDK6 Overexpression 30 
Notch1 Overexpression 75  HIC1 Hypermethylation 70 
Notch2 Overexpression 12 – 15  EEF1D Overexpression  
Notch3 Overexpression   RPL30 Overexpression  
FOXG1 Overexpression >90  RPS20 Overexpression  
Musashi Overexpression   STMN1 Overexpression  
ErbB signalling  hTERT Overexpression 42 
ErbB4 Overexpression 66  SGNE1/7B2 Hypermethylation 70 
ErbB2 Overexpression 70 - 86  RASSF1A Hypermethylation 80 - 90 
CIC Overexpression   CASP8 Hypermethylation 90 
NRG-1β Overexpression 87  ZIC2 Hypermethylation  
c-Myc Amplification 5 – 10  P14-ARF Hypermethylation 4 - 50 
Overexpression 42 
Mnt Underexpression 43  P16INK4A Hypermethylation 2 - 14 
JPO2 Overexpression   TIMP3 Hypermethylation 0 - 11 
N-Myc Ampification 5  CDH1 Hypermethylation 8 
IGF signalling   P18INK4C Hypermethylation 20 
MCJ Hypermethylation 33  S100A6 Hypermethylation 12 
RB1 Hypermethylation 18  S100A10 Hypermethylation 12 
DKK1 Histone acetylation   S100A4 Hypomethylation 17 
* Ref. De Bont et al. Neuro Oncol 2008. ** In this study we are primarily interested in the role of BMI1.  
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1.2.5 Current treatment strategies:    
 
Following patients’ clinical, radiological and pathological evaluation, a 
multidisciplinary team makes the treatment recommendation. The treatment options 
are based on patient stratification into average, intermediate and high risk groups, 
which takes into account several factors including age of the patient, associated co-
morbidities, stage of the tumour/extent of resection, histological tumour type and 
associated genetic markers (Packer, Cogen et al. 1999). The criteria for patient risk 
stratification may further evolve owing to advances in understanding  the tumour 
biology (Packer, Rood et al. 2003). Generally, the main modalities of treatment are 
surgical excision, radiotherapy and chemotherapy; mostly a combination of all the 
three. Rarely (especially in recurrent cases) stem cell/bone marrow transplantation 
may be recommended. In advanced or terminal cancer, palliative care/support may 
be the only appropriate management option.  
Surgery 
Surgery is considered as the gold-standard treatment, which remove/reduce tumour 
bulk and provides tumour material for histologic confirmation of tumour type. It is 
crucial to maximally resect the primary MB tumour, and therefore aggressive surgical 
approaches are undertaken to always excise the tumour as much as possible 
(Albright, Wisoff et al. 1996). In most cases of MB in children, the tumour is located 
at the midline in the posterior fossa, and can be accessed via sub-occipital 
craniotomy, in a prone (face down) position (Cogen and Donahue 1999). It may 
necessitate partial resection of the cerebellar vermis to access the tumour, but the 
floor of IV ventricle needs to be protected. Neuronavigation using stereotactic 
guidance and operating microscope to carefully identify crucial neural structures are 
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used. Associated hydrocephalus is treated by ventriculostomy [shunt catheter] (Lee, 
Wisoff et al. 1994), which may have to be left in place permanently in a proportion of 
the patients; the likelihood of which is increased in infants and those children with 
leptomeningeal dissemination. Common postoperative complications include diplopia 
(sixth-nerve palsies), ataxia (due to vermis dissection) incoordination (if cerebellar 
peduncles are resected), and rarely (5-15%) mutism-associated pseudobulbar signs 
(Pollack, Polinko et al. 1995). Most of these findings tend to resolve over a few 
weeks post operatively (Packer, Cogen et al. 1999). Post operatively MRI scan is 
done routinely, to ensure that ‘total’ or ‘near total’ resection has been achieved. If 
not, a second operation to remove the residual tumour is undertaken in non-
metastatic disease (MacDonald, Rood et al. 2003).  
Radiation treatment 
Adjuvant radiation therapy is usually given 4-6 weeks after surgery, and remains the 
single most effective means of postoperative treatment for children with MB (Packer, 
Cogen et al. 1999; Taylor, Bailey et al. 2004). Prophylactic craniospinal radiotherapy 
(csRT, covering entire craniospinal axis) is administered routinely to the newly 
diagnosed patients, independent of radiological or cytological (CSF) evidence of 
spinal metastasis, as this is shown to maximise survival (Bouffet, Bernard et al. 
1992). In children less than 3 years of age, conventionally, 3600 cGy and 5400-5960 
cGy is given to entire neuraxis and the posterior fossa (total dose) respectively 
(Landberg, Lindgren et al. 1980; Hershatter, Halperin et al. 1986)(Hershatter et al., 
1982; Landberg et al., 1980). It is of note that use of next generation radiotherapy 
such as proton therapy and intensity modulated radiotherapy (IMRT) are emerging 
(St Clair, Adams et al. 2004). 
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Chemotherapy 
Untoward neurocognitive and endocrine effects resulting from irradiation of the 
developing neuraxis in children poses a great obstacle for this treatment, prompting 
clinical trials using adjuvant chemotherapy. These clinical trials showed variable 
benefits (Bailey, Gnekow et al. 1995; Deutsch, Thomas et al. 1996; Kuhl, Muller et 
al. 1998), including preserved intellectual or neurocognitive ability (Ris, Packer et al. 
2001) compared to those of conventional radiotherapy alone. Chemotherapy, is a 
standard component of the treatment in older children (> 3 years of age), and is 
usually given during and after radiation therapy (for about 12 months following 
radiotherapy).In younger children (< 3 years of age), chemotherapy is used to delay 
or sometimes to avoid the need for radiotherapy in localised MB. As the treatment 
regime differs depending on the age of the patient and their risk group, this will be 
discussed under different headings (NCI 2013).  
Children aged 3 years or younger: The main principle in this age group is to 
achieve adequate cure with chemotherapy alone, removing the need of adjuvant 
radiotherapy. Several studies have observed that desmoplastic and MBEN histology, 
which is common in younger children, have favourable outcome even with 
chemotherapy alone (Geyer, Sposto et al. 2005; von Bueren, von Hoff et al. 2011), 
while other histologic subtypes fare less well (Grill, Sainte-Rose et al. 2005), 
necessitating adjuvant radiotherapy. Newer regime using higher dose chemotherapy 
(marrow ablative) followed by autologous bone marrow/stem cell rescue, has been 
shown to ablate the need of radiotherapy in a subgroup of patients younger than 3 
years of age (Chi, Gardner et al. 2004; Dhall, Grodman et al. 2008).  
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Children older than 3 years, with average-risk MB: Prospective randomised and 
single-arm trials have demonstrated that adjuvant chemotherapy during and after 
radiotherapy improve overall survival in children with average-risk MB. (Bailey, 
Gnekow et al. 1995; Kortmann, Kuhl et al. 2000; Carrie, Grill et al. 2009).  A 
prospective multi-centre trial shows a favourable outcome (5-year overall survival of 
85%) when risk-adapted radiotherarpy, followed by a short (4-month) dose-intensive 
chemotherapy supported by stem cell rescue was used (Gajjar, Chintagumpala et al. 
2006). This study also showed a poor survival associated with large cell/anaplastic 
type of MB, compared to other histological subtypes.  
Children older than 3 years with high-risk MB: The drugs that are used for 
average-risk patients have been used extensively in high-risk (Jakacki, Burger et al. 
2012). Post radiation, short, dose-intensive chemotherapy supported by stem cell 
rescue study mentioned above, also showed favourable outcome in high-risk MB ([5-
year overall survival and 5-year progression free survival of ~70%] (Gajjar, 
Chintagumpala et al. 2006). Innovative drug delivery system and decreased 
neurotoxicity of chemoradiotherapy are major directives for future clinical trials.  
Adults: Because of the rarity of MB in adults, prospective comparative 
chemotherapy trials are limited. Adolescents and young adults tolerate 
chemotherapy relatively poorly (Tabori, Sung et al. 2005). Several studies have 
shown no benefit of addition of chemotherapy to radiotherapy (Carrie, Lasset et al. 
1994; Prados, Warnick et al. 1995; Chan, Tarbell et al. 2000), but the studies have 
been small and underpowered, suggesting that further comparative studies are 
needed. 
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Shortfalls of current therapy: Despite recent advances and multimodality in 
treatment MB is still associated with high morbidity and mortality. Approximately 40% 
of childhood tumours are treatment refractory, leading to recurrence, and about 30% 
of the patients die because of the tumour. Those who survive the treatment often 
have a significantly impaired quality of life (Jones, Jager et al. 2012). Novel therapies 
targeting specific molecular pathway and improved classification are necessary to 
improve patient stratification and response to less toxic therapies. Therefore 
understanding different molecular and genetic pathway giving rise to this 
heterogeneous tumour is crucial. 
   
1.2.6 Recent advances in molecular classification of medulloblastoma 
(molecular subgroups) 
 
As discussed previously (section1.2.5), clinical prognostication and stratification in 
patients with MB include clinical factors, histological type and expression of certain 
molecular markers. However, it is increasingly clear that MB is not a single disease 
entity.  Based on their gene expression profiles, DNA copy number aberrations, and 
analysis of transcriptional profiles, several research studies (Pomeroy, Tamayo et al. 
2002; Thompson, Fuller et al. 2006; Kool, Koster et al. 2008; Fattet, Haberler et al. 
2009; Northcott, Nakahara et al. 2009; Al-Halabi, Nantel et al. 2011; Cho, Tsherniak 
et al. 2011; Northcott, Korshunov et al. 2011) have provided evidence to suggest that 
MB can be classified into multiple molecular subgroups. Furthermore, it has been 
suggested that the tumours belonging to each subgroup differ in their demographics 
and clinical outcomes. A consensus conference, which took place in 2010 in Boston, 
USA, came to a consensus that the overall evidence supported the distinction of MB 
into four main non overlapping molecular subgroups, namely, WNT, SHH, Group 3 
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and Group 4 (Taylor, Northcott et al. 2012). Two groups, characterized by activation 
of WNT and SHH pathways respectively, are better characterized molecularly, while 
the molecular signatures underlining Groups 3 and 4 are less well defined. There 
was evidence that further subtypes existed within each of these groups (decided to 
be named with Greek letters - α, β, γ etc.). The participants of the consensus agreed 
that molecular classification will continue to evolve in the future, as larger cohorts are 
analysed in greater depth (Northcott, Korshunov et al. 2011). .      
 
1.2.6.1 WNT subgroup  
 
WNT subgroup has a very good long term prognosis compared to other subgroups 
(Clifford, Lusher et al. 2006; Ellison, Dalton et al. 2011). Due to their good prognosis, 
the possibility to undertake a clinical trial to de-escalate therapy (to avoid morbidities 
associated with treatment) is being discussed for this group of patients. The gender 
ratio for this subgroup is equal in males and females, and they can occur in all ages, 
but are uncommon in infants. Genetic abnormalities that define tumours in this 
subgroup (Hamilton, Liu et al. 1995; Zurawel, Chiappa et al. 1998) are: i) germline 
mutations of WNT pathway inhibitor APC (that predisposes to Turcot’s syndrome), 
and ii) somatic mutations of CTNNB1 encoding β-catenin (Fig 1.5). The tumours in 
this group showed monosomy 6 (92.6% of cases as opposed to 7.4% in SHH 
subgroup) as the predominant cytogenetic abnormality, and one of the genetic 
abnormality associated with monosomy 6 is serum/glucocorticoid regulated kinase 1 
[SGK1] (Ellison, Dalton et al. 2011). However occasional reports of cases with WNT 
transcriptional signature without monosomy 6 (Northcott, Korshunov et al. 2011), and 
those with mutations in both CTNNB1 and PTCH together (Parsons, Li et al. 2011), 
complicate the definition of this subgroup. Immunohistochemical marker DKK1 
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(dickkopf WNT signalling pathway inhibitor 1) has been found to be strongly 
associated to this subgroup of tumours (Northcott, Korshunov et al. 2011; Remke, 
Hielscher et al. 2011).  The majority of the tumours in this group have classic 
histology; and although tumours with large cell/anaplastic histology have been 
reported, this does not seem to affect the prognosis negatively (Ellison, Kocak et al. 
2011). A mouse model of Wnt group has been established, which suggest that the 
tumours from this subgroup arise from lower rhombic lip of the cerebellum (Gibson, 
Tong et al. 2010).       
1.2.6.2 SHH subgroup 
 
The SHH subgroup MB have an intermediate prognosis, similar to Group 4 patients, 
worse  than WNT (good) and better than Group 3 (poor). There is no difference in 
gender ratio, and they show a dichotomous age distribution, being common in infants 
(0-3 years) and in adults (> 16 years), but less common in children (3-16 years) [Fig 
1.5]. Genetic abnormalities that define this subgroup of tumours (Bale, Falk et al. 
1998; Brugieres, Pierron et al. 2010; Northcott, Hielscher et al. 2011; Northcott, 
Korshunov et al. 2011) are i) germline mutations in Shh receptor PTCH 
(predisposing to Gorlin syndrome), ii) germline mutations in SHH inhibitor SUFU 
(particularly in infantile MB), iii) somatic mutations of SHH pathway members such 
as PTCH, SMO and SUFU, and, amplifications of GLI1 and GLI2, and iv) deletion of 
chromosome 9q (where PTCH gene is located). Although this MB subgroup can be 
identified on the basis of transcriptional profiling (Taylor, Liu et al. 2002; Northcott, 
Fernandez et al. 2009),  other approaches (Al-Halabi, Nantel et al. 2011; Ellison, 
Dalton et al. 2011; Northcott, Korshunov et al. 2011) to identify this subgroup by 
immunohistochemical staining for SFRP1(secreted frizzled-related protein 1) or 
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GAB1 (GRB2-associated binding protein 2) have been described. The most common 
histology type associated with SHH is nodular/desmoplastic MB, although this is 
considered not be an effective marker as up to 50% of MB in SHH subgroup are not 
of the nodular/desmoplastic type. The majority of the mouse models for MB 
established so far belong to Shh subgroup of tumours and they have been shown to 
originate from Math1-positive granule cell progenitors (Hatten and Roussel 2011).  
 
1.2.6.3 Group 3 
 
Group 3 MB is characterized by the worst prognosis as compared to all other 
subgroups (Taylor, Northcott et al. 2012). They are more common in males than in 
females, and are found in children and infants, but almost never in adults (Fig 1.5). 
Although no specific molecular pathway characterises this subgroup, their main 
genetic abnormalities include i) MYC amplification/overexpression (Cho, Tsherniak 
et al. 2011; Hatten and Roussel 2011), ii) amplification/overexpression of OTX2  (de 
Haas, Oussoren et al. 2006; Adamson, Shi et al. 2010), iii) overexpression of several 
genes that are associated with retinal development [although the role of these genes 
in Group 3 MB pathogenesis is yet to be completely understood] (Kool, Koster et al. 
2008) and iv) gain of chromosome 1q, loss of chromosome 5q and chromosome 10q 
(more likely to have these compared to Group 4).  
There is a high association of Group 3 MB with c-MYC (or MYC) overexpression; 
and MYC amplification appears to be almost always limited to Group 3 (Northcott, 
Korshunov et al. 2011). In fact, Group 3 patients are being subdivided into different 
subgroups based on MYC amplification status namely, 3α (harbor) and 3β (do not 
harbor), where the latter show similar prognosis as Group 4 patients (Cho, Tsherniak 
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et al. 2011). The gold standard for diagnosis of Group 3 tumours is by means of 
transcriptional profiling , but  immunohistochemistry for the marker NPR3 (natriuretic 
peptide receptor 3) has been suggested as a reliable Group 3 marker (Northcott, 
Korshunov et al. 2011). Group 3 MB mostly show classic and large cell/anaplastic 
type histology, and are frequently metastatic (Northcott, Korshunov et al. 2011). 
There is a need to focus on further understanding of underlying pathogenesis, 
establish practical biomarkers, and develop accurate mouse models for MB of this 
subgroup in particular, as they bear the worst prognosis. Recently however, Pei et al. 
have described a novel model of Myc expressing and mutant p53 bearing cerebellar 
stem cell orthotopic xenograft as a representative model of Group 3 (Pei, Moore et 
al. 2012).     
1.2.6.4 Group 4 
 
Group 4 MB are characterised by an intermediated prognosis as discussed above. 
They are prototypical MBs, arising in young boys (i.e. Common in children with male 
preponderance) and displaying a classic histology, and with isochromosome 17q 
(Fig 1.5). However this subgroup has a diverse molecular pathogenesis, and 
currently tumours belonging to this subgroup are identified through transcriptional 
profiling (Cho, Tsherniak et al. 2011; Taylor, Northcott et al. 2012). Isochromosome 
17q is also seen in Group 3 tumours, but its association with Group 4 tumours is 
much stronger  [26% vs 66%] (Northcott, Korshunov et al. 2011). Isolated deletion of 
17p is seen Group 3 and Group 4, but not in SHH or WNT subgroups. The other 
notable genetic alteration in Group 4 tumours is loss of X chromosome in females. 
Multiple studies have identified over-representation of genes involved in neuronal 
differentiation and development in Group 4 MB (Kool, Koster et al. 2008; Cho, 
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Tsherniak et al. 2011; Northcott, Korshunov et al. 2011), although their clinical 
relevance is not yet clear.  The Polycomb group gene BMI1 (the gene that we are 
interested in our study, which will be discussed in details in the next section below) is 
also more prominently overexpression in Group 4 MB (or Northcott Group D) MBs 
(Behesti, Bhagat et al. 2013; Manoranjan, Wang et al. 2013). .   
KCNA1 (potassium voltage-gated channel, shaker-related subfamily, member 1) has 
been suggested as the immunohistochemical marker for Group 4 MB, but requires 
further validation (Northcott, Korshunov et al. 2011). In addition FSTL5 (follistatin-like 
5) has been suggested as an effective marker indicative of poor prognosis for non-
WNT/non-SHH group of MBs (Remke, Hielscher et al. 2011) . The 
immunohistochemical markers currently suggested for  the identification of the 
various subgroups (Taylor, Northcott et al. 2012) are listed in Table 1.4. However, at 
the consensus conference it was felt that until definitive immunohistochemical 
markers are established, histopathological classification (discussed in section 1.2.3) 
continues to play an important role in the diagnosis and risk stratification of 
medulloblastoma. Currently no mouse model for Group 4 MB has been reported. 
Although Group 4 tumours make >30% of all MBs, the molecular pathogenesis of 
this tumour subtype is the least understood, highlighting the need of further studies 
to clarify the pathogenesis of this subgroup.  
1.2.6.5 Adult MB 
 
SHH tumours make up to two-thirds of cases in adults, while Group 3 tumours are 
exceptionally rare (Remke, Hielscher et al. 2011). SHH MBs are extensively studied, 
and small molecules (GDC-0449) targeting smoothened (SMO) have been shown to 
be temporarily highly effective against SHH MBs (Rudin, Hann et al. 2009; Yauch, 
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Dijkgraaf et al. 2009). As the cerebellar development in adults is complete, targeting 
the molecular pathways involved in the normal cerebellum development may cause 
less toxicity in adults, making them an attractive cohort for molecular-targeted 
therapies. However there are still doubts about the degree of molecular and clinical 
similarities between adult and paediatric MBs. Some studies suggest a distinct 
molecular profiles and clinical behavior between the two tumour groups (Tabori, 
Sung et al. 2005; Tabori, Sung et al. 2006; Korshunov, Remke et al. 2010) . The 
transcriptomic differences between adult and paediatric patients defined under same 
subgroups have yet to be studied in detail.  
      
 
Fig. 1.5 Comparison of different molecular subgroup of MB 
 
Comparison of demographics, clinical features, genetics and expression profiles of the four major MB 
subgroups defined by the consensus conference. The affiliations of previously published papers on 
MB molecular subgrouping (prior to consensus) is mentioned on top. The terminology used to classify 
the subgroups by respective publication is mentioned (Eg. Consensus Group 4 was referred to as 
Group D by Northcott et al, 2010). This picture is reproduced from an open access article from 
Springerlink.com, with licence permitting any non-commercial use. Ref: Taylor M.D et al. Acta 
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Neuropathol 2011. Copyright - © The Author(s) 2011, including Michael D Taylor and Stefan M 
Pfister. 
 
Table 1.4 List of immunohistochemical markers being defined for different MB subgroup 
association* 
Subgroup Immunohistochemical marker 
suggested (pending further 
validation). 
 
WNT CTNNB1 (nuclear), DKK1 
 
SHH SFRP1, GLI1, GAB1 
 
WNT/SHH FILA, YAP1 
 
Group 3  NPR3 
 
Group 4  KCNA1 
 
Group 3/Group 4  FSTL5 
* Ref. Taylor et al. Acta Neuropathol, 2011. 
1.3 BMI1 gene 
 
The BMI1 (B lymphoma Moloney murine leukaemia virus Insertion region 1) gene 
was first isolated as an oncogene that cooperates with c-myc in the generation of 
mouse lymphomas through repression of tumour suppressor Cdkn2a or ink4a/Arf 
(Haupt, Alexander et al. 1991; van Lohuizen, Verbeek et al. 1991). Subsequently 
Bmi1 was identified as a transcriptional repressor belonging to the Polycomb group 
of genes in the vertebrates (van Lohuizen, Frasch et al. 1991; Alkema, van der Lugt 
et al. 1995; Jacobs, Kieboom et al. 1999; Jacobs, Scheijen et al. 1999). The gene 
(located on chromosome 10p in humans and 2 A3 in mice) encodes for a highly 
conserved nuclear protein with 326 amino acid sequence (mass of 37 kD) that 
contains a zinc-finger motif, and is closely related to other zinc-finger proteins such 
as Mel-18 (Tagawa, Sakamoto et al. 1990).  BMI1 (protein) is a component of the 
Polycomb group (PcG) multi-protein complex and is also known as Polycomb group 
RING finger protein 4 (PCGF4).  
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1.3.1 Polycomb group (PcG) proteins 
 
The PcG proteins are chromatin-modifying complexes that are essential for 
embryonic development. They were originally identified in the fruitfly  Drosophila 
melanogaster, as a repressor of Hox (homeobox) genes (Ringrose and Paro 2004), 
which define the position of structures and appendages along the anterior-posterior 
axis of the adult body. The name ‘Polycomb’ was introduced as mutation in these 
genes led to additional sex combs in the developing Drosophila embryo (Sparmann 
and van Lohuizen 2006). This function of PcG proteins is essentially conserved in 
vertebrates (including humans), with mutations leading to skeletal malformations 
(Akasaka, Kanno et al. 1996). At molecular level, PcG proteins are classified into two 
groups, termed Polycomb repressive complexes (PRCs) – 1) PRC 2 initiation 
complex (E.g. EED, EZH1), and 2) PRC1 maintenance complex, which contain core 
components such as Polycomb (PC), Polyhometoic (PH), really interesting new gene 
(RING) and Posterior sex combs (PSC). The best characterised members of the 
PRC1 complex in humans are BMI1 and RING1 (containing RING finger protein 
domain), CBX2 (containing chromodomain), and EDR1 (containing Zinc finger SPM 
domain). PRC2 is responsible for trimethylation of lysine 27 and lysine 9 of histone 
H3 (H3K27 and H3K9me3 respectively) and deletion of PRC2 member genes in mice 
has shown to result in early embryonic lethality, highlighting their importance in 
development (Schumacher, Faust et al. 1996; O'Carroll, Erhardt et al. 2001). PRC1 
acts via chromatin remodelling and modification of histones, and is able to recognise 
H3K27me3 mark through the chromodomain of PC. In addition, PRC1 possesses 
ubiquitin E3 ligase activity that targets H2AK119 (monoubiquitinates nucleosomal 
histone H2A at lysine 119), which is associated with gene repression (Wang, Wang 
et al. 2004). However the PRC core components are thought to assemble into 
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various distinct sub-units depending on the cellular functional context (Otte and 
Kwaks 2003). Although the role of PRCs in epigenetic gene silencing is well 
recognised,  the precise molecular mechanisms of PRC-mediated repression are still 
poorly understood (Sparmann and van Lohuizen 2006).  
1.3.1.1 Role of PcG in cancer 
 
The first association of PcG with cancer came from functional characterisation of 
BMI1 (discussed below), which is one of PcG protein most strongly associated with 
neoplastic development (Sparmann and van Lohuizen 2006). Other PcG members 
associated with cancer are SUZ12 (overexpression) in colon and breast cancer 
(Kirmizis, Bartley et al. 2003), and EZH2 (overexpression) in lymphoma, prostate 
and breast cancer (van Kemenade, Raaphorst et al. 2001; Varambally, 
Dhanasekaran et al. 2002; Kleer, Cao et al. 2003). Interestingly, an 
extranuclear/cytosolic role of EZH2, influencing cell adhesion and migration, thereby 
contributing to the metastatic capacity of the tumour cells has been described (Su, 
Dobenecker et al. 2005). Bracken et al. have shown [by chromatin 
immunoprecipitation (ChIP) and genome-wide screenings to identify PcG target 
genes in human fibroblast cells] that the PRC complex could contribute to cancer 
development by specifically silencing tumor-suppressor genes by DNA methylation 
(Bracken, Dietrich et al. 2006). In relation to this, they have also found an inverse 
correlation between the expression levels of the PcGs, EZH2, SUZ12, and BM11, 
and the target genes MT1G, HOXA5, and RARB in breast cancer.    
Stem cells are defined as cells that have the ability to extensively self-renew and to 
differentiate into progenitors. In addition to transcriptional repression of tumour 
suppressor genes, there is evidence that PcGs might influence tumour development 
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through modulation of stem cells (Valk-Lingbeek, Bruggeman et al. 2004). This is 
strengthened by the results demonstrating that PcGs maintain stem cell state (or 
stemness) by repression of alternative lineages genes necessary for differentiation 
(Boyer, Plath et al. 2006; Lee, Jenner et al. 2006). Moreover, there are results 
highlighting that stem cell fate is in part governed by the PcG genes, one of the first 
indications coming from Bmi1-deficient mice, which show loss of hematopoietic cells 
and cerebellar neurons (van der Lugt, Domen et al. 1994). An RNA expression 
signature associated with ‘stemness’, based on BMI1-driven transcriptional changes 
was predicted to have poor treatment outcome in patients with different types of 
cancer (Glinsky, Berezovska et al. 2005). 
1.3.2 Bmi1 in cerebellar development 
 
Bmi1 is essential for maintenance and self-renewal of haematopoietic and neural 
stem cells (Richie, Schumacher et al. 2002; Molofsky, Pardal et al. 2003). In fact, 
targeted deletion of Bmi1 in a mouse model (null mutant) causes severe neurological 
and haematopoietic defects (van der Lugt, Domen et al. 1994). Origin and fate of 
cerebellar granule cell precursors (GNPs) during the development of the cerebellum 
have been discussed before (section 1.1.2.3.2). Leung et al. have shown that Bmi1 
is expressed in the EGL precursors during embryonic (E16.5 in mouse and 26 
gestational week in human) and early postnatal (P8 in mouse, 2 months in human) 
development of the cerebellum (Leung, Lingbeek et al. 2004). In addition, they 
demonstrated that postnatal mice with targeted Bmi1 deletion (Bmi1-/-) showed 
reduced brain mass and developed cerebellar signs/symptoms (ataxia, balance 
disorders and behavioural changes) due to phenotypic changes in cerebellum. The 
cerebellar phenotypes included reduced cellularity in the granular and molecular 
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layers, reduced Math-1 positive EGL precursors and wider expression of postmitotic 
marker p27 at P1. There was also reduction in BrDU incorporation (indicating 
reduced proliferation), and an increase in apoptosis in the EGL at P8. They also 
noted reduction in cell density and size of the internal granular layer (IGL) at P15 
(Leung, Lingbeek et al. 2004). Bmi1 is expressed in the EGL as well as in the 
ventricular zone neuroepithelium from E16.5 onwards, but it has been shown to be 
involved mainly in postnatal GNP proliferation.  
There is a peak of proliferation of GNPs in the EGL during early post-natal 
development, induced by Shh secreted by Purkinje neurons (Dahmane and Ruiz i 
Altaba 1999; Wechsler-Reya and Scott 1999). The GNPs later differentiate and 
migrate inwards past the molecular layer (ML) to reach their final destination, IGL 
(Wang and Zoghbi 2001). Studies have demonstrated that addition of Shh in vitro 
induced proliferation in cerebellar granule cells [CGCs] (Dahmane and Ruiz i Altaba 
1999; Wechsler-Reya and Scott 1999). Leung et al. have further shown that Bmi1 is 
upregulated in response to Shh treatment in CGCs in a similar fashion as Gli1, Sufu 
and cyclin D2, indicative of Shh pathway activation (Leung, Lingbeek et al. 2004).  
1.3.2.1 Bmi1 is a downstream target of Shh pathway 
 
The results described above suggest that Bmi1 is a downstream target of Shh 
pathway. The pathway has been briefly discussed in section 1.1.2.3.2 and is 
diagrammatically represented in Fig 1.6. Further evidence supporting this is 
discussed here.  
Bruggeman et al. have later confirmed that the process of GNP proliferation in the 
EGL is linked to Bmi1 as a downstream target of the Shh pathway (Bruggeman, 
Valk-Lingbeek et al. 2005). They show that Ink4a and to a lesser extent Arf 
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expression is increased in Bmi1-/- GNPs and cerebella. The Ink4a/Arf locus is 
located on chromosome 9, comprising two genes with overlapping reading frames, 
encoding tumour suppressors p16INK4a (inhibitor of cyclin dependent kinase 4) and 
p19ARF (alternate reading frame, p14ARF in humans), both of which play an 
important role in regulating cell, growth, survival and senescence (reviewed in 
Sharpless and DePinho 1999). They demonstrated that stimulation of GNPs with 
Shh led to Bmi1 protein expression, and a concomitant down-regulation of both 
Ink4a and Arf mRNA expression. This was consistent with the notion of Bmi1 
mediates regulation of Ink4a/Arf by Shh. Jacobs et al. have demonstrated that 
removal of Ink4a/Arf partly rescued the cerebellar (and lymphoid) defects seen in 
Bmi1-/- mice (Jacobs, Kieboom et al. 1999), indicating that ink4a/Arf is a critical in 
vivo target for Bmi1. This also connects transcriptional repression role of Bmi1 (a 
PcG protein) with cell-cycle control and senescence.  
Kenney et al. have shown that N-Myc is a direct downstream target of the canonical 
Shh pathway regulating GNP proliferation (Kenney, Cole et al. 2003).  They 
demonstrate that Shh stimulation directly induces N-myc in GNPs and that N-myc is 
expressed in proliferating GNPs. They also observed that when N-myc is 
upregulated in GNPs, Cyclin D1 protein expression was maintained (which was 
abolished by Shh inhibitor cyclopamine treatment), despite treatment with the Shh 
inhibitor cyclopamine. Other studies have also shown that proliferation of GNPs in 
vitro can be induced by Shh and that it induced N-myc and cyclin D1 [and cyclin D2] 
(Ciemerych, Kenney et al. 2002; Knoepfler, Cheng et al. 2002). In keeping with the 
above results, Bruggeman et al. show that Bmi1-/- GNPs are only partially 
responsive to Shh (Bruggeman, Valk-Lingbeek et al. 2005), and propose a model in 
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which Shh controls proliferation in these cells via an alternate, i.e. N-Myc/Cyclin D2 
mediated route.  
Valk-Lingbeek et al reviewed the potential link between Shh signalling and Bmi1 
suggesting a novel regulatory pathway of external morphogen interacting with cell-
intrinsic epigenetic pathway controlling cell fate programs (Valk-Lingbeek, 
Bruggeman et al. 2004). In this model, Bmi1, induced by Gli1, negatively regulates 
the Ink4a/Arf locus. This locus encodes the cell cycle regulators/tumor suppressors 
p16Ink4a and p19Arf (p14ARF in humans).  p16Ink4a impacts  on Rb 
(retinoblastoma) regulation  via inhibition of  cyclin D/cyclin dependent kinase 
complexes. The pRb (hypophosphorylated Rb) sequesters E2F transcription factors 
and repress their target genes - leading to a cellular context dependent cell cycle 
arrest, senescence or apoptosis (reviewed in (Sharpless and DePinho 1999)).  
p19Arf binds MDM2 and inhibits p53 transcription factor degradation which results in 
activation of its target genes - leading to cell cycle arrest and apoptosis (reviewed in 
(Lowe and Sherr 2003)).  
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Fig. 1.6 Diagrammatic representation of Shh pathway in cerebellar granule cell  progenitor 
development. 
 
Bmi1 as a downstream effector of Shh signalling is highlighted here, thus indicating that Bmi1 is 
required for proliferation and/or self-renewal of cerebellar progenitor cells, in association with N-myc. 
Abbreviations: Shh, Sonic Hedgehog; Ptch, Patched; Smoh, Smoothened.  
 
1.3.3 The role of Bmi1 in medulloblastoma pathogenesis  
 
In agreement with Bmi1 being associated with GNP proliferation during cerebellar 
development as discussed above, there is ample evidence that Bmi1 is implicated in 
pathogenesis of medulloblastoma. Leung et al., demonstrated higher BMI1 
expression in three human MB cell lines and twelve primary human medulloblastoma 
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samples, when compared to normal cerebellum (Leung, Lingbeek et al. 2004). 
Furthermore, in their study, BMI1 overexpression correlated well with overexpression 
of PTCH and SUFU, suggesting that there is SHH pathway activation in BMI1-
overexpressing MB. As they also observed BMI1 overexpression in the fraction 
overexpressing N-MYC, they suggest that BMI1 is not a target for N-MYC. In another 
study, Northcott et al. observed greater than two fold BMI1 expression in more than 
80% of the MBs as compared to normal foetal cerebellum (Northcott, Nakahara et al. 
2009).  
Michael et al., have demonstrated 100% MB formation between P14 and P26 in a 
transgenic mouse model, SmoA1, expressing an oncogenic Hedgehog effector, 
(Michael, Westerman et al. 2008). However, they did not detect MB in any of the 
SmoA1 crossed to Bmi1-/- mice, but only small ectopic cell collections in the regions, 
suggesting that the tumours were initiated but did not undergo expansion. They also 
detected alterations in proliferation and apoptosis in the ectopic cells of 
SmoA1;Bmi1-/-, which were associated with reduced Cyclin D1 and elevated 
expression of p19Arf. These results suggest that Bmi1 is required for progression 
and maintenance of MB and implicate Bmi1 as a key factor in SHH pathway driven 
tumour pathogenesis (Michael, Westerman et al. 2008) 
Wiederschain et al., have demonstrated in a human MB cell line that shRNA-
mediated BMI1 (and Mel-18) knock down resulted in their inhibition of proliferation, 
loss of clonogenic survival and anchorage-independent growth in vitro 
(Wiederschain, Chen et al. 2007). They also show that BMI1 knock down led to 
suppression of tumour formation in vivo. Furthermore, gene expression analysis 
identified a number of cancer-relevant pathways that may be controlled by BMI1 
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(and Mel-18). Altogether, this study highlights the importance of BMI1 (and Mel-18) 
in cancer cell growth (Wiederschain, Chen et al. 2007).  
Recently, Wang et al. have demonstrated the functional relevance of BMI1 as 
downstream target of SHH pathway in human medulloblastoma context (Wang, 
Venugopal et al. 2012). They show that BMI1 expression positively correlated with 
SHH ligand concentrations when stem cell-enriched populations from 
medulloblastoma cell lines and primary medulloblastoma samples were treated with 
SHH ligand and SHH antagonist, cyclopamine. By Chromatic Immunoprecipitation 
(ChiP) assay they show that SHH pathway affector GLI1 preferentially binds to the 
BMI1 promoter, and that BMI1 transcript levels increased or decreased when GLI1 
was overexpressed or downregulated respectively. Furthermore, by knockdown 
experiments of BMI1 in vitro and in vivo, they demonstrated that Shh signalling not 
only drives BMI1 expression, but a feedback mechanism exists wherein downstream 
effectors of BMI1 may, in turn activate SHH pathway genes. These data implicate 
SHH and BMI1 as mutually indispensable pathways in medulloblastoma 
maintenance, and correlates well with the previous evidence of Bmi1 as a 
downstream effector of Shh pathway seen in the context of GNP proliferation.     
Manoranjan et al., have shown that BMI1 is essential for self-renewal and 
tumorigenicity of MB stem cells. In addition to demonstrating that BMI1 knock down 
reduced in vitro self-renewal capacity, they show that overexpression of BMI1 (and 
FOXG1) in CD15+ MB stem cells, generated much larger and more infiltrative 
tumours in vivo, compared to controls xenografts (Manoranjan, Wang et al. 2013).  
1.3.3.1 The role of Bmi1 in Group 4 medulloblastoma    
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Bmi1 is expressed at high levels in human and mouse proliferating GNPs, and at low 
levels in postmitotic granule cells and in adult cerebellum. As Bmi1 is viewed as a 
downstream effector of Shh pathway in relation to GNP proliferation and MB 
pathogenesis (as discussed above), it can be hypothesised that BMI1 expression 
would be enriched in MB tumours driven by SHH pathway mutation (i.e. SHH 
subgroup). However contrary to this expectation, emerging evidence show that 
although BMI1 overexpression is found across all subgroups, it is most highly 
expressed in Group 3 and Group 4 (i.e. Non-SHH/WNT subgroup) tumours.    
Wang et al., having analysed the MB dataset derived from exon array profiling 
(Northcott, Korshunov et al. 2011), show that BMI1 is overexpressed across all MB 
subgroups (compared to normal foetal and adult cerebellum) , but their levels were 
highest in the aggressive subtypes – Group 3 and Group 4 MB (Wang, Venugopal et 
al. 2012). Similarly, Manoranjan et al., having probed four of the existing 
transcriptional databases [Boston (Cho, Tsherniak et al. 2011), Amsterdam (Kool, 
Koster et al. 2008), Toronto (Northcott, Korshunov et al. 2011), and Memphis 
(Thompson, Fuller et al. 2006)), of MB for differential stem cell gene expression 
patterns in the subgroups identified BMI1 (and FOXG1) as being preferentially 
expressed in non-Shh/Wnt MBs.  
Behesti et al. analysed BMI1and TP53 expression in a data set derived from 103 
primary human MBs and 14 normal cerebella. They observed BMI1 overexpression 
in 54% of tumours, relative to median foetal cerebellar levels of expression, which 
occurred across all subgroups of MB. However, BMI1 was found to be most highly 
expressed in Group 4 (with >3-fold compared to median of foetal cerebellar 
expression), followed by Group 3 (>1.93-fold), SHH (>1.92-fold) and WNT (>1.60-
fold) subgroups (Behesti, Bhagat et al. 2013). They also observed a statistically 
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significant enrichment of Group 4 MB across tumours expressing higher levels of 
BMI1 and low levels of TP53. These results are interesting as it was seen that MB 
formation could not be initiated by Bmi1 overexpression alone in mice, and raises the 
possibility that this combination of mutations plays a role in the pathogenesis of 
Group 4 human MBs.  
1.3.4 The role of Bmi1 in systemic carcinogenesis  
 
Bmi1 is ubiquitously expressed in almost all tissues, but it is higher in the brain, 
spinal cord, kidney, gonads, lungs and placenta. Many studies have shown that 
Bmi1 is frequently upregulated in various types of human cancers, including lung 
cancer, ovarian cancer, acute myeloid leukemia, nasopharyngeal carcinoma, breast 
cancer, neuroblastoma and gliomas (reviewed in (Jiang, Li et al. 2009)). As with MB, 
BMI1 is generally associated with aggressive human cancers. Its association is 
known for its principal role in regulating cancer cell proliferation and senescence via 
suppression of p16Ink4a/p19Arf tumour inhibitor pathways (Jacobs, Kieboom et al. 
1999; Jacobs, Scheijen et al. 1999; Meng, Luo et al. 2010). However, studies 
investigating the role of Bmi1 in cancer cell migration and invasive properties have 
also emerged. Bmi1 is shown to induce epithelial-mesenchymal transition (EMT) in 
human nasopharyngeal carcinoma (Song, Li et al. 2009). Suppression of 
endogenous Bmi1 has been shown to reduce cell motility and invasive properties in 
breast cancer cells (Guo, Feng et al. 2011) and in gliomas cells (Jiang, Wu et al. 
2012). Due to its role in cancer stem cell maintenance and self-renewal (Park, Qian 
et al. 2003), Bmi1 has attracted attention as a potential target for cancer therapy.  
BMI1 has been associated with other mechanisms essential to promote EMT and 
tumour initiating capabilities such as Twist1 (Yang, Hsu et al. 2010) and PTEN 
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(Song, Li et al. 2009). BMI1 is known to be transcriptionally regulated by a number of 
factors including SALL4, c-Myc, E2F-1, HDAC, Mel-18 and FoxM1 (reviewed in 
(Cao, Bombard et al. 2011)).  
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1.4 Bone Morphogenetic Proteins and their role in medulloblastoma 
pathogenesis  
 
Bone Morphogenetic Proteins (BMPs) are multi-functional growth factors that belong 
to and form the largest group of the Transforming Growth Factor Beta (TGF-β) 
superfamily. TGF-β family of polypeptides are known to control cellular functions that 
underwrite embryonal development and tissue homeostasis, which act by modifying 
the expression of their target genes (reviewed in (Massague and Chen 2000)). BMP 
and TGF-β signaling pathways seem to act synergistically on various biological 
processes (Miyazono, Maeda et al. 2005). The activity of BMPs was first identified in 
1960s while studying the process of bone induction (Urist 1965), but it was not until 
they were purified and sequenced in 1980s that they were recognised as proteins 
responsible for bone induction [and hence the nomenclature] (Wozney, Rosen et al. 
1988; Luyten, Cunningham et al. 1989).  
1.4.1 BMP signalling pathway 
 
Around twenty different members of BMP family have been characterised in humans 
so far (reviewed in (Chen, Zhao et al. 2004)). Due to their association with 
medulloblastoma (discussed below), BMPs that are important and relevant to this 
project are BMP-2 (gene encoding this, BMP2 is located on chromosome 20p), 
BMP-4 (chromosome 14q) and to some extent BMP-7 (chromosome 20q). The BMP 
signal is mediated through serine/threonine kinase receptors, which are Types I and 
II, with further subtypes. Three Type I receptors have been shown to bind to BMP 
ligands – i) BMPR (BMP receptor) IA, also known as ALK-3, ii) BMPR-IB or ALK-6, 
and iii) ActR-IA (type IA activin receptor) or ALK-2 (ten Dijke, Yamashita et al. 1994). 
Three Type II receptors have also been identified which bind to BMPs, namely i) 
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BMPR-II, ii) ActR-II, and iii) ActR-IIB (Rosenzweig, Imamura et al. 1995). While 
BMPR-IA, IB and II are specific to BMP ligands, the rest of the receptors bind to 
Activins too. Both Type I and II receptors are essential for signal transduction, and 
these receptors are expressed differentially in various tissues. Following ligand 
binding, they form a heterotetrameric, transphosphorylated (activated) receptor-
complex comprising pairs of Types I and II receptors [Fig 1.7] (Moustakas, Pardali et 
al. 2002).  
The signalling cascade is mediated through SMAD (homologue of mothers against 
decapentaplegic, MAD) proteins. Briefly, SMAD family members are intracellular 
proteins involved with TGF-β signal transduction, and comprise of Receptor –
regulated SMADs (R-SMADs, SMAD2/3 and SMAD1/5/8), common partner SMADs 
(co-SMADs, SMAD4) and inhibitory SMADs [I-SMADs, SMAD6/7]  (reviewed in 
(Miyazono, ten Dijke et al. 2000)). R-SMADs are anchored to the cell membrane. 
Upon BMP receptor complex activation, R-SMADs are phosphorylated (pSMADs) 
and form oligomeric complexes with co-SMADs (SMAD4).  
The BMP receptors phosphorylate SMAD1, 5 and 8 (to form pSMAD1,5,8) in a 
ligand-dependent manner, and this is thought to be a reliable indicator of BMP 
pathway activation (Hoodless, Haerry et al. 1996; Chen, Bhushan et al. 1997; 
Nishimura, Kato et al. 1998; Grimmer and Weiss 2008). The pSMAD and SMAD4 
oligomeric complexes then translocate into the nucleus, where they regulate the 
transcription of their target genes by direct binding to DNA, interaction with various 
DNA-binding proteins, and recruitment of transcriptional co-activators or repressors. 
The BMP signalling pathway is represented in Fig 1.7.  
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Fig. 1.7 BMP - SMAD signalling pathway. 
 
Upon BMP ligand stimulation, the BMP receptors (BMPR Types I and II) are activated by 
phosphorylation. In turn, these receptors phosphorylate intracellular receptor-regulated SMAD 
proteins (pSMADs). The pSMADs form a complex with SMAD4 (co-SMAD) and the complex 
translocates into the nucleus to act as transcriptional regulators on target genes. Noggin and 
Dorsomorphin are some of the BMP pathway inhibitors. This is a simplified structure of the pathway 
and highlights only BMP-2/4 mediated signalling via SMAD1,5,8.    
 
The target genes of BMP pathway are numerous and  variable (reviewed in 
(Miyazono, Maeda et al. 2005)). Among the target genes, Id (inhibitor of 
differentiation or inhibitor of DNA binding, Id1-4) are known to be one of the most 
important targets of BMP (Ogata, Wozney et al. 1993).  Peng et al. have revealed by 
expression profiling analysis, that the most significantly upregulated (target) genes 
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upon BMP-2 (and BMP-6 or BMP-9) stimulation are Id1, Id2, and Id3 (Peng, Kang et 
al. 2004). Other target genes induced by BMP-2/BMP-4 include TEIG-1 (TGF-B-
early inducible gene 1), Msx1, GATA2 and Snail (Miyazono, Maeda et al. 2005). 
Since the I-SMADs, induced by the TGF-beta superfamily proteins, inhibit the BMP 
receptor mediated signalling, they are thought to have an auto-inhibitory signalling 
role.  The functions of SMADs can also be regulated by other signalling pathways, 
such as the MAP kinase pathway. SMADs interact with and modulate the functions 
of various transcription factors which are downstream targets of other signalling 
pathways.  
1.4.2 Functional relevance of the BMPs/BMP pathway 
 
BMPs play an important role in embryonic development as well as in regulation of 
post-natal cellular functions. Their best characterized roles include regulation of 
lineage commitment, differentiation, proliferation, patterning or morphogenesis, 
cellular maintenance/survival and apoptosis (Hogan 1996). With regards to bone 
development, they are known to be involved in intramembranous and endochondral 
bone formation, as well as cartilage formation (Reddi 1981; Wozney and Rosen 
1998). BMPs are known to have broad roles in regulating the biology of stem cells 
and in maintaining embryonic stem cells (Varga and Wrana 2005). With regards to 
the role of BMPs in cancer, there are contradictory reports in different cancers. 
Thawani et al., have published a literature review after evaluating MEDLINE, 
EMBASE and Cochrane databases, and conclude that there is no definitive 
association between BMPs and the promotion of tumorigenesis or metastasis 
(Thawani, Wang et al. 2010). Few  examples of the contradictory reports  on the role 
of  BMPs in cancers include: BMP-2 and/or BMP-4 were shown to promote 
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tumorigenesis and metastasis in breast carcinoma (Raida, Clement et al. 2005), lung 
carcinoma (Langenfeld, Calvano et al. 2003), prostate cancer (Ye, Lewis-Russell et 
al. 2007), ovarian cancer (Shepherd, Theriault et al. 2008), osteosarcoma (Arihiro 
and Inai 2001) and medulloblastoma (Iantosca, McPherson et al. 1999) but they 
were also shown to have the opposite effects on same cancers, in different studies 
[using different models of study] (Soda, Raymond et al. 1998; Zhao, Ayrault et al. 
2008). Similarly the roles of other BMPs such as BMP-6, BMP-7 and BMP receptors 
(BMPR Types I/II) are also shown to have contradictory roles in different cancers 
(reviewed in (Thawani, Wang et al. 2010).   
From the above evidence, we feel that the role of different BMPs in each cancer 
should be considered and interpreted individually.   
 
1.4.3 BMPs in cerebellar development  
 
During cerebellar development the BMPs, in particular, BMP-2 and BMP-4 inhibit 
SHH-induced GNP proliferation, resulting in GNP differentiation, whereas BMP7 has 
the opposite effect (reviewed in (Behesti and Marino 2009)).  
It is shown that  BMPs induced Math1 expression and that BMP-treated GNPs 
formed mature granule neurons upon transplantation into early postnatal cerebellum 
(Alder, Lee et al. 1999). The above evidence highlights the role of BMPs in fate 
specification of GNPs. Expression of BMP-4 and Smad1 have been demonstrated in 
the EGL of rat cerebellum at early postnatal stages, and BMP-4 was shown to 
promote neuronal and astroglial differentiation of cerebellar cell cultures, suggesting 
that BMP-4 (via SMAD1 signalling) participate in regulating postnatal cerebellar 
differentiation (Angley, Kumar et al. 2003). Rios et al. have shown using mouse and 
chick embryos, that BMP-4 (in EGL), to a lesser extent BMP-2 (in IGL) and BMP-7 
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(in Purkinje cells, which also produces Shh) are expressed in the developing 
cerebellar cortex (Rios, Alvarez-Rodriguez et al. 2004) . Furthermore they 
demonstrate that BMP-2 and BMP-4, significantly antogonised Shh-induced GNP 
proliferation in vitro and ex vivo, with a slightly opposite effect with BMP-7, and that 
BMP-2 mediated GNP differentiation via Smad5 signalling. Later in a separate study 
they also showed that BMP-2 antagonizes Shh-dependent proliferation by 
expressing TIEG-1 which directly represses N-myc transcription (Alvarez-Rodriguez, 
Barzi et al. 2007). Zhao et al. have shown that BMPs antagonize Shh-dependent 
proliferation and induce differentiation of GNPs (Zhao, Ayrault et al. 2008). 
Furthermore they demonstrate that BMP treatment led to downregulation of 
Atoh1/Math1 protein, and that this occurred in a post transcriptional manner.  
 
Recently, our group have demonstrated that Bmi1 controls cellular interactions 
between granule and glial progenitors during cerebellar development through 
repression of the BMP pathway (Zhang, Santuccione et al. 2011). 
 
1.4.4 BMPs are potential targets for medulloblastoma treatment   
 
In keeping with the above discussion regarding the role of BMPs in inhibiting GNP 
proliferation and induction of differentiation, there is emerging evidence to suggest 
that BMPs, in particular BMP-2 and BMP-4, inhibit medulloblastoma growth 
(reviewed in (Roussel and Hatten 2011)).  
Math1/Atoh1 has been demonstrated to be essential for MB development (Flora, 
Klisch et al. 2009), and has been shown to collaborate with Gli1 to transform normal 
GNPs into tumor initiating cells (Ayrault, Zhao et al. 2010). Gene profiling of mouse 
and human MBs with a constitutively activated SHH pathway revealed that most 
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genes within the BMP signalling pathway are downregulated in tumours compared to 
proliferating GNPs and neurons, whereas Math1/Atoh1 levels were high (Zhao, 
Ayrault et al. 2008). Moreover, in addition to showing that BMPs inhibit (Shh-
dependent) proliferation and induction of differentiation of GNPs and GNP-like MB 
cells, they show that BMP-2 and BMP-4 suppress primary murine MB cell growth in 
vivo (Zhao, Ayrault et al. 2008).  GNP-like tumour cells from the murine MBs were 
infected with retroviral vectors co-expressing human BMP4 and tumour allografts 
were generated using athymic mice. They observed a smaller tumour size among 
BMP4 co-expressing tumours compared to controls. Importantly, they also observed 
that the tumour allografts failed to grow when the cells were pre-treated in vitro with 
BMP-4 (for 3 days), whereas allografts of untreated cells grew quickly. In this study 
they also go on to demonstrate that BMP-4 and cyclopamine (Shh inhibitor) 
treatment in combination, achieved tumour inhibition at lower concentrations as 
compared to treatment with either method alone, suggestive of potential therapeutic 
role of BMP agonists.  
 
Hallahan et al., have demonstrated that retinoids [all-trans retinoic acid (ATRA), 
RAR-α agonist (AGN195183) or RAR-β/γ agonist (tazarotene)] induced a significant 
apoptosis in seven of nine (77%) primary human medulloblastoma cells  compared 
to vehicle only treatment. The two with no significant apoptosis were of large cell 
type and showed neuronal differentiation in response to retinoids (Hallahan, 
Pritchard et al. 2003). Gene expression array of human MB cell lines treated with 
retinoids revealed that BMP-2 was one of the small set of genes (related to 
apoptosis) that were induced in retinoid-sensitive cells only. BMP-2 is known to be a 
mediator of retinoid-induced apoptosis in several developmental paradigms 
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(Rodriguez-Leon, Merino et al. 1999) and it is known to induce apoptosis in myeloma 
cells (Kawamura, Kizaki et al. 2000). Retinoid treatment (ATRA) increased BMP-2 
expression in primary MB cells, and furthermore, addition of BMP-2 resulted in 
significant apoptosis of primary MB cells and cell lines in a time and dose dependent 
manner. The above observations support the notion that BMP-2 mediates retinoid-
induced apoptosis in medulloblastoma (Hallahan, Pritchard et al. 2003). In this study 
they also show that BMP antagonist noggin blocked both retinoid and BMP-2 
induced apoptosis and that BMP-2 induced p38 mitogen-activated protein kinase 
(MAPK), which may be necessary for BMP-2 and retinoid-induced apoptosis in MB. 
This was the first study to show that BMP-2, as a secreted protein mediates 
apoptosis in medulloblastoma cells that express or do not express BMP-2  
 
Similar to the above study, Spiller et al., used human MB cell lines and genetically 
engineered mouse models to show that 13-cis Retinoic acid in combination with 
suberoylanilide hydroxamic acid (SAHA, a histone deacetylase inhibitor), induced 
BMP-2 mediated MB apoptosis (Spiller, Ditzler et al. 2008). They observed a 3-fold 
increase in BMP-2 transcription when Retinoic acid (RA) was added to the MB cell 
(D283) culture and 7-fold with both agents. Although the induction of p38 MAP 
kinase partially blocked the apoptotic activity of RA alone, there was no inhibition of 
RA + SAHA activity, indicating a separate mechanism for SAHA mediated apoptosis. 
Furthermore, the tumour cell graft in athymic mice showed a slower growth when 
orally treated by RA + SAHA, compared to single drug controls. In addition, tumours 
arising in the background of ND2:SmoA1 mice treated with RA + SAHA + cisplatin 
showed a 4-fold increase in apoptosis over controls. Retinoic acid acts by 
transcriptionally activating BMP-2 and SAHA facilitates transcriptional activity 
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through chromatin accessibility. Both drugs cross the blood brain barrier, have been 
given safely to children, and achieve brain concentrations that are at or near 
therapeutic levels (Miller 1998; Spiller, Ravanpay et al. 2006). 
 
In the context of a different aggressive brain tumour, but related to BMPs, Piccirillo et 
al., show that BMPs, amongst which BMP4 had the strongest effect, trigger a 
significant reduction in the stem-like, tumour-initiating precursors of human 
glioblastomas [GBMs] (Piccirillo, Reynolds et al. 2006). Even transient in vitro 
exposure to BMP-4 rendered the GBM cells incapable of generating in vivo tumours. 
Importantly, in vivo delivery of BMP-4 effectively blocked the tumour growth in 
intracerebral grafted mice. They demonstrate that BMPs acted through SMAD 
signalling cascade and in vitro they led to reduced proliferation, increased 
differentiation and reduced clonogenic ability.  
 
The above evidence is suggestive that BMPs (or BMP analogues/ 
agonists/activators) could represent therapeutic targets in the development of novel 
drugs for the treatment of aggressive brain tumours including medulloblastoma.  In a 
recent study, Vrijens et al., have reported identification of small molecule activators 
of BMP signaling (Vrijens, Lin et al. 2013). Using a BMP-responsive clone C33A-
2D2, they have screened a bioactive library containing approximately 5,600 small 
molecules. They have identified four small molecules of the flavonoids family, two of 
which (isoliquiritigenin and 4’hydroxychalcone) induced phosphorylation of SMAD1/5 
and Id1/Id2 expression in a dose-dependent manner. Although the suitability of these 
molecules for treatment is yet to be established, they support the notion that 
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BMPs/BMP pathway could be targets for the treatment of MB in the foreseeable 
future.    
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1.5 Hypothesis and aims of the study 
 
1.5.1 Hypothesis 
 
In this project, we want to test the hypothesis that:  
Repression of the BMP signalling pathway through BMI1 is an essential event in 
human medulloblastoma pathogenesis, potentially through deregulation of cell 
adhesion and of cell-cell or cell-extracellular matrix interactions, and that BMI1 
expression could be a potential bio-marker for the identification of MB which could 
profit from treatment with BMP analogues.  
 
1.5.2 Aims 
 
This aims of this study are: 
i) To analyse the impact on the BMP pathway of BMI1 downregulation in MB cell 
lines and in primary human MB cells of Group 4,  
ii) To study any functional changes in particular those related to cell adhesion or cell 
migration properties in vitro and in an ex vivo organotypic cerebellar co-culture 
model 
iii) To study the effects of BMI1 downregulation in primary human MB cells on BMP 
pathway in vivo in a xenograft model 
iv) To use primary human MB tumour samples to assess any correlative expression 
of BMI1 and BMP pathway activation   
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CHAPTER 2 General Materials and Methods    
   
2.1 Production of lentivirus vector for shRNA delivery  
 
Stable BMI1 gene silencing (knock down) in MB cells was achieved by short hairpin 
RNA (shRNA) technology (Brummelkamp, Bernards et al. 2002; Yu, DeRuiter et al. 
2002) using a lentivirus-based delivery system (Rubinson, Dillon et al. 2003) . The 
glycerol stock of human GIPZ lentiviral shRNAmir BMI1 constructs (Open 
Biosystems) containing a CMV-driven GFP reporter and seven clones of target 
sequences of human Hs BMI1 (NM_005180) was used. The glycerol stocks of 
pGIPZ scrambled, HIV1 and VSVG, also containing GFP reporter, were a gift from 
Dr Paolo Salomoni’s group in UCL. The latter vectors were used to package BMI1 
shRNA construct.  
2.1.1 Purification of Plasmids:  
 
First, plasmids were purified from the above mentioned glycerol stocks using 
QIAfilter maxikit (Qiagen) to yield low-copy plasmids.   
Luria broth (LB) (Invitrogen) which contains peptone 140, yeast extract and sodium 
chloride, was diluted in sterile H2O to prepare 200 ml of LB solution in each of 4 
glass flasks. The flasks were autoclaved and after cooling, ampicillin (Sigma) 100 
μg/ml was added to each of the flasks to allow selection of ampicillin resistant 
bacterial growth. A small amount of each bacterial glycerol stock was scraped with a 
20 μl pipette and added into separate LB containing flasks and labelled. The 
openings of the flasks were sealed with paraffin film and were incubated at 370C 
overnight on a rocker set at 220 rpm, ensuring vigorous shaking until the broth 
turned turbid due to bacterial proliferation. The broth containing the respective 
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bacterial culture were transferred to labelled large centrifuge tubes and centrifuged 
at 6000 rpm for 15 min at 40C. After removal of the excess broth medium by careful 
suction, the pellets were either temporarily stored (for up to 2 weeks) at -200C or 
used immediately for plasmid purification.        
The bacterial pellets of the respective vectors were resuspended in each tube with 
10 ml Buffer PI (after adding RNase A to Buffer P1) at room temperature. The tube 
containing the pellet is vortexed and pipetted thoroughly and ensured that no clumps 
remained. 10 ml of Buffer P2 was added to each tube, mixed by vigorously inverting 
the tubes 4-6 times and incubated at room temperature for 5 min. The resulting cell 
suspension after adding Buffer P2 turned blue homogeneously. The tubes were not 
vortexed at this stage to avoid DNA damage. 10 ml of pre chilled lysate Buffer P3 
was added and mixed immediately by vigorous inverting 4-6 times until the blue 
colour disappeared. The resulting lysate was poured into QIAfilter cartridge (with 
capped outlet nozzle) and incubated at room temperature for 10 min. A precipitate 
(containing proteins, genomic DNA, and detergent) formed as a layer on top of the 
solution. Qiagen-tip 500 was equilibrated with 10 ml of Buffer QBT and the column 
was allowed to empty by gravity flow. The cap from the QIAfilter cartridge was 
removed from the outlet nozzle and the plunger was gently inserted into the cartridge 
to filter the cell lysate into the previously equilibrated Qiagen-tip. Approximately 25 
ml of cell lysate was recovered. The cleared lysate was allowed to enter the resin by 
gravity flow. The Qiagen-tip was washed with 30 ml Buffer QC twice (using gravity 
flow). The DNA was eluted with 15 ml Buffer QF, and the elute was collected in 50 
ml falcon tube. The elute was either stored temporarily at 40C overnight or used 
immediately to precipitate the plasmid DNA. 10.5 ml of isopropanol was added to the 
elute and mixed to precipitate the plasmid DNA. The tube was centrifuged at 15000 
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rmp for 30 min at 40C. The supernatant was carefully removed. The DNA pellet was 
washed with 5 ml of 70% ethanol (to remove precipitated salt and to replace 
isopropanol) and centrifuged at 15000 rpm for 10 min at 40C. The supernatant was 
carefully removed without disturbing the pellet. The site of the pellet was marked on 
the outside of the tube and the pellet was air dried for 5-10 min. The pellet was then 
dissolved with 200 μl of filtered sterile water and temporarily stored in labelled 
eppendorfs at -800C. The process of purification of plasmid DNA is summarised in 
Fig 2.1 A. 
2.1.2 Determination of yield:  
 
The concentration of the plasmid DNA was determined both qualitatively and 
quantitatively by agarose gel analysis and by spectrometry respectively.  
Agarose gel 0.8% was prepared by heat dissolving 0.48 g of Agarose gel powder 
(Starlab) with 60 ml of 1 X TAE buffer (Qiagen) and adding 4.8 μl of ethidium 
bromide. The gel solution was poured into the electrophoresis chamber and allowed 
to set for 10 – 15 min. The 4 DNA samples (10 μl each) were mixed with 3 – 4 μl of 
dye and loaded into the wells along with 1Kb ladder (10 μl). The electrophoresis was 
performed at 80 – 100 V for 30 min. The gel was photographed in the UV chamber to 
detect the bands – pGIPZ, BMI1 and HIV vectors at ~ 8000 bp and VSVG at ~ 6000 
bp (Fig 2.1 B). 
The yield of DNA was quantitated using NanoDrop spectrometry (Thermo scientific) 
by selecting Nucleic Acid DNA-50 measurement after normalising with distilled water 
(blank). The measurements are shown in Fig 2.1 B.     
2.1.3 Packaging:  
 
92 
 
The purified plasmids were then packaged (Chang, Marran et al. 2013) using 
HEK293T cells (discussed in section 2.2.4) to produce lentiviral particles. The 
procedure is categorised as Class II biohazard level and was therefore carried out in 
Genetic Modification Organisms (GMO) suite after appropriate risk assessment 
under GMO regulations 2000 (Project Ref. no 774/0801/07). On day 1, HEK293T 
cells were plated at a density of 5 – 6 x 106 cells in 20 ml of IMDM medium (Gibco) 
enriched with glutamate, 10 % FBS and 1% penicillin/streptomycin (sigma) in 15 cm 
culture dish. Two culture dishes for each virus were prepared. The cells were 
incubated for 12 – 24 hr at 370C with 5% CO2.  On day 2, the transfection mix was 
prepared in a falcon tube with quantities mentioned in Table 2.1.  
Table 2.1 Preparation of transfection mix for lentiviral packaging. 
Contents Quantity for one 15 cm dish 
 
Transfer vector pGIPZ (with or without shRNA) 28 μg 
pCMV-G (VSV-G) 8.4 μg 
pCMV-HIV1 18.1 μg 
2.5M CaCl2 140 μl 
Filtered H2O To make up to 1 ml 
2X HBS 
(NaCl, HEPES, Na2HPO4, pH 7.12) 
1 ml  
(added drop wise while vortexing 
the rest of the mix) 
 
The transfection mix (2 ml) was immediately added to the cell culture dish gently 
along the side wall of the dish. The dish was gently shaken several times in all 
directions to ensure thorough mix. The cell culture medium was replaced with 25 ml 
fresh medium 8 – 16 hr after transfection. On day 3, the transfected cells were 
checked under UV microscope and showed HEK293T cells positive for GFP 
fluorescence (Fig 2.1 C). On day 4 (48 hr post transfection), the supernatant from the 
cell culture dish (2 dishes per each virus) was collected in 50 ml falcon tube and 
centrifuged at 3000 rpm for 5 min to remove cells and cell debris. The resulting 
supernatant was filtered through a 0.45 μm PVDF filter to further eliminate cellular 
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debris. The filtered supernatant was transferred to a sterile falcon tube and the viral 
particles were precipitated by adding cold 5X polyethylene glycol (PEG) solution. 
The PEG solution was prepared by mixing polyethylene glycol (Sigma), NaCl, Tris 
1M, pH 7.5 and H2O. The tubes were stored overnight at 4
0C.   
On day 5, the supernatant and PEG mixture was centrifuged at 1500 g for 30 min at 
40C to obtain the viral pellet. The supernatant was aspirated and the tube was 
centrifuged again at 1500 G for 5 min to remove any traces of residual PEG solution. 
The supernatant was carefully removed by aspiration. The lentiviral pellet was 
diluted with 1000 μl (1:50 dilution compared to original volume which was 50 ml) of 
cold sterile PBS and resuspended to dissolve the pellet. The lentiviral suspensions 
were aliquoted in labelled cryovials and stored at -800C until further use. 
2.1.4 Titration:  
 
0.5 x 105 HEK293T cells were plated in each well of a 12 well plate with 1 ml IMEM 
medium and incubated for 24 hr at 370C, 5 % CO2. Six wells were prepared per viral 
stock to be titrated (including one well as negative control) ensuring that the cells 
were uniformly distributed within the well. It was estimated that the cell number is 
doubled after 24 h in culture. Five serial dilutions of each viral stock were prepared 
as follows – dilution 1 (1:10): 110 μl of virus to 990 μl of medium, dilution 2: (1:100) 
100 μl from dilution 1 to 900 μl of medium, dilution 3 (1:1000): 100 μl from dilution 2 
to 900 μl of medium, dilution 4 (1:10,000): 100 μl from dilution 3 to 900, dilution 5 
(1:100,000): 100 μl from dilution 4 to 900 μl of medium. The medium in the five cell 
culture wells were replaced with 1 ml of corresponding serial dilution and labelled. 1 
ml of media without virus was added to the sixth well (negative control). The infected 
cells were incubated for 12 – 24 hr at 370C, 5 % CO2. The media was replaced with 
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fresh media after 12 – 24 hr. After 96 hr post infection, the cells were collected in 
FACS tubes for flow cytometry to analyse the percentage of lentivirus infected cells 
which would be GFP positive. Following the flow cytometry analysis, the titre of viral 
stock in calculated as transducing units/ml (TU/ml) as per the formula:  
[(% GFP positive cells) x (number of cells infected)] / [(volume of virus in ml) x 
(dilution)] 
The final titre of the lentivirus prepared ranged 2.5 – 11 x 108 TU/ml. 
 
Fig. 2.1 Lentivirus production and packaging.  
 
(A) Schematic of plasmid purification using QIAfilter maxikit. (B) The yield of plasmids determined 
qualitatively by agarose gel analysis (left panel) which shows plasmid bands at 6-8 Kbp, and 
quantitatively (right panel) showing the concentration of each plasmid. (C) Packaging of lentiviral 
particles using HEK293T cells which show marked GFP positivity 24 hr after treating them with the 
transfection mix. Scale bars in C = 100 μm  
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2.2 Cell culture   
 
2.2.1 General methodology 
 
2.2.1.1 Thawing:   
 
The frozen aliquots of cells stored in liquid nitrogen were transported on dry ice and 
incubated in the 370C water bath. The vials were gently shaken during the incubation 
until the cells were completely thawed. The thawed cells were immediately 
transferred to 15 ml falcon tubes containing 10 ml pre-warmed media and 
centrifuged at 1000 rpm for 5 min. The resulting supernatant was carefully discarded 
and the cells were resuspended in 1-2 ml of appropriate media and pipetted to 
dissociate the cell pellets. While the cell lines were pipetted using standard 1 ml 
pipette tip, the primary cells were pipetted using 200 μl fine tip pipettes to achieve 
adequate dissociation.  The dissociated cells were transferred to a 10 cm tissue 
culture dish (cell lines) or a 6 well plate (primary cells) containing appropriate media 
for culture. The cell culture plates were incubated at 370C, and were replaced with 
fresh media after 12 - 24 h.  
2.2.1.2 Sub culture:  
 
The cells were sub cultured (split or passaged) when > 90% confluence was reached 
– which was 3-4 days for the cell lines and 5-7 days for the primary cells. The non-
adherent or loosely adherent (primary cells, D-458) cells were gently scraped off the 
culture dish using a cell scraper. The adherent (DAOY and HEK293T) cells were first 
washed with PBS and detached using pre-warmed 1% trypsin EDTA solution 
(Sigma) followed by neutralization of trypsin by serum containing medium. The cells 
were collected in a 15 ml falcon tube, centrifuged and resuspended as above. The 
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cells were sub cultured at a ratio of 1:3 to 1:8 dilutions. The cell culture plates were 
incubated at 370C, and were replaced with fresh media after 12 - 24 h. The primary 
cells were maintained in in vitro culture for a limited number of passages, up to 4-5 
weeks.      
2.2.1.3 Cell count:  
 
The cell count was performed using Neubauer haemocytometer. A glass coverslip 
was placed over the haemocytometer chamber and 10 μl of dissociated cell 
suspension was introduced under the coverslip. Using an inverted bright field 
microscope (X20 mag.) the number of cells in the peripheral 4 squares of the 
chamber was counted. The average cell count from the total count was calculated 
which gives the cell count per ml. The average count was multiplied by the original 
volume of the media (number of ml) to obtain the final cell count. Non-viable cells 
were excluded from the counting by the Trypan blue method (Strober 2001), where 
the cells were treated with 0.4% trypan blue solution at 1:5 dilutions for 5 min, and 
only the viable clear (unstained) cells were counted using haemocytometer as 
above.     
2.2.1.4 Screening for Mycoplasma contaminants:  
 
The cell were checked for any Mycoplasma contamination using Mycoalert™ 
detection kit (Lonza) which is a biochemical test to detect the Mycoplasma enzymatic 
activity in the cell culture supernatants. The reagent and buffer were reconstituted 
with 600 μl of buffer and incubated for 15 min at RT according to manufacturer’s 
instructions. The supernatant from the cell culture media were collected and spun at 
1500 rpm for 5 min. 100 μl of clear supernatant were placed in Brand 96 well plates 
and 100 μl of reagent was added to each well, incubating for 5 min at RT. The 
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luminescence (referred to as A) was measured using microplate reader. 100 μl of 
substrate was added to each sample and incubated for 10 min at RT. The 
luminescence (referred to as B) was detected. The ratio B/A was calculated. If the 
ratio was > 1 then the test was considered to be positive and the cells were 
discarded. If the ratio was < 1 it was considered negative for contamination and the 
cells were cultured for further studies.   
2.2.1.5 Cryopreservation:  
 
The cells were harvested from culture, counted, and centrifuged as described  
above. 1 – 5 x 106 cells were diluted in 1 ml freezing medium containing 10% DMSO 
and 20% FBS in DMEM medium. The cells were then transferred in to labelled 
Nunc® cryovials (Thermo Scientific) and the vials were gradually cooled by placing 
them in Mr Frosty freezing container (Thermo Scientific) which was filled with 
isopentane along the lining of the container and kept -800C freezer for 24 hr. The 
frozen cells were transported on dry ice and stored in liquid nitrogen.   
2.2.2 Medulloblastoma cell lines   
 
Established human MB cell lines UW228-2, D-425, D-458, D-341 and DAOY were 
obtained from American Type Culture Collection (ATCC). DAOY and D-458 were 
used for functional studies in this project. The DAOY cell line was originally 
established by P.F Jacobsen from Royal Perth Hospital in 1985 (Jacobsen, Jenkyn 
et al. 1985). It was derived from desmoplastic medulloblastoma originating in 
cerebellum from a 4 year old boy. Although the original tumour exhibited neuronal 
and glial differentiation, the cell line did not retain either of them. They are polygonal 
cells which grow as adherent monolayer cultures in vitro (Fig 2.2 A).  D-458 is known 
to have predominantly neuronal phenotype (He, Wikstrand et al. 1991) and grow in 
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suspension mainly as multicellular aggregates with some cells also adhering to the 
bottom of the dish (Fig 2.2 B). All MB cell lines were cultured and maintained in 
Improved MEM media (Gibco) containing L-lysine and Glutamate, supplemented 
with 10% FBS (Gibco), 1 % penicillin/streptomycin (Sigma). Prior to passaging, 
DAOY cells were detached using 1% trypsin EDTA (Gibco) and D-458 were gently 
scraped off the culture dish. 
2.2.2.1 Small interfering RNA (siRNA) transfection:  
 
Transient BMI1 gene silencing (knock down) was achieved by siRNA technology 
(McManus and Sharp 2002; Schutze 2004) in which transfection was carried out 
using cationic and neutral lipid based transfection method. FlexiTube siRNA 
(Qiagen) specific for BMI1, containing a mix of Hs BMI1 1, Hs BMI1 2 and Hs BMI1 3 
(also known as Polycomb Ring Finger 4, PCGF4) was used. All Stars Negative 
siRNA (Qiagen), referred to as scrambled (Scr) was used as control. The 
transfection mix in combination with HiPerFect Transfection Reagent (Qiagen) was 
prepared as detailed in Table 2.2. DAOY or D-458 (0.5 – 1 x 105 cells in 420 μl of 
media) were plated in each well of a 24 well plate. After 12 – 24 h incubation, and 
when 70-80% confluence was achieved, the cells were treated with siRNA 
transfection mix (~83 μl/well) at a final concentration of 30 nM and gently mixed.  
The transfected cells were incubated for 48 hr prior to functional studies for 
maximum knock down efficiency, as assessed by Western blot and qRT-PCR 
analysis.  
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Table 2.2 BMI1 siRNA transfection mix preparation*. 
Reagent  Scrambled (per well) Bmi1 SiRNA (per well) 
 
 
Medium 
 
80 μl 
 
80 μl 
 
Hi Perfect Transfection reagent 
 
3 μl 
 
3 μl 
 
Negative 
 
0.72 μl 
 
- 
SiRNA kit (Quiagen) 
1. Hs BMI1 1 
2. Hs BMI1 2 
3. Hs BMI1 3 
 
 
- 
 
0.24 μl 
0.24 μl 
0.24 μl 
(Total of 0.72 μl) 
Total volume 83.72 μl 83.72 μl 
 
*To obtain a final concentration of 30 nM. 
 
   
2.2.3 Primary human medulloblastoma cells  
 
Primary human MB cells  ICb-1299, were obtained from Dr Xiao-Nan Li, Baylor 
College of Medicine, Texas Children’s Cancer Centre, USA. These cells were 
isolated from primary MB tumours arising in cerebellum in a 2.8 year old girl who 
underwent surgery at the Texas Children’s Hospital. The tissue was obtained in 
regulation with local institutional review board policy and appropriate consent. The 
original tumour was diagnosed as an anaplastic MB, stage M3. The tumour cells 
were maintained as intracerebellar xenografts in mice after orthotopic transplantation 
of fresh tumour (Shu, Wong et al. 2008). Genetic profiling of the original tumour and 
of the primary cells has classified them as Group 4 (Northcott Group D) MB (Zhao, 
Liu et al. 2012). For expansion and knock down studies, these cells were cultured in 
Dulbecco’s Modified Eagle Medium (D-MEM) with high glucose (Gibco) 
supplemented with 10% FBS (Gibco) and 1% Penicillin/Streptomycin (Sigma). The 
cells grew in suspension mainly as multicellular aggregates (tumour spheres) with 
some cells also adhering to the bottom of the dish (Fig 2.2 C). 
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Fig. 2.2 Cells in culture. 
 
(A) DAOY cells which grow as an adherent monolayer. Relatively larger size and polygonal shape of 
the cells is evident. (B) D-458 growing in suspension mainly as multicellular aggregates but also 
showing some adherence to the floor of the dish (C) short term cultures of ICb-1299 which grew in 
suspension mainly as tumour spheres. Scale bars in A,B and C = 200 μm. 
 
2.2.3.1 Infection with lentivirus shRNA and stable selection  
 
Stable BMI1 silencing was achieved by shRNA technique using lentiviral vectors. 
Both DAOY and ICb-1299 were infected with shRNA BMI1 lentivirus, and a separate 
cohort of cells were infected with shRNA scrambled (Scr) lentivirus to be used as 
controls. Multiplicity of infection (MOI) is defined as the number of virions that are 
required to infect each cell.  
The formula to calculate MOI = [μl of viruses used X titration in TU/μl]/no. of cells 
transduced.  
Having calculated the titres of each virus group (after packaging, described in 
section 2.1.4), we decided to carry out infection at high MOI (based on Poisson 
distribution) in order to achieve adequate infection. First, the cells were harvested 
from cultures, mechanically dissociated and plated at a density of 1 x 106 cells on a 
10 cm culture dish. Having calculated the titres of each virus group, the cells were 
infected at MOI of 12.5 for DAOY and MOI of 25 for ICb-1299, and incubated at 370C 
for 24 hr. The media was then replaced with fresh media and the cells were 
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incubated for a total of 72 hr from the time of infection. The cells were then checked 
for GFP expression under UV microscope. There were > 90% cells showing GFP 
positivity. The cells were harvested 72 hr post infection and the GFP positive 
(infected) cells were selected for stable culture.  
Initially, stable selection by Puromycin was attempted. 1 x 105 cells in 1 ml media 
were plated in each well of 24 well plate and Puromycin (Sigma) was added to the 
wells at increasing concentrations – 1 μg/ml, 2 μg/ml, 3 μg/ml, 4 μg/ml and 5 μg/ml. 
The cells in all the wells including that of the lowest concentration failed to survive 
possibly due to drug toxicity. Therefore this method for stable selection was 
discontinued. 
The lentivirus treated cells were selected for stable cultures by fluorescent activated 
cell sorting (FACS) by flow cytometry. The procedure was carried out with the help of 
Dr Gary Warnes, manager of the flow cytometry core facility, Blizard Institute, Barts 
and the London school of Medicine and Dentistry.  The procedure was carried out as 
per the COSSH biohazard risk assessment protocol. The lentiviral infected cells 
were harvested from their cultures (in sterile PBS at density of 5 x 106 cells/ml sterile 
PBS) and collected in FACS tubes through a filter to remove any debris. The cells 
were passed through the flow cytometer machine BD FACS Canto II analyser aided 
by FACS Diva™ v6.1.3 software (BD Biosciences) set for 488 nm excitation and 509 
nm emission FITC fluorochrome gate (Fig 2.3). The GFP positive cells were 
collected, washed with PBS and incubated at 370C in complete medium. The cells 
were incubated for at least 96 hr prior to expansion or use for further studies.  
The efficacy of knock down was assessed by western blot and qRT-PCR analysis at 
multiple time points after passaging. 
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BMI1 knock down studies on DAOY and D-458 MB cell lines to investigate BMP 
pathway activation by immunofluorescence and to demonstrate cell aggregate 
formation were performed using siRNA method. All other knock down experiments 
were conducted following lentiviral mediated shRNA method.  
 
Fig. 2.3 Selection of stable shRNA transfected cells by FACS.  
 
The FITC gate (P3) was set to select only lentivirus shRNA infected  cells which expressed GFP. 
Approximately 25% of the cells were selected from (A) DAOY population, and approximately 10% of 
the cells were selected from (B) ICb-1299 population. In each, left panel is for shRNA Scr and right 
panel is for BMI1 shRNA. The selected cells were allowed to recover for at least 96 hr prior to 
expansion or use for further studies.       
 
2.2.4 HEK293T cells  
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HEK293T (human embryonic kidney) cell lines used for packaging of lentiviral 
vectors were obtained from Denise Sheer’s group in our institute (Jones, 
Ogunkolade et al. 2011). HEK293T cells were chosen for packaging because 
compared to HEK293 cells, HEK293T cells constitutively express SV40 large T 
antigen, are neomycin resistant and have better transfectability (Pear, Nolan et al. 
1993).  
These cells were cultured using IMDM media enriched with 10% FBS, and 1% 
penicillin/streptomycin and passaged when they reached confluence of  >90%. Prior 
to passaging, they were detached using 1% Trypsin EDTA.  
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2.3 Activation and inhibition of BMP pathway 
 
To assess if the functional effects of BMI1 silencing were BMP signalling dependent, 
we concomitantly used BMP pathway inhibitor (for DAOY and D-458) or recombinant 
BMPs (for DAOY) in in vitro studies.    
2.3.1 Recombinant BMP-4 
 
Use of recombinant BMP-2 and/or BMP-4 for BMP pathway activation is well 
established (Iantosca, McPherson et al. 1999; Hallahan, Pritchard et al. 2003; 
Piccirillo, Reynolds et al. 2006; Zhao, Ayrault et al. 2008). Use of BMP ligands is 
justified in DAOY cells as they are shown to express BMP receptors - BMPRI 
isoforms and BMPRII - which activate phosphorylation of SMAD1,5,8 proteins 
(Iantosca, McPherson et al. 1999; Fiaschetti, Castelletti et al. 2011). To induce BMP 
signaling pathway in our study, we used recombinant human BMP-4 (R&D systems) 
on DAOY. The lyophilized form was reconstituted with 4 mM HCl and 0.1% BSA as 
recommended by the manufacturer. Aliquots of 10 μg/ml were prepared and stored 
at -200C. 1 x 105 cells (with or without prior treatment with shRNA lentivirus) were 
plated in 2 ml medium in each well of a 6 well plate and treated with BMP-4 at a 
concentration of 100 ng/ml for 24 – 36 hr. The BMP signaling activation was 
assessed by the increased pSMAD1,5,8 expression by Western Blot analysis. The 
BMP-4 treated cells were used in Transwell migration and cell proliferation assays.    
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2.3.2 Noggin 
 
Noggin is a well characterised BMP signalling inhibitor (Zimmerman, De Jesus-
Escobar et al. 1996) and has been used previously in medulloblastoma studies as a 
BMP antagonist (Hallahan, Pritchard et al. 2003).   
To inhibit BMP signaling pathway in our study, we used recombinant Noggin/Fc 
Chimera (Sigma). The lyophilized form was reconstituted with sterile PBS containing 
0.1% BSA as recommended by the manufacturer. Aliquots of 50 μg/ml were 
prepared and stored at -200C. 1 x 105 cells (with or without prior treatment with 
siRNA or shRNA lentivirus ) were plated in 2 ml medium in each well of a 6 well and 
treated with Noggin at a concentration of 1μg/ml for at least 24 hr prior to functional 
analysis. The BMP signaling inhibition was assessed by reduction of pSMAD1,5,8 
expression by immunocytochemistry and Western blot. Noggin was used in all in 
vitro functional studies using DAOY or D-458 cells.    
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2.4 Western Blot 
 
Semi-quantitative assessment of BMI1 and pSMAD1,5,8 protein expression in MB 
cells and in mouse MB tumour tissue samples was performed using Western Blot. 
2.4.1 Sample preparation:  
 
MB cells: 105 – 106 cells were harvested from the culture, washed with sterile PBS to 
remove medium containing serum, and centrifuged to obtain cell pellets in eppendorf 
tubes. The pellets were either temporarily freeze-stored or used immediately for 
protein extraction. 
Tumour tissue: The frozen tumour tissue was thawed and weighed. About 80 - 100 
mg of tissue was collected for protein extraction and the rest was re-frozen and 
stored at -800C. The collected sample was homogenised using a tissue chopper 
prior to protein extraction.       
 
2.4.2 Protein extraction and protein measurement  
 
The samples were resuspended in Radioimmunoprecipitation assay (RIPA) buffer 
(Table 2.3) containing a freshly added solution of protease inhibitor (Complete Mini, 
Roche, 1 tablet added to 1ml of d. H2O to make 10X solution).  The amount of RIPA 
buffer + protease inhibitor (1%) solution was proportional to the size of the cell pellet 
– as a guide100 μl of RIPA buffer was used for a cell pellet containing 0.5 - 1 x 106 
cells and 200 μl for 80 – 100 mg of tissue homogenate.   
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Table 2.3 Preparation of RIPA buffer for Western blot. 
Contents Quantity 
 
Igepal CA-630 or NP40 1 ml 
2M Tris HCl (2M), pH 8.0  2.5 ml 
Sodium deoxycholate 0.5 g 
20% Sodium dodecyl sulphate (SDS) 500 μl 
0.5M Ethylene diamine tetraacetic acid (EDTA) 400 μl  
1M Sodium chloride (NaCl, 1M) 15 ml 
Distilled water Total up to 100 ml 
 
The sample suspension was sonicated for 4 - 5 brief spells using Soniprep 150 
ultrasonic disintegrator (MSE UK Ltd.) at amplitude of ~ 20 μ. The cell suspension 
was kept on ice for 20 – 60 min, and then spun at 13,000 rpm for 15 min at 40C to 
collect the supernatant containing total proteins.  
The protein concentration was measured using Pierce BCA protein assay kit 
(Thermoscientific). First, Parts A and B were mixed at 50:1 ration to obtain the 
working reagent. Five dilutions of albumin standards were prepared – 0.125 mg/ml, 
0.25 mg/ml, 0.5 mg/ml, 1 mg/ml and 2 mg/ml. Each albumin standard is then diluted 
with the working reagent at ratio of 1:20 in a 72 well plate and gently mixed. The 
same amount of test protein supernatant is added with working reagent in separate 
wells. Blank wells containing RIPA buffer with working reagents are also prepared. 
The 72 well plates is incubated at 370C for 15 min, and then cooled to room 
temperature, while the solution is protected from the light. The absorbance is 
measured @ 562 nm using NanoDrop photospectrometer (Thermo Scientific). The 
standard albumin curve is first obtained using the 5 prepared dilutions of albumin, 
followed by blank solution and then the test solutions. The readings are obtained in 
triplicates and the average reading is calculated.  
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2.4.3 Gel electrophoresis and ECL detection  
 
25 μg of each protein sample was taken in an eppendorfs, mixed with 2.5 μl loading 
buffer (final concentration of 25%) and diluted with RIPA buffer to make a final 
working volume of 12.5 μl.  The samples were boiled at 990C on eppendorf thermo 
mixer for 5 min. The boiled samples were quickly spun and kept on ice until 
electrophoresis.   
The running and stacking gel were prepared as in Table 2.4. After polymerisation of 
the gels, 10 μl working solution of protein samples were loaded on to the gel along 
with the 10 μl standard ladder (Bio-Rad), in an electrophoresis chamber filled with 1X 
running buffer. Electrophoresis was carried out at 80 V first (until the proteins passed 
through the stacking gel) and then at 100 V for 90 – 120 min.  
Table 2.4 Western blot gel preparation. 
Contents Running gel (10%) Stacking gel 
 
30% Acrylamide mix 3.3 ml 0.5 ml 
1.5M Tris HCl  2.5 ml (pH 8.8) 0.38 ml (pH 
6.8) 
10% SDS 0.1 ml 0.03 ml 
10% Ammonium persulfate 
(APS) 
0.1 ml 0.03 ml 
Tetramethylethylenediamine 
(TEMED) 
0.004 ml 0.003 ml 
Distilled water 4 ml 2.1 ml 
 
Following separation, the proteins were transferred on to Nitrocellulose membrane 
(Protran) by electrophoresis. The immunoblot sandwich for the transfer was in the 
order – Negative charge (black side) – sponge – Whatman paper -  gel with 
separated proteins – nitrocellulose membrane – Whatman paper – sponge – positive 
charge (red side). The sandwich was carefully inserted into electrophoresis chamber 
filled with pre-chilled 1X transfer buffer and an ice tray was placed in the chamber to 
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keep the temperature low. Transfer electrophoresis was carried out at 32 V in the 
cold room overnight. The contents of running and transfer buffer are listed in Table 
2.5.  
Table 2.5 Contents of electrophoresis buffers 
Running buffer (10X) Transfer buffer (10X) 
 
248 mM Tris 300g 
1.918M glycine 1440 g 
1% SDS 100 g 
d.H2O add to total 10 L 
1.2M glycine 90 g 
156 mM Tris 18.9 g 
0.25% SDS 2.5 g 
d.H2O add to total 1 L 
  
Following overnight transfer, the nitrocellulose membrane was treated with Ponceau 
S solution (Sigma) to confirm protein transfer. The membrane was washed 
thoroughly with 1X TBST solution and treated with 5% non-fat milk solution for at 
least 1 hr at room temperature to block unspecific binding of antibodies to antigens.  
The membrane was incubated with appropriate primary antibody for the desired 
duration (see Table 2.6) and rinsed with 1X TBST 2 x 5 min on a rocker. The 
membrane was treated with the appropriate secondary antibody (Table 2.6) at a 
concentration of 1:3000 for 1 hr at RT, and then rinsed with 1X TBST for 3 x 5 min 
on a rocker. The HRP conjugated protein was detected by Enhanced 
Chemoluminiscence (ECL) substrate (supersignal west PICO, Thermo Scientific). 
The solutions 1 and 2 were mixed in equal ratios and added on to the membrane, 
followed by incubation at room temperature for 5 min. The ECL treated membrane is 
wrapped in cling film, fixed in lead cassette and exposed to a film. The exposure time 
varied between 1 – 10 min for different protein band detection. The film was 
processed using the developer in the dark room. The nitrocellulose was soaked in 
TBST and stored at 40C. For repeat immuboblotting, the membrane was treated with 
Piercenet stripping buffer (Thermo Scientific) for 5 – 15 min at RT and washed with 
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TBST. The immunoprobing procedure was repeated from blocking antigen step 
onwards.   
Table 2.6 Primary and secondary antibodies used in WB 
Primary antibody Company Incubation 
conditions  
 
Secondary antibody 
used 
Mouse monoclonal 
anti-Bmi1   
Millipore (05-
657) 
1:500, 
overnight at 
4
0
C. 
ECL peroxidase anti-
mouse  IgG from sheep 
(GE Healthcare, 
NA931VS) 
Mouse monoclonal 
anti-alpha-tubulin  
Sigma 
(T6199) 
1:5000, 2 hr 
at RT. 
 
 
Rabbit polyclonal anti-
pSMAD1,5,8  
 
Cell Signaling 
(9511) 
1:500, 
overnight at 
4
0
C. 
HRP anti-rabbit IgG 
(Santa Cruz 
Biotechnology, sc-
2030)  
Rabbit polyclonal anti-
SMAD1,5,8 
Santa Cruz 
Biotechnology 
(sc-6031-R) 
1:400, 6 hr at 
RT 
HRP anti-rabbit IgG 
(Santa Cruz 
Biotechnology, sc-
2030) 
   
 
2.5 Quantitative Real-Time PCR (qRT-PCR).  
 
The efficiency of siRNA/shRNA induced BMI1 gene silencing was determined in MB 
cell lines and primary MB cells by qRT-PCR TaqMan Assay. The expression levels 
of Bmi1 in MB tumours arising from transgenic mouse model Math1Cre;Smo 
(comparing to the expression level of wild type mouse cerebellum) was also tested 
with this method. To evaluate the downstream targets of BMP pathway in MB cells, 
ID (inhibitor of differentiation) gene expression, namely, ID1 and ID2 expression was 
analysed by qRT-PCR SYBR Green method.     
2.5.1 Sample preparation:  
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MB cells: 105 – 106 were harvested from the culture, washed with sterile PBS and 
centrifuged to obtain cell pellets in eppendorf tubes. The pellets were either 
temporarily freeze-stored or used immediately for RNA extraction.  
Tumour tissue – The frozen tumour tissue was thawed and weighed. About 80 - 100 
mg of tissue was collected for RNA extraction and the rest was re-frozen and stored 
at -800C. The collected sample was homogenised using a tissue chopper and 
transferred to RLT lysis buffer containing eppendorf tube and pipetted using a 21G 
needle to ensure thorough mixing.    
2.5.2 RNA extraction:  
 
Total RNA was extracted using RNeasy minikit (Qiagen). First, lysis buffer was 
prepared by adding 30 μl of β-mercaptoethanol to 2970 μl of guanidine-
isothiocyanate containing RLT Buffer. 80% ethanol and 70% ethanol solutions were 
prepared by diluting absolute alcohol in RNase free water. 350 μl of lysis buffer was 
added to the eppendorfs containing cells/tissue sample and vortexed to homogenise 
the sample. 350 μl of 70% ethanol was added and mixed by inverting the tube. The 
lysate was then transferred to gDNA eliminator mini elute spin column and 
centrifuged at 10,000 rpm for 15 sec at room temperature (RT). 75 μl of DNase 
solution (prepared by mixing DNase in Buffer RDD) was added to the lysate and 
incubated at RT for 15 min. The column was centrifuged at 10,000 rpm at RT for 15 
sec and the filtered liquid was discarded. 500 μl of RPE Buffer with ethanol was 
added and centrifuged at 10,000 rpm at RT for 15 sec. The above process 
eliminated genomic DNA. Then, 500 μl of 80% ethanol was added to provide 
appropriate binding conditions for RNA and was centrifuged at 10,000 rpm at RT for 
2 min and again at 13,000 rpm for 5 min. The filtered liquid was discarded at all 
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stages. RNA was then eluted with 30 µl of RNase free water by spinning at 13000 
rpm at RT for 1 min. The RNA yield was determined by NanoDrop 
photospectrometry.   
2.5.3 Reverse Transcription:   
 
cDNA synthesis was performed using Quantitect kit (Qiagen). The RNA samples, 1 
μg each were first treated with 2 μl of gDNA wipe out buffer and totalled to 14 μl of 
working volume. The mix was incubated at 420C for 2 min to remove any DNA 
contamination. The samples were then placed on ice. Reverse Transcriptase III (RT 
III) mix was prepared by adding 1 μl of Quantiscript RT, 4 μl Quantiscript Buffer and 
1 μl of RT primer mix. 6 μl of prepared RT III mix was added to each sample and 
gently shaken. The samples are then incubated at 420 C for 15 min and at 950 C for 
3 min – to synthesise respective cDNA. The cDNA samples were stored at -800C 
until further analysis.  
An alternative method to synthesise cDNA using SuperScript III Reverse 
Transcriptase kit (Invitrogen) was also used.  First, 1 μg of RNA was annealed with 2 
μl of random primers(Invitrogen) to give a final volume of 14 μl, for 5 min at 650C. 
The master mix was prepared by mixing 4 μl of first strand buffer 5X, 1ul of DTT 
0.1M, 1 μl of dNTP 10 mM, 0.5 ul of Reverse Transcriptase III and 3.5 ul of RNase 
free water. The master mix was then added to the annealed primers to give a total 
volume of 24 μl. Reverse transcription was carried out at 250C for 5 min, 500C for 1 
hr and 720C or 10 min cycle. The resulting cDNA was stored at -800C until further 
analysis. 
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2.5.4 Polymerase chain reaction (PCR):  
 
To evaluate ID1 and ID2 expression in MB cells, we performed qRT-PCR using ID 
primer sequences. Prior to qRT-PCR, we checked for primer functionality by 
performing PCR. The RNA was extracted from MB cells and cDNA was prepared as 
above. The primers (Table 2.7) were designed using PRIMER3 software – 
frodo.wi.mit.edu/primer3/. The primers were validated for specificity using NCBI 
primer-Blast - http://www.ncbi.nlm.nih.gov/tools/primer-blast/.  Forward and reverse 
primer templates were ordered and obtained from Sigma and reconstituted with Milli-
Q® water to achieve the recommended working dilution. The PCR was performed 
using the cDNA samples. The PCR mix was prepared as in Table 2.8 and PCR 
amplification was carried out at 650C for 40 cycles. Dimethyl sulfoxide (DMSO) was 
added to increase specificity.  RNA or genomic DNA was used as controls to exclude 
contamination. The samples were then loaded on 1.2% agarose gel for 
electrophoresis for 45 min at 200V. The gel was photographed for band analysis. 
Clean bands for ID1 were identified at ~ 193 bp and for ID2 at ~ 347 bp (Fig 2.4), 
confirming that the primers were suitable for qRT-PCR. 
Table 2.7 Primer sequences of ID genes 
Gene  RefSeq  Primer sequence  
 
ID1  NM_002165.3 Forward 5'-CCCCAGAACCGCAAGGTGAGC-3' 
Reverse 5'-CAGGAACGCATGCCGCCTCG-3' 
 
ID2  
 
NM_002166.4 Forward 5'- TCTCGCCTTCCCTCGCGGTC-3' 
Reverse 5'- CGTGTTGAGGGTGGTCAGCGG-3' 
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Table 2.8. Preparation of PCR mix 
Contents Volume 
 
Buffer 10X 2.5 μl 
dNTP 2.5 μl 
Forward Primer (working solution) 2.5 μl (10 μM) 
Reverse Primer (working solution) 2.5 μl (10 μM) 
TaqMan Polymerase 0.35 μl 
cDNA (100 ng) or RNA (100 ng) 2 μl 
DMSO 0.1 μl 
Sterile dH2O Make up to 25 μl 
 
 
 
Fig. 2.4 PCR for ID1 and ID2 genes.  
 
DAOY and ICb-1299 cDNA were screened for (A) ID1, and (B) ID2 gene expression. Clean bands 
were noted on PCR indicating their suitability for qRT-PCR analysis.   
 
2.5.5 qRT-PCR and data analysis:  
 
2.5.5.1 TaqMan assay:  
 
To briefly describe, in TaqMan probe-based assay (Maeda, Fujimoto et al. 2003), 
reporter dye and a quencher are attached to the 5' and 3' ends of a TaqMan probe. 
When the probe is intact, the reporter dye emission is quenched. During the 
extension cycle, DNA polymerase cleaves the reporter dye from the probe and once 
separated from the quencher the reporter dye emits its characteristic fluorescence. 
TaqMan based system is known to have a high specificity as compared to SYBR 
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Green method (Applied Biosystems). Here TAMRA dye was used as the quencher 
dye, and the methodology is discussed below.  
Triplicates of cDNA templates (~ 25 ng each) were mixed with TaqMan gene 
expression master mix (Applied Biosystems), TaqMan gene expression assay and 
RNase free H2O (to a working volume of 25 μl) to prepare the qRT-PCR samples (as 
in Table 2.9) in MicroAMP optical 96 well plate (Applied Biosystems). The gene 
expression assays used are listed in Table 2.10.  
Table 2.9 qRT-PCR Master mix preparation for TaqMan Assay. 
Contents Volume per well 
 
Master Mix 2X 12.5 μl 
TaqMan Assay Mix 20X 
(Bmi1 or β-actin primer) 
1.25 μl 
cDNA  1 μl 
RNAase free H2O 10.25 μl 
 
Table 2.10. Details of TaqMan gene expression Assay.  
Gene Assay ID Reference sequence Exon 
boundary 
Amplicon 
length (bp) 
 
BMI1 
(human) 
Hs00180411_m1 NM_005180.8 3-4 105 
Bmi1 
(mouse) 
Mm00776122_gH NM_007552.4 6-7 150 
ACTB (human β-
actin)  
 
Hs99999903_m1 NM_001101.3 1-1 171 
Actb (mouse) 
β-actin 
 
Mm00607939_S1 NM_007393.3 6-6 115 
 
The samples along with negative controls were run on the SDS 7500 system 
(Applied Biosystems) set for the detection of the FAM reporter and the TAMRA 
quencher. The expression levels of the Bmi1 gene was determined by calculating the 
∆CT ratio between this gene and the house-keeping gene beta-actin. Mean 
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expression (fold change) with standard deviation relative to controls were calculated 
using Excel spread sheet.  
2.5.5.2 SYBR Green assay:  
 
In SYBR Green assay (Maeda, Fujimoto et al. 2003), the SYBR Green dye 
fluoresces when bound to double-stranded DNA. When the DNA is denatured, the 
SYBR Green dye is released and the fluorescence is drastically reduced. During 
extension, primers anneal and PCR product is generated and when polymerisation is 
complete, SYBR Green dye binds to the double-stranded product resulting in a net 
increase in fluorescence detected by PCR machine. The specificity of this method 
depends on the template quality and primer optimisation. The methodology used is 
described below.  
Triplicates of cDNA templates (~ 25 ng each) were mixed with SYBR Green master 
mix as stated in Table 2.11.  
 
Table 2.11 Preparation of Master mix for qRT-PCR by SYBRgreen method 
Contents Volume 
 
SYBR Green JumpStart Taq ReadyMix 5 μl 
Forward Primer (10 uM) 0.5 μl 
Reverse Primer (10 uM) 0.5 μl 
Reference dye 0.1 μl 
cDNA 1 μl 
RNAase free H2O Make up to 10 μl 
 
The samples along with negative controls were analysed in microAMP optical 96 well 
plate, run on a Rotor Gene machine (Corbett Research). The cycling profile was as 
follows: 950C for 10 min, 600C for 30 sec, 720C for 30 sec for 40 cycles. The 
expression levels of ID1 and ID2 genes were determined by calculating the ∆CT ratio 
between these genes and house-keeping gene GAPDH. Mean expression (fold 
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change) with standard deviation relative to controls were calculated using Excel 
spread sheet.  
 
2.6 Cell migration assays 
 
To assess the effects of BMI1 silencing on MB cell migration/motility and cell 
invasion in vitro, we used wound healing assay and Transwell® migration assay.  
2.6.1 Wound healing assay using time lapse videomicroscopy 
 
Wound healing assay allows studying cell migration and cell interactions. The 
experiment was performed as per published protocols from literature (Hu and 
Verkman 2006; Kurayoshi, Oue et al. 2006) and was modified and optimised 
according to our requirements. First, shRNA lentivirus treated cells were plated in a 
24 well plate (2 cm2 growth area per well) at a constant density  of 0.5 x 105 cells/well 
in 0.5 ml serum free media. The culture plates were not plated with ECM substrates 
to maintain uniform culture conditions. No growth factors were added to the medium 
to exclude any effect due to a potential proliferation difference. At this stage, Noggin 
was added to the cultures, if required and labelled. The cells were incubated at 370C 
for 24 hr ensuring they attain >90% confluence. Using a 20 µl pipette tip, three 
different linear wounds (scratches) were incised in each to remove ~80 µm wide strip 
of cells. The wounded monolayer was washed with medium to remove floating cells 
and cell debris. Fresh medium containing 10% FBS was added and the cells were 
incubated in dark time lapse chamber at 370 C, 5% CO2 flow. The time lapse stage 
was set to acquire images from three areas from each well, a total of 9 areas for 
each group. The images were acquired using phase contrast inverted microscope 
(Nikon), 10X magnification, every hour, for 12 hr. Three sets of wells were analysed 
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for each condition tested. The images were compiled and a movie was created using 
Metamorph software (Molecular Devices, Sunnyvale, California). The healed wound 
area or the area of migration was analysed and tabulated as mean ± SD. The 
relative area of migration was compared to controls. The experiments were 
conducted in triplicates.  
2.6.2 Time lapse videomicroscopy to assess cell motility (without wound) 
 
Time lapse videomicroscopy is also used to track and study individual cell 
characteristics (Simpson, Selfors et al. 2008). This experiment was performed to 
confirm that the area of migration that was assessed by wound healing assay was 
not confounded by cell proliferation. Individual cells were tracked and distance of 
motility was analysed in this experiment, to complement the wound healing assay. 
shRNA lentivirus treated DAOY cells (36 hr after transfection) were plated in 24 well 
plate at a density of 0.5 x 105 cell/well in 0.5 ml serum free medium for 12 hr at 370C. 
Fresh medium containing 10% FBS was replaced and the cells were incubated in 
dark time lapse chamber at 370 C, 5% CO2 flow. The time lapse stage was set to 
acquire images from five random areas in each well. The images were acquired 
using phase contrast inverted microscope (Nikon), 20X magnification, every 30 min, 
for 6 hr. Three sets of wells were analysed for each condition tested. The images 
were compiled and a movie was created using Metamorph software (Molecular 
Devices, Sunnyvale, California). Ten cells in each movie were tracked and the 
distance of migration was calculated and expressed as mean ± SD. The distances 
were compared with controls. The experiments were conducted in triplicates.  
 
2.6.3 Transwell migration assay 
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In contrast to cell motility assay, cell invasion assay requires cell to migrate through 
a basement membrane extract (BME) or extracellular matrix (ECM) barrier by 
enzymatic digestion of the barrier to reach the new location.  Transwell® inserts 
(Corning); 24mm diameter wells with polycarbonate membrane of pore size 8 μm 
and base area of 4.5 cm2 were used for this assay. Transwell migration assay is a 
well-established method to assess cancer cell invasion in vitro (Hu and Verkman 
2006; Moskovits, Kalinkovich et al. 2006). The procedure was performed according 
to manufacturer’s protocol and was modified or optimised according to our 
requirements. First, shRNA lentivirus treated cells were plated in a 6 well plate (10 
cm2 growth area per well) at a constant density of 4 x 105 cells/well in 2ml serum free 
media to starve the cells (to synchronise them prior to migration assay).  Noggin or 
BMP was added to the cultures at this stage, if required, and the cultures were 
labelled. The cells were incubated for 24 hr at 370C ensuring less than 80% 
confluence. The Transwell® inserts were simultaneously coated with 1 ml/well of 
ECM extract – either type I Collagen (First Link) 20 μl /ml,  laminin (Sigma) 20 μl /ml 
or BD Matrigel™ (BD Biosciences) 100 μg/ml - and incubated overnight at 370C. 
Excess ECM solution was then carefully removed by aspiration. The cells were 
harvested from their cultures, dissociated, resuspended in serum free medium and 
plated on top surface in Transwell insert wells at a constant number of 4 x 105 cells 
in 2 ml serum free medium per well.  Noggin or BMP was added in to the cultures at 
this stage, if required, and the cultures labelled. 2 ml complete media containing 10% 
FBS was added in the reservoir or base of each well which acted as a chemo 
attractant for cells to migrate. The cultures were incubated for 12 hr (overnight) at 
370C to allow invasion. Following 12 hr incubation, the medium was removed from 
the reservoir well by careful suction at the periphery, the wells were rinsed with PBS 
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and the cells were fixed with 4% PFA for 10 min. The wells were washed with 0.5% 
Triton to increase cell permeabilization, and stained with 1 ml Gill’s Haematoxylin on 
both top and bottom of the membrane. The non-migrated cells from the top surface 
of the insert membrane were gently scraped off using a wet cotton bud and washed 
with PBS, preserving only the migrated cells on the bottom surface of the membrane. 
Five random images from each insert membrane were acquired using light 
microscopy at 20X magnification. The number of cells migrated (stained nuclei) were 
counted using ImageJ software. The average number of cells per group was 
calculated, values were expressed as mean ± SD, comparing to controls. Three 
wells per each group of cells were prepared. The experiments were conducted in 
technical and biological triplicates.  
 
2.7 Proliferation assays 
 
The effect of BMI1 silencing on cell proliferation was assessed in DAOY cells by 
three independent methods – growth curve analysis, CyQuant NF assay and EdU 
assay.  
2.7.1 Growth curve analysis 
 
The proliferation of cells was assessed by time course experiment to produce a 
growth curve (Horiuchi, Huskey et al. 2012). The DAOY cells were plated at a 
constant density of 1x105 cells per well in a 6 well plate and incubated for 3 days 
until they reached confluence. They were then collected by trypsinisation, and the 
number of live cells were counted using Neubauer chamber. Multiplication factor (f) 
was generated where f = no. newly counted cells/no. of originally plated cells. 
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Estimated number of cells (e) was calculated during each passage where e = f x 
previous e. During each passage, 1x105 cells were plated, for a total of 7 passages, 
P1 to P7, corresponding to day 0, 3, 5, 7, 10, 12 and 14. Triplicates of each group of 
cells were prepared and counted. The experiment was done in three biological 
replicas. The estimated number of cell counts (e) for each passage was tabulated 
and the growth curve graph was generated using Excel spread sheet.   
2.7.2 CyQuant NF assay 
 
The CyQUANT® NF proliferation assay kit (Hong, Jiang et al. 2007) [Invitrogen] was 
used. This assay is based on the measurement of cellular DNA content by 
fluorescent dye binding capacity. The cells were plated in Costar® 96 well plate 
(Corning Inc.) at a constant density of 1 x 103 cells per well in 100 μl medium and 
were incubated at 370C overnight to achieve cell adherence. Initially, 11 ml of 1X 
Hank’s balanced salt solution (HBSS buffer) was prepared by diluting 2.2 ml of 5X 
HBSS buffer (Component C) with 8.8 ml of deionized water. 1X Dye Binding solution 
was prepared by mixing 1X Hank’s balanced salt solution (HBSS buffer) with Dye 
Reagent (Component A, containing digitonin and dimethylsulfoxide), as per 
manufacturers protocol. Following overnight incubation, the medium from the 
cultures were removed and replaced by 100 μl of 1X Dye Binding solution in each 
well. The plate was incubated at room temperature for 30 min in the dark to allow 
equilibration of the dye-DNA binding. After a stable fluorescence endpoint was 
reached, the fluorescence intensity (excitation set at 480 ±10 nm, and emission 
detection at 530 ± 10 nm) of each sample was measured by Synergy HT microplate 
reader (BioTek) supported by KC4™ v3.4 software (BioTek). Three independent 
experiments with three technical replicas each were performed.  
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2.7.3 EDU assay: 
 
The Click-iT® EdU Alexa Fluor® 594 Imaging kit (Life Technologies) was used for 
this assay. This assay is based on detecting newly synthesised DNA by EdU (5-
ethynyl-2´-deoxyuridine) that is incorporated into new DNA by quick click chemistry 
reaction. 0.5 x 105 cells (lentivirus treated) per well in 0.5 ml media were plated in 
each well of a 24 well plate over Polylysine (PLL) coated coverslips, and incubated 
overnight to obtain adherence.  250 μl 2X working solution of EdU (Component A) 
was replaced in to each well by removing 250 μl of the media and  added to each 
well to achieve  a 1X concentration (10 μM). The EdU was pulsed for 3 hr at 370C. 
The cells were fixed with 4% PFA for 15 min at RT and washed with 3% BSA in PBS 
for 5 min x 2. The cells were permeabilised using 500 μl 0.1% triton in PBS for 20 
min at RT. Alexa Fluor® azide working solution was prepared by diluting it 
(component B) with 70 μl DMSO (component C). 1X Click-iT reaction buffer was 
prepared by diluting 10X solution (component D) with water. 1X Click-iT reaction 
buffer additive was prepared by freshly diluting 10X solution (component F) with 
deionised water. Click-iT cocktail was prepared by mixing 430 μl of reaction buffer, 
20 μl CuSO4 (component E), 2 μl Alexa Flour® azide working solution and 50 μl 
reaction buffer additive to make a final volume of ~ 500 μl per coverslip. The cocktail 
was added into each well and incubated for 30 min in dark at RT. The coverslips 
were then placed on the glass slide for imaging and analysis. The fluorophore used 
in this experiment was Alexa Flour® 594 which was detected at excitation 590 nm 
and emission 615 nm.     
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2.8 Apoptosis assay 
 
The effect of BMI1 silencing on apoptosis was assessed in DAOY cells by Annexin V 
assay and by Cleaved Caspase-3 assay.   
2.8.1 Annexin V and flow cytometry  
 
Annexin V is a Ca2+ dependent phospholipid binding protein that has a high affinity 
for phospholipid phosphatidylserine (PS). PS is translocated from the inner to outer 
leaflet of the plasma membrane in early apoptotic cells. Annexin V conjugated with 
fluorochrome could be used to detect early apoptotic cells without compromising its 
affinity for PS (Vermes, Haanen et al. 1995). PE Annexin V Apoptosis Detection Kit I 
(BD Pharmingen™, BD Biosciences) was used with Alexa Fluor 647 Annexin V 
conjugate (Invitrogen) as per manufacturer’s protocol.  Initially, 1X binding buffer was 
prepared by diluting 1 part of 10X Annexin V binding buffer with 9 parts of distilled 
water. The cells were collected from cultures and washed with sterile cold PBS twice 
and resuspended using 1X binding buffer. 1x105 cells in 100 μl of 1X binding buffer 
per group were collected in FACS tube. 5 μl of Annexin V conjugate was added to 
each tube along with 10 μl of 1:1000 DAPI. The samples were gently mixed and 
incubated at room temperature in the dark for 15 min. 400 μl of 1X binding buffer 
was then added to each tube and the samples were kept on ice until flow cytometry. 
Three controls (DAPI only, Annexin V only, green fluorescent cells only) were 
prepared along with the test sample for each cohort to facilitate optimisation of flow 
cytometer detection probes. The cells were run through the flow cytometer machine 
(BD FACS Canto II analyser) set at 633 nm excitation and 660 nm emissions for 
Annexin V conjugate. The percentage of early apoptotic cells was determined using 
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FACS Diva™ v6.1.3 software (BD Biosciences). Average percentage of three 
independent experiments was used for analysis. 
2.8.2 Cleaved Caspase-3 assay: 
 
This assay is based on detection of cleaved caspase-3 which is responsible for 
photolytic cleavage of several key proteins and is a measure of apoptosis. Cleaved 
Caspase-3 rabbit monoclonal antibody (Cell Signaling) was used for this assay. 0.5 x 
105 cells (lentivirus treated) were plated with 0.5 ml media in each well of a 24 well 
plate over Polylysine (PLL) coated coverslips, and incubated overnight to obtain 
adherence. The cells were fixed with 4% PFA for 15 min at RT and blocked with 3% 
BSA in PBS for 30 at RT. The cells were permeabilised using 500 μl 0.1% triton in 
PBS for 20 min at RT. 250 μl per well of antibody was added at a concentration of 
1:200 diluted in PBS and incubated in the dark for 3 hr at RT. The coverslips were 
washed with PBS for 5 min x 2. Secondary antibody 1:500 Alexa Fluor® goat anti-
rabbit 647 (Invitrogen) diluted in PBS was added and incubated for 1 hr at RT. The 
coverslips were then placed on the glass slide, mounted with DAPI medium and 
used for imaging and analysis.     
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2.9 Animal procedures 
 
All animal procedures were carried out as per the Animals Scientific Procedures Act 
1986, under the Home Office approval licences – Project licence PPL 70/7275 and 
Personal licence PIL – 70/23444. The mice were housed at the Biological Services 
Unit (BSU) Whitechapel Campus, Queen Mary University of London.  The mice were 
temporarily transferred to the BSU Charter House Square Campus, Barts Cancer 
Institute for in vivo imaging. Nonobese diabetic –severe combined immunodeficiency 
(NOD-SCID) mice were used for intracranial injection to generate MB xenografts, 
and C57/BL6 mice were used to isolate cerebellum for organotypic cerebellar slice 
and MB tumour spheres co-culture assay. The animals were humanely killed as per 
Schedule 1 procedures.   
2.9.1 Anaesthesia:  
 
The mice were anesthetised using standard protocols (Wixon 1997; Arras, Autenried 
et al. 2001). For intracranial xenografts, the adult mice were anaesthetised by 
injectable anaesthetics Ketamine (Ketanest®, Chemdex) 50 – 120 mg/kg and 
Xylazine (Rompun®, Bayer) 5 – 10 mg/kg. The anaestheic mix was prepared by 
diluting 1 ml of Ketanest® and 0.5 ml of Rompun® in 5.7 ml distilled water making a 
total volume of 7.2 ml. Each mouse was weighed, and the anesthetics mixture was 
administered by intraperitoneal (IP) injection at the dose of 7.2 µl per gram of body. 
This provided an anaesthesia time of 15 – 30 min. For in vivo imaging the adult mice 
were anaesthetised using inhalational anaesthetic isoflurane. The gas was delivered 
using face mask at 4.5% for induction and 1-2% for maintenance, for anaesthesia 
time of 15 – 20 min. 
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The neonatal mouse pups were anaesthetised by hypothermia method. The pups 
were held in crushed ice for 2-4 min, with precautions taken to avoid freeze injuries 
to the skin. This provided an anaesthesia time of 10 – 15 min.   
Following the procedure, the mice were allowed to recover on a heated mat for 10 – 
30 min until they were alert and mobile before transferring them to their respective 
cages.   
2.9.2 Stereotaxic intracranial transplantation:  
 
Intracranial injections for xenograft tumour generation in mice were performed using 
SR6M Stereotaxic instrument (Narishige). The stereotactic frame was sterilized and 
a 25 μl Hamilton syringe/ 26G needle filled with the cell suspension was fixed to the 
frame. The anaesthetized mouse was then mounted on to the frame (Fig 2.5). First, 
the ear bar was fixed anchoring it to the ears of the mouse, and then the bar was 
fixed to the frame, supporting the snout (keeping the nostrils patent) and slightly 
tilting the head forward to expose the cerebellum landmarks. The area of procedure 
was sterilized and an incision was made to expose the skull. The lambda suture was 
identified and the needle was adjusted using the frame scales to necessary co-
ordinates. The co-ordinates used to inject MB cells for intracerebellar xenograft were 
1 – 2 mm posterior, 1 – 2 mm lateral from the lambda suture (Shu, Wong et al. 
2008). The needle was inserted at 100 – 150 angles to a depth of 2 - 3 mm and 2 – 5 
μl of cell suspension, containing 1 x 105 cells was slowly injected into the right 
hemisphere with gradual retraction of the needle. Prior to completely withdrawing the 
needle, a skin suture was placed to cover the scalp wound. After completion of 
injection the mouse was dismounted from the frame, and allowed to recover on a 
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heated mat. The position of the mouse was changed every 10 - 15 minutes during 
the recovery phase to ensure adequate circulation.  
 
Fig. 2.5 Use of stereotaxic frame. 
 
(A) Picture of Narishige Stereotaxic instrument used. (B) Fixation of the mouse to the ear barto keep 
the head stable during the procedure. (C) The mouse is mounted on the bars of the frame and the 
snout is supported. (D) Mid-line incision of scalp to expose the skull prior to injection. 
 
2.9.3 In vivo fluorescence imaging  
 
Following intracranial MB cell transplants, the mouse brains were imaged in vivo 
using Xenogen IVIS® Lumina II imaging system (Caliper Life Sciences). The 
procedure was carried out in collaboration with Dr Julie Foster from Prof. Steve 
Mather’s group at Barts Cancer Institute. The anaesthetised mice were labelled by 
tail tipping or tail marker and imaged in IVIS chamber for GFP fluorescence. As the 
transplanted MB cells were GFP labelled, we expected to detect GFP emission 
which would enable us to monitor the tumour growth. But due to inadequate 
penetration of fluorescence signalling through the skull bones, the acquired images 
did not show any GFP detection (Fig 2.6). As positive controls, vials of lentivirus 
infected cell pellets were used.  
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Fig. 2.6 Attempt to acquire in vivo fluorescence images using IVIS system.  
 
The overlay images show GFP radiance (yellow) in lentivirus infected control cells in vials ‘C’. 
However the xenografted mice show no GFP radiance in both (A) DAOY or (B) ICb-1299 transplants 
6-8 weeks after injection. This is thought to be due to non-penetrance of GFP emission through the 
skull. The capture (red) on the body of the animals is auto fluorescence from the coats of the animals. 
Eventually it was decided to analyse the xenografts by an alternative method - to harvest the 
xenografts and examine by fluorescent microscopy.     
 
Because no in vivo fluorescence could be detected due to non-penetrance, we 
decided to harvest the brain at the end of the experiment and study the invasive 
properties of the transplants by in vitro fluorescence imaging as described in chapter 
6.  
2.9.4 Organ harvest:  
 
2.9.4.1 Brain harvest for organotypic co-culture assay:  
 
The cerebellum was isolated from C57/BL6, P4 – P6 neonates. The pups were 
sacrificed by decapitation and the brain was collected on ice cold dissecting buffer. 
The cerebellum was isolated and the meninges were carefully peeled off the surface. 
Freshly isolated cerebellum was then sectioned using McIlwain tissue chopper (The 
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Mickle Lab. Engineering Co. Ltd.) to obtain cerebellar slices for ex vivo studies as 
described in chapter 5.  
2.9.4.2 Brain harvest following xenograft generation:  
 
Following MB tumour cell engraftment, the animals were sacrificed when they 
developed neurological symptoms or at the end of the experiment by exposure to 
raising concentrations of CO2 gas. The brain and spinal cord from each mouse were 
harvested immediately. The brain was fixed in 4% PFA in view of cryopreservation of 
tissue and examination of GFP positive (lentiviral infected) MB cells using 
fluorescent microscopy. The spinal cords were fixed in 10% formalin and embedded 
in paraffin in view of further morphological examination to study any tumour burden 
as described in chapter 6.   
The brain samples were incubated in 4% PFA for 2 hr at 40C for initial fixing. The 
forebrain was then separated from the cerebellum and brain stem pedicle. The latter 
was bisected coronally and fixed in 4% PFA at 40C for further 24 hr. The bisected 
samples were then transferred to 30% sucrose solution (30 g sucrose in 100 ml 0.1 
M phosphate buffer) for 24 – 48 hr at 40C (until the tissues sank) for cryoprotection 
and avoidance of crystal formation. After dehydration, each bisected sample was 
placed cut side down in  15 x 15 x 15 mm tissue moulds (Tissue-Tek), labelled and 
filled with Optimum Cutting Temperature (OCT) compound (VWR) until total 
immersion at room temperature . The moulds were kept in cooled isopentane (on dry 
ice) to gradually freeze the tissue. Once the OCT hardened the moulds were stored 
in – 800C until cryostat sectioning.  
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2.9.4.3 Spinal cord dissection for tumour burden analysis  
 
The spinal cords of the xenografted animals were harvested to assess the spread of 
the tumour. The mice were prepared by shaving their dorsum. A long incision was 
made along the mid-line extending from head to hip. The skin was retracted to 
adequately expose the vertebral column. The vertebral column was disarticulated 
just below the skull and at the hip level and the cross section of the spinal cord at the 
upper and lower end of the disarticulation sites were identified. Starting from the tail 
end of the vertebral column (because the spinal foramen is larger at this end), the 
vertebral bones were cut on either sides of the spinal cord using a small dissecting 
scissors. The blood was rinsed away with PBS in order to see the cord.  The bony 
vertebrae along the lateral aspect were cut on both sides from below upwards (ie. 
lumbar to cervical). Care was taken to avoid damaging the spinal cord which is 
identified as a white and glistening structure (with dural covering). Once the whole 
length was dissected, the bone was removed from the dorsal side to expose the 
spinal cord. The spinal cord was gently peeled with blunt forceps by disconnecting 
the nerve roots/chords and fixed in formalin for at least 48 hr. It was then sectioned 
in to 4-5 pieces along its longitudinal axis and embedded in paraffin blocks. The 
blocks were sectioned at 4-5 μm thickness and were stained with H&E for 
morphological analysis of tumour burden. The sections from all the samples were 
screened for presence of tumour deposits in the spinal cord, identified by 
morphological characteristics of medulloblastoma. The rate of tumour positivity in 
shRNA BMI1 silenced xenografts were compared with control xenografts.    
 
2.9.4.1 Cryostat sectioning: 
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The cerebellum and brain stem samples, fixed and frozen in OCT compound, were 
sectioned in their entirety using Leica CM1850 cryostat (Leica) to study the invasive 
properties of the xenografted tumour. The cryostat chamber was maintained at -
200C. Each half of the bisected sample was fixed on to the cryostat tissue holder 
using OCT compound and sectioned at 20 μm thickness. The sections from each 
sample were transferred to 12 SuperFrost® Plus glass slides (VWR) serially (ie. 1-12 
sections to slides 1-12 and 13 – 24 sections to slide 1 – 12 again etc.),  to ensures 
that each slide would be representative of the entire sample. The slides were 
labelled and left to dry overnight. The dried sections were stored at -800C until 
stereology and confocal microscopy analysis was performed as described in chapter 
6.  
     
2.10 Histology and immunohistochemistry 
 
2.10.1 Haematoxylin and eosin (H&E) staining 
 
The tissue morphology was examined histologically using conventional H&E staining 
on the tissue sections. The sections were dewaxed (if FFPE) or thawed (if 
cryopreserved) and were rehydrated with PBS for 5 min. The slides were then 
incubated in PBS + 0.1% Triton X for 10 min followed by immersion in haematoxylin 
for 2-3 min and washed with distilled water briefly and tap water for 5 min. They were 
then immersed in eosin for 2 min and briefly washed with distilled water followed by 
tap water for 5 min. The stained sections were dehydrated in 70% alcohol for 30sec, 
100% alcohol for 30sec and in Xylene for 30 sec in succession. The sections were 
mounted using DPX (mixture of distyrene, plasticizer, and xylene), covered with 
coverslips and left drying for 2-3 hr.   
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2.10.2 Immunohistochemistry by Avidin-biotinylated Complex (ABC) method:  
 
The Formalin fixed paraffin embedded (FFPE) tissue and cell block sections were 
stained by avidin-biotinylated complex (ABC) method of immunohistochemistry. The 
slides were dewaxed by incubating them in the oven at 600C for 20 min. The 
sections were then deparaffinated by treating them in xylene for 10 min x 2 followed 
by 100% ethanol for 5 min x 2 and 90% ethanol for 5 min x 2. They were then 
treated with H2O2 solution (1% hydrogen peroxidase, H2O2, in cold methanol) for 20 
min to block endogenous peroxidase and rehydrated in 70% ethanol for 5 min 
followed by rinsing in dH2O for 5 min x 2. Antigen retrieval was done by the heat 
method – the slides were immersed in 10 mM citrate buffer (2.1 g of citric acid 
monohydrate dissolved in 1 L dH2O), pH 6 and microwaved (Panasonic apparatus) 
for 1 min at high power and 15 min at medium power. The slides were allowed to 
cool and rinsed with PBS for 5 min x 3. The block to prevent unspecific binding of 
antibodies to antigens was carried out using appropriate serum (Table 2.13) diluted 
in 0.2% triton + 0.1% sodium azide solution at room temperature for 1 hr. After 
blocking, the sections were treated with the primary antibody diluted in 0.2% triton + 
0.1% sodium azide solution and incubated overnight at room temperature in a moist 
chamber. The primary antibodies used with the respective concentration are listed in 
Table 2.12. After primary antibody treatment, the sections were washed with PBS + 
0.1% tween 20 solution for 5 min x 3 and appropriate biotinylated secondary 
antibody (Table 2.13) was applied at room temperature for 1 hr. The sections were 
washed with PBS + 0.1% tween 20 solution for 5 min x 3 and incubated with 
avidin/biotinylated enzyme complex using Vecstatin ABC reagent (Vector labs) for 30 
min. They were washed again with PBS + 0.1% tween 20 solution for 5 min x 2 and 
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enzymatic detection was carried out with 3,3’- diaminobenzidine tetrahydrochloride 
(DAB solution,Sigma). Working solution of DAB was prepared by mixing 1 ml of DAB 
liquid chromogen with 9 ml of DAB liquid buffer as per manufacturer’s instructions. 
The duration of DAB incubation varied for different antibodies – the reaction was 
stopped when brown staining appeared – which was between 1 – 10 min. The slides 
were rinsed in dH2O to stop the reaction, and counterstained with haematoxylin for 
30 sec. The slides were washed with dH2O to remove the excess dye and 
dehydrated with 50% ethanol for 5 min, 70% ethanol for 5 min, 90% ethanol for 5 
min x 2, 100% ethanol for 10 min x 2 and xylene for 10 min x 2 successively. The 
sections were then mounted using DPX, covered with coverslips and allowed to dry 
for 2-3 hr at RT. For membrane antigen detection, PBS without Triton was used 
during the wash steps.   
Table 2.12 List of primary antibodies used for immunohistochemistry using ABC method.  
For antigen to be 
detected 
Primary antibody 
used 
Company Concentration Positive 
control  
 
Bmi1 (mouse) or  
BMI1 (human) 
Rabbit polyclonal anti-
Bmi1 
Abcam 
(ab38295) 
1:100  Gastric 
carcinoma 
pSMAD1,5,8 Rabbit polyclonal anti-
phosphoSmad1/5/8 
Millipore 
(AB3848) 
1:100 Breast 
carcinoma 
CD44 Rabbit polyclonal anti-
CD44 
Abcam 
(ab24504) 
20 μg/ml Glioblastoma 
Thrombospondin 
(THBS) 
Mouse monoclonal 
anti-thrombospondin 
Abcam (ab1823) 1:25 Glioblastoma 
MMP8  Goat polyclonal anti-
MMP8 
Santa Cruz (sc-
8848) 
1:50 Breast 
carcinoma 
MMP10 Rabbit polyclonal anti-
MMP10 
Abcam 
(ab59437) 
1:500 Breast 
carcinoma 
Synatophysin  Rabbit polyclonal to 
synaptophysin 
Abcam 
(ab14692) 
1:500 Brain  
GFAP Rabbit polyclonal anti-
glial fibrillary acidic 
protein 
DakoCytomation 
(Z0334) 
1:500 Brain  
KCNA1 (Kv1.1) Rabbit polyclonal anti-
Kv1.1 
Abcam 
(ab86211) 
1:1000 Brain   
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Table 2.13 Biotinylated secondary antibody and blocking serum used 
For primary antibody source 
 
Secondary antibody used Blocking agent 
Rabbit or Mouse Universal biotinylated anti-
mouse/anti-rabbit IgG (Vector) 
raised from horse. 
2.5% Normal horse serum 
(Vector)  
 
 
Goat  1:400 Anti-goat IgG (Vector) 
raised from rabbit 
5% Normal rabbit serum    
 
OCT embedded tissue: Freshly frozen tissue sections (xenografts fixed with 4% PFA 
and embedded in OCT) were initially treated with cold methanol for 10 min followed 
by either 5% Normal Goat Serum or 10% Normal Donkey Serum for 1 hr. They were 
then incubated with either goat polyclonal anti-BMI1 (Santa Cruz Biotechnology) 
1:100 or rabbit polyclonal anti-pSmad1/5/8 (Cell Signalling) 1:100 primary antibody 
overnight at room temperature. Appropriate secondary antibody was used: donkey 
anti-goat 568 (red, Invitrogen) 1:400 or goat anti-rabbit 546 (red, Invitrogen) 1:400 for 
2 hr at room temperature. The sections were counterstained with DAPI and 
examined using Confocal 710 microscope (Zeiss).  
2.10.3 Immunofluorescence  
 
2.10.3.1 Cell preparation:  
 
DAOY or D458 were plated at a concentration of 0.5 x 105 cells (with or without 
siRNA transfected) in 0.5 ml medium in each well of 24 well plate, containing Poly-
lysine (PLL) coated coverslips. The PLL coated coverslips allowed cells to adhere 
better and contributed to better fluorescent imaging because the coverslips could be 
transferred on to a glass slide. After 24 – 48 hr in culture, the cells were fixed using 
4% PFA for 15 min at RT. The antigen block was carried out using 5% Normal Goat 
Serum (NGS), and incubated with primary antibodies for 2 hr at RT (Table 2.14). 
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Appropriate fluorescent secondary antibodies were used at a concentration of 1:400 
for 2 hr at RT. The coverslips were counterstained with DAPI (blue, nuclear staining) 
and mounted on glass slides. Fluorescent imaging was carried out using a Leica 
DFC350 microscope (Leica) and the cell counts analysed as described in chapter 3.  
2.10.3.2 Cryosections:  
 
The tissue sections that were embedded in OCT compound were removed from - 
800C, thawed and washed in PBS for 5 min x 3 on a rocker. The sections were 
placed in cold methanol for 5-10 min at RT to enable penetration of antibodies into 
the sections and to optimal staining. The slides were placed in 0.1% Tween in PBS 
for 5 min at RT. The edges of the slides were dried and the section areas were 
marked with PAP pen to limit the antibody usage. The sections were incubated with 
blocking solution – either 5% normal goat serum (NGS) or 10% normal donkey 
serum (NDS) diluted in PBS + 0.2% Triton + 0.1% NaAzide, for 1hr at RT in a 
humidified chamber. The sections were then incubated with theprimary antibody pre-
diluted in PBS + 0.2% Triton + 0.1% NaAzide overnight at RT in a humidified 
chamber.  The primary antibody was removed and sections were washed in PBS for 
5 min x 2 and then with PBS/0.1%Tween for 5 min x 1. The sections were incubated 
with appropriate prediluted fluorescent secondary antibody in PBS + 0.2% Triton + 
0.1% NaAzide for 2 hr in a humidified chamber. The sections were washed in PBS 
for 5 min x 2 and in PBS/0.1%Tween for 5 min x 1. The sections were coverslipped 
and mounted with Vectashield Mounting Medium (Vector) contains DAPI nuclear 
stain. The slides were allowed to dry for 10-15 min and the coverslips were sealed 
with nail polish. The sections were stored in the dark at 40C until microscopic 
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examination. The sections were evaluated at the confocal microscopy and analysed 
as described in chapter 6.   
 
Table 2.14 List of primary antibodies used in immunofluorescence analysis.  
For antigen to 
be detected 
Primary antibody used Company Concentration Alexa Fluor® 
secondary 
antibody 
(Invitrogen) 
Cell preparation 
BMI1  
 
Mouse monoclonal anti-
Bmi1  
Millipore  (05-637) 1:500 Goat anti-
mouse 546 
(red) IgG, 
A11003 
 
Synaptophysin Mouse monoclonal anti-
synaptophysin 
DakoCytomation 
(M0776) 
1:50 
GFAP Rabbit polyclonal anti-
glial fibrillary acidic 
protein 
DakoCytomation 
(Z0334) 
1:1000 Goat anti-
rabbit 488 
(green) IgG, 
A11008 
Cryosections 
BMI1 Goat polyclonal anti-
Bmi1 
Santa Cruz 
Biotechnology (sc-
8906) 
1:200 Donkey anti-
goat IgG 568 
(red)  
A11057 
pSMAD1,5,8 Rabbit polyclonal anti-
phosphoSmad1/5/8 
Cell signalling  
(9511) 
1:100 Goat anti-
rabbit 546 
(red) IgG  
A11035 
CD44 Rabbit polyclonal anti-
CD44 
Abcam (ab24504) 1:100 (20 
μg/ml) 
Laminin β-1 
(LAMB1) 
Rabbit polyclonal anti-
Lamb1 
Abcam (ab65986) 1 μg/ml 
Thrombospondin 
(THBS) 
Mouse monoclonal anti-
Thsb 
Abcam (ab1823) 1:25 
 
2.11 Statistical analysis  
 
All in vitro and ex vivo experiments were performed at least in triplicates unless 
otherwise stated. Minimum of 6 in vivo xenograft models in each group were used for 
tumour volume and invasion analysis, and three xenograft tumours from each group 
were used for pSMAD1,5,8 expression analysis. The statistical significance of the 
quantitative data was calculated using student’s t test, and presented as mean ± SD. 
The statistical significance was set at P < 0.05.  Spearman non parametric tests and 
cross-tabulations were used for correlation analysis on TMA data using SPSS® 
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statistical package version 20 (IBM®). Kaplan-Meir survival estimation among 
xenograft mice were also done using SPSS, where statistical significance was 
calculated using Log-Rank analysis.    
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CHAPTER 3  BMI1 represses the BMP signalling pathway 
in MB cell lines and in primary MB cells of Group 4.  
 
3.1 Introduction 
 
BMI1 plays a role in the pathogenesis of several human cancers (Sparmann and van 
Lohuizen 2006) including brain tumours such as gliomas (Bruggeman, Hulsman et 
al. 2007) and MBs.  (Leung, Lingbeek et al. 2004). Recently, using genome-wide 
expression analysis, MB has been classified into four distinct molecular subgroups – 
SHH, WNT, Group 3 (Consensus Group 3 or Northcott Group C) and Group 4 
(Consensus Group 4 or Northcott Group D) (Northcott, Korshunov et al. 2011; 
Taylor, Northcott et al. 2012). Using a genetically engineered mouse model, our 
group have recently demonstrated that Bmi1 critically influences cell-cell interactions 
during cerebellar development, and more importantly it does so through specific 
inhibition of BMP signalling (Zhang, Santuccione et al. 2011). In this study, we 
hypothesise that BMI1 represses BMP pathway also in human medulloblastoma. 
BMP signalling is deregulated in MB cells (Zhao, Ayrault et al. 2008), hence the 
system seemed appropriate to study whether Bmi1 contributed to its deregulation.  
To test our hypothesis, we used well characterised MB cell lines with high BMI1 
expression and checked for BMP signalling status. BMI1 overexpression is known to 
be more significantly associated  with aggressive MB subtypes – most significantly 
with  Group 4 tumours  (Behesti, Bhagat et al. 2013).  Because of the known 
association of Group 4 MB with high BMI1 expression, we decided to validate the 
findings obtained in cell lines on primary human MB cells belonging to Group 4 (or 
Northcott Group D) specifically.    
 
139 
 
3.2 Experimental design and methodology  
 
3.2.1 BMI1 gene silencing by RNA interference (RNAi):  
 
Transient BMI1 gene silencing (knock down) in DAOY and D-458 was achieved by 
siRNA technology. FlexiTube siRNA (Qiagen) specific for BMI1, containing a mix of 
Hs BMI1 1, Hs BMI1 2 and Hs PCGF4 3 was used. All Stars Negative siRNA 
(Qiagen), referred to as scrambled (Scr) was used as control. The transfection mix 
was prepared and added to the cell cultures as described in Materials and Methods 
(M&M, chapter 2, section 2.2.2.1). To obtain maximum knock down efficiency, the 
transfected cells were incubated for 48 hr with the transfection mix prior to any 
functional study. The efficiency of BMI1 knock down was assessed by Western blot 
and immunofluorescence (explained in section 3.3, Fig 3.2). 
Stable BMI1 silencing in DAOY cell lines and in ICb-1299 primary cells was achieved 
by shRNA technique using GFP labelled lentiviral vectors. Production and packaging 
of lentivirus is described in M&M (chapter 2, section 2.1). The cells were infected 
with either shRNA BMI1 or shRNA scrambled (Scr) lentivirus at a Multiplicity of 
Infection (MOI, formula stated in chapter 2, section 2.2.3.1) of 12.5 for DAOY and 25 
for ICb-1299. After 72 hr incubation, they were sorted by FITC gated flow cytometry 
(FACS) for stable selection. The cells were incubated for at least 96 hr prior to 
expansion or use for further studies. The efficacy of knock down was assessed by 
Western blot and qRT-PCR analysis at multiple time points after passaging. 
Stable BMI1 knock down (in DAOY cell lines and in primary cells ICb-1299), using 
the above method was used for all of the knock down experiments, except for i) 
investigation of BMP pathway status (section 3.3, Fig 3.5 and Fig 3.6), and ii) 
investigation of cell adhesion phenotype (chapter 4, section 4.3.1, Fig 4.2), where 
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transient BMI1 knock down (in DAOY and D-458 cell lines), using siRNA method 
was used.   
3.2.2 BMP pathway inhibition:  
 
To inhibit BMP signalling in DAOY or D-458 cell cultures, recombinant Noggin 
(Sigma) was used at a concentration of 1μg/ml (which showed low cell toxicity and 
efficient BMP pathway inhibition, explained in section 3.3.2.1 (Fig 3.4). Noggin was 
used either alone or concomitantly with siRNA BMI1 knock down. The cultures were 
incubated for at least 24 hr prior to assessment of BMP signaling inhibition by 
reduction of pSMAD1,5,8 expression. Where the cultures had to be incubated for 
longer than 24 hr, they were supplemented with Noggin every 24 hr. 
3.2.3 Immunocytochemistry:  
 
The cells treated with siRNA/shRNA BMI1 for knock down studies were cultured on 
Poly-lysine (PLL) coated coverslips and were treated concomitantly with Noggin 
where appropriate to inhibit BMP signaling. Following incubation for 48 hr they were 
fixed using 4% Paraformaldehyde (PFA) and antigen blocked with 5% Normal Goat 
Serum. They were treated with BMI1 and pSMAD1,5,8 antibodies (details below) for 
2 hr at RT, followed by fluorescent secondary antibodies (details below) for 2 hr at 
RT. The coverslips were transferred to glass slides and mounted using DAPI 
medium. Five random fluorescent micrographs (20X magnification) were obtained 
using Leica Confocal microscope DFC350 set with Y3 (red), A4 (blue) and L5 
(green) filters. The number of cell nuclei staining for DAPI (blue, representing total 
number of cells present) and the number of cells positive only for pSMAD1,5,8 
(green) was counted using ImageJ software and expressed as percentage of cells 
141 
 
expressing pSMAD1,5,8. The results were tabulated under scrambled and BMI1 
siRNA group for both DAOY and D458.  
Primary antibodies used are:  
1) Mouse monoclonal anti-Bmi1, (Millipore, 05-637), 1:500 
2) Rabbit polyclonal anti-phosphoSmad1/5/8, (Cell signalling, 9511), 1:100 
Secondary antibodies used are (incubated at 1:400 for 2 hr at RT): 
1) Alexa Flour® goat anti-mouse 546 (red) IgG (Invitrogen, A11003), 1:400 
2) Alexa Fluor® goat anti-rabbit 488 (green) IgG (Invitrogen, A11008), 1:400 
 
3.2.4 Western blot:  
 
This method was used:  
i) To screen MB cell lines for BMI1 expression levels,  
ii) To confirm efficacy of BMI1 knock down in DAOY and ICb-1299, and  
iii) To study pSMAD1,5,8 and SMAD1,5,8 expression levels following BMI1 silencing 
in DAOY and ICb-1299.  
The results were normalised against expression of α-tubulin. The procedure was 
carried out as explained in M&M (chapter 2, section 2.4). Briefly, total protein 
extraction, gel separation and transfer to nitrocellulose membrane by electrophoresis 
were carried out. The membrane was blocked with 5% fat free milk solution and 
incubated with primary followed by secondary antibodies. The complex was exposed 
to ECL detection system and processed using film developer. The protein bands 
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were compared for semi-quantitative expression analysis. The antibodies used are 
as follows -   
Primary antibodies:   
1) Mouse monoclonal anti-Bmi1 (Millipore, 05-657), 1:500, ON at 40C. 
2) Mouse monoclonal anti-alpha-tubulin (Sigma, T6199), 1:5000, 2 hr at RT. 
3) Rabbit polyclonal anti-pSMAD1,5,8 (Cell Signalling, 9511), 1:500, ON at 40C. 
4) Rabbit polyclonal anti-SMAD1,5,8 (Santa Cruz Biotechnology, sc-6031-R), 
1:400. 6 hr at RT. 
Secondary antibodies:  
1) ECL peroxidase anti-mouse IgG from sheep (GE Healthcare, NA931VS), 
1:3000, 1 hr at RT. 
2) HRP anti-rabbit IgG (Santa Cruz Biotechnology, sc-2030), 1:3000, 1 hr at RT. 
 
3.2.5 qRT-PCR:  
 
The efficacy of BMI1 silencing following lentiviral shRNA treatment in DAOY and Icb-
1299 was tested using TaqMan Assay. Expression analysis of ID1 and ID2 
(Inhibitors of DNA binding 1 & 2 respectively) genes to check for activation of 
downstream targets of BMP-pSMAD1,5,8 signalling was done by SYBR Green 
assay. The details of qRT-PCR is explained in M&M (chapter 2, section 2.5.5).  
ID1 and ID2 primers were designed using PRIMER3 software and validated using 
NCBI primer-BLAST system. The forward and reverse primers were obtained from 
Sigma. RNA was extracted from the cells and cDNA was prepared by reverse 
transcription. qRT-PCR was carried out using the following primers -  
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TaqMan Assay (Applied Biosystems): 
1) BMI1 (human), Hs00180411_m1, NM_005180.8  
2) ACTB (human β-actin), Hs99999903_m1, NM_001101.3  
SYBR Green method: 
1) ID1 (transcript variant 1) NM_002165.3 
Forward 5’-CCCCAGAACCGCAAGGTGAGC-3’ 
Reverse 5’-CAGGAACGCATGCCGCCTCG-3’ 
2) ID2, NM_002166.4  
Forward 5’- TCTCGCCTTCCCTCGCGGTC-3’ 
Reverse 5’- CGTGTTGAGGGTGGTCAGCGG-3’ 
3) GAPDH, NM_002046.4 
Forward - GCACAGTCAAGGCCGAGAAT 
Reverse- GCCTTCTCCATGGTGGTGAA 
 
The expression levels of required genes were determined by calculating their ∆CT 
values and were normalised to that of house-keeping gene, GAPDH expression. 
Mean expression (fold change) with standard deviation relative to controls were 
calculated.    
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3.3 Results 
3.3.1 Efficient BMI1 knock down was achieved by RNAi methods in human 
medulloblastoma cell lines known to express high levels of BMI1 
  
To test our hypothesis that BMI1 overexpression suppressed BMP signalling 
pathway in human medulloblastoma, we set out to study the BMP pathway status in 
those MB cell lines which had high BMI1 expression. Five human MB cell lines - 
UW228-2, D-425, D-458, D-341 and DAOY (obtained from ATCC) were screened for 
BMI1 protein expression by Western Blot (test carried out by Xinyu Zhang, 
Department of Neurosciences, Blizard Institute, Barts and the London School of 
Medicine and Dentistry). BMI1 expression in these cell lines was observed (Fig 
3.1A), and the expression levels were comparable to that previously observed by 
Leung et al. Fig 3.1B) (Leung, Lingbeek et al. 2004), and in majority of the 12 
primary human tissue samples analysed (Fig 3.1C) (Leung, Lingbeek et al. 2004).  
 
Fig. 3.1 Western blot analysis of BMI1 expression in human MB cell lines and primary tumour 
samples. 
 
(A) BMI1 is expressed in the fiveMB cell lines screened – UW228-2, D-425, 4-458, D-341 and DAOY. 
The expression levels of the cell lines is estimated by means of Western blot  compared to previous 
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results (B), and twelve primary human primary MB tissue samples (C), from Leung et al. study (Leung 
et al. 2004, Nature). Similar BMI1 expression levels were observed with a slightly lower expression in 
D-341. DAOY and D-458, which had stable BMI1 expression levels were further used in our study, 
 
Having established that BMI1 was highly expressed in the above cell lines, we chose 
DAOY and D458 for further studies. We chose these cell lines because i) they are 
extensively characterised, and ii) stable BMI1 expression levels were detected. BMI1 
knock down was carried out using both transient lipofection-mediated siRNA delivery 
and stable lentiviral-mediated shRNA delivery.  To assess efficiency of knockdown 
immunocytochemistry for BMI1 antibody was performed. Five fields in each well 
were imaged and the experiments were conducted in triplicates. Although the 
number of cells expressing BMI1was not quantified, optical imaging suggested 
consistently reduced BMI1 expression (number and/or intensity) in both DAOY (Fig 
3.2A) and D-458 (Fig 3.2B) cultures upon BMI1 knock down.  
To confirm the above finding, a semi-quantitative assessment using the Western Blot 
method was performed. Total protein was extracted from siRNA treated cells 
cultures and immunoblot was performed against BMI1 antibody. There was a 
reduced BMI1 protein expression noted in BMI1 siRNA treated DAOY and D-458 
extracts as compared to siRNA Scr and untreated controls (Fig 3.2C), thus 
corroborating the immunocytochemistry results. It is noted that the BMI1 bands in Fig 
3.2C appear different for DAOY and D458. The possible reason for this could be 
partial degradation of BMI1 protein in the DAOY lysates used, giving a smear like 
appearance. Other possible influencing factors could be the exposure time, and 
quality of primary and/or secondary antibody used.  
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Fig. 3.2 Immunofluorescence and Western blot demonstrating an effective siRNA mediated 
BMI1 knock down in MB cell lines. 
 
Transient BMI1 knock down was carried out using lipofection-mediated siRNA delivery. 
Immunohistochemistry suggested an effective BMI1 knock down 48 hr of transfection  in both (A) 
DAOY and (B) D-458, where a reduction in number and intensity of BMI1 expression was observed in 
all five representative fields (n=3). Left panel showing DAPI channel with total number of cell nuclei; 
middle panel showing BMI1 positive cells; and right panel showing merged image. (C) Western blot 
analysis confirming a reduction in BMI1 protein expression in siRNA BMI1 treated DAOY (left) and D-
458 (right) cells, as compared to untreated and siRNA scrambled treated controls. Scale bar in both 
(A) and (B) = 50 μm.        
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The procedure for stable BMI1 knock down using lentivirus mediated shRNA 
constructs is detailed in section 3.2.1 and in M&M (chapter 2, section 2.2.3.1). 
Briefly, DAOY cells were infected with shRNA lentivirus at an MOI of 12.5, incubated 
for 72 hr and stable selection was achieved by FACS-mediated enrichment for GFP 
positive cells, which were expanded for further studies. The efficacy of knock down 
in the cultures was assessed by qRT-PCR analysis at three different time points after 
passaging. The average of relative fold change in shRNA BMI1 treated cells as 
compared to shRNA Scr treated cells was calculated. There was an average of five 
fold reductions in BMI1 mRNA levels in DAOY cells confirming an effective BMI1 
knock down (Fig 3.3 A).  Reduction in BMI1 protein levels was also demonstrated by 
Western Blot analysis (Fig 3.3 B) using protein extracts from cells collected 96 hr 
after FACS selection following shRNA lentiviral infection.   
This shows that lentivirus mediated shRNA-technique is suitable for BMI1 knock 
down in DAOY; and was used for further experiments. From here on shRNA Scr 
treated DAOY cells will be referred to as DAOYScr and shRNA BMI treated cells as 
DAOYBMI1kd. 
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Fig. 3.3 Successful reduction of BMI1 expression in DAOY cells upon lentivirus shRNA-
mediated knock down.  
 
(A) qRT-PCR showing an average (n=3) of five-fold relative reduction in BMI1 expression (normalised 
against β–actin expression) in shRNA BMI1 treated cells as compared to shRNA Scr treated cells. (B) 
Western blot confirming reduction in BMI1 protein expression 96 hr after FACS sorting of shRNA 
BMI1 Treated cells. Error bar represents SD (n=3). **, P<0.01.   
 
3.3.2 BMI1 silencing leads to aberrant activation of BMP signalling pathway in 
MB cell lines. 
 
3.3.2.1 Efficacy of Noggin as BMP pathway inhibitor was demonstrated in 
DAOY and D-458 
 
Having established efficient BMI1 knock down techniques, the next step was to 
identify a method to efficiently inhibit BMP pathway to enable us to study if any 
functional impact observed upon BMI1 silencing was mediated by a putative BMP 
pathway activation.  
Noggin is a 26 kd secreted protein that was first described as a neural inducer in 
Xenopus, required for normal dorsal development (Smith and Harland 1992). Noggin 
is an established inhibitor of BMP pathway (Zimmerman, De Jesus-Escobar et al. 
1996) which acts by competitively binding to BMP-2 and BMP-4 preventing ligand 
activation of BMP receptors and SMAD1,5,8 mediated signalling. Noggin has been 
previously used as a BMP inhibitor in medulloblastoma cells (Hallahan, Pritchard et 
al. 2003).  
DAOY and D-458 were plated in a density of 0.5 x 105 cells in 0.5 ml media/well in 
triplicates. Noggin was added to the cultures at 1μg/ml and incubated for 24 hr. The 
cells were then fixed and immunocytochemistry for pSMAD1,5,8 was performed to 
assess BMP pathway inhibition. Phosphorylation of SMAD1/5/8 proteins (pSMAD 
1/5/8) via activated BMP receptors (BMPR) is the main functional indicator of BMP 
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pathway activation (Grimmer and Weiss 2008), and its detection is commonly used 
to assess pathway status (see Fig 1.7 in chapter 1). The number of cells expressing 
pSMAD1,5,8 was assessed by fluorescence imaging and compared to that of 
untreated cells. Five fields in each coverslip were imaged at 20X magnification, and 
the experiments were conducted in triplicates. The average number of cells 
expressing pSMAD1,5,8 among Noggin treated cells were reduced compared to the 
untreated cultures – 57.88% (± 2.85) vs. 77.05% (± 3.25) in DAOY (p=0.0007) [Fig 
3.4 A and C] and 23.69% (± 7.19) vs. 36.06% (± 5.19) in D-458 (p=0.036) [Fig 3.4 B 
and D].  
Western blot was also performed using DAOY protein lysates, which showed that 
pSMAD1,5,8 expression was reduced in relation to total SMAD1,5,8 among Noggin 
treated cells as compared to the untreated control cells (Fig. 3.4 E).  
We concluded that Noggin behaved as a BMP signalling inhibitor in our cell lines, in 
keeping with existing literature (Hallahan, Pritchard et al. 2003). Noggin was 
therefore used in further experiments to study if functional changes induced upon 
BMI1 knock down were BMP pathway related.  
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Fig. 3.4 Noggin treatment reduces the pSMAD1,5,8 expression in MB cell lines.   
 
After 24 hr of Noggin treatment at 1 μg/ml, a reduction in the number of cells expressing pSMAD1,5,8 
as well as a reduction in the staining intensity was noted in both (A) DAOY and in (B) D-458 cells, 
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suggestive of inhibition of BMP pathway. Left panel showing DAPI channel with total number of cell 
nuclei; middle panel showing pSMAD1,5,8 positive cells; and right panel showing merged images. (C 
and D) Quantification of the percentage of pSMAD1,5,8 positive cells (per 20x field), from three 
independent experiments shows a significant reduction in the number of positive cells in Noggin 
treated DAOY (C) and D-458 (D) cells as compared to corresponding untreated counterparts.  (E) 
Western blot showing a reduction of pSMAD1,5,8 expression upon Noggin (Ng) treatment in DAOY 
cells, as compared to  total SMAD1,5,8 expression and Tubulin expression as a loading control. Scale 
bar in both (A) and (B) = 50 μm. Error bars in (C) and (D) represent SD (n=3). *, p<0.05; ***, P<0.001.   
 
3.3.2.2 Increased pSMAD1,5,8 expression upon BMI1 knock down in DAOY and 
D-458 cell linesis reversed by Noggin. 
 
Next, the effect of BMI11 knock down on BMP pathway in MB cell lines was 
assessed by checking pSMAD1,5,8 expression upon Bmi1 knock down in these cell 
lines.   
DAOY and D-458 were plated in a density of 0.5 x 105 cells in 0.5 ml media/well  in 3 
wells of 24 well plates. The cells were transfected with BMI1 siRNA using lipid based 
transfection agent and incubated for 48 hr. Negative siRNA (Scramble or Scr) 
treated cells were used as controls. The cells were then fixed and 
immunocytochemistry for pSMAD1,5,8 was performed . The number of cells 
expressing pSMAD1,5,8 was assessed in DAOYBMI1kd and D-458BMI1kd cultures  as 
compared to that of DAOYScr and D-458Scr. Five fields in each well were imaged and 
the experiments were conducted in triplicates. The average number of cells 
expressing pSMAD1,5,8 among  DAOYBMI1kd and D-458BMI1kd was increased when 
compared to those with DAOYScr and D-458Scr cultures respectively - 86.63% (+/- 
2.41) vs. 77.05% (+/- 3.25) in DAOY (p=0.017) [Fig 3.5 A and C] and 51.17% (+/- 
1.74) vs. 36.06% (+/- 5.19) in D-458 (p=0.004) [Fig 3.5 B and D].  
In parallel, DAOY cells were treated with lentivirus mediated BMI1 shRNA to achieve 
stable knock down (DAOYBMI1kd). As controls DAOY cells infected with empty vector 
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(Scrambled or Scr) lentivirus (DAOYScr) were used. After FACS sorting cells were 
collected and total protein was extracted. Western blot was performed to assess 
pSMAD1,5,8 expression in comparision to SMAD1,5,8 (α-tubulin used for loading 
control). In keeping with above findings, there was an increase in pSMAD1,5,8 
expression in DAOYBMI1kd as compared to DAOYScr control (Fig. 3.5 E).  
To assess if the above differential expression is indeed related to BMP pathway, we 
assessed the pSMAD 1,5,8 expression in cultures concomitantly treated with 
Noggin. Noggin treatment in DAOY and D-458 significantly reduced the pSMAD1,5,8 
expression in both DAOY and D-458 (Fig 3.4) thereby confirming its efficacy as a 
BMP signalling inhibitor in our experimental setting. Noggin was further added 
concomitantly to siRNA BMI1 treated cultures at 1μg/ml, incubated for 48 hr and 
immunofluorescence was performed as above. The average number of pSMAD1,5,8 
positive cells were reduced as compared to siBMI1 only treated cells – 78.47% (+/- 
1.69) vs. 86.63% (+/- 2.4) in DAOY (p=0.006) [Fig 3.5 A and C] and 39.67% (+/- 
1.35) vs. 51.17% (+/- 1.74) in D-458 (p=0.0004) [Fig 3.5 B and D]. These results 
support the notion that BMI1 mediated repression of pSMAD1,5,8 is BMP pathway 
related.  
To exclude any non-specific effect of the Noggin treatment on BMI1 expression, 
qRT-PCR was performed on DAOYScr or DAOYBMI1kd cells. BMI1 expression levels 
(normalised to β-actin) were unchanged upon Noggin treatment (Fig 3.5 F).      
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Fig. 3.5 Aberrant activation of BMP pathway upon BMI1 knock down in MB cell lines is 
reversed by Noggin treatment.  
 
(A and B) Immunohistochemistry showing an increase in the average number (and intensity) of cells 
expressing pSMAD1,5,8 between siRNA BMI1 treated (A) DAOY or  (B) D-458 cells, and  siRNA Scr 
treated controls. This finding is indicative of BMP pathway activation. Concomitant addition of Noggin 
to BMI1 knock down cultures shows a decrease in pSMAD1,5,8 expression, to levels similar to that 
seen in siRNA Scr treated cultures. Left panel showing DAPI channels with total number of cell nuclei; 
middle panel showing pSMAD1,5,8 positive cells; and right panel showing merged images. (C and D) 
Quantification of percentage of pSMAD1,5,8 positive cells (per 20x field) from three independent 
experiments shows a significant increase in siRNA BMI1 treated cells compared to corresponding 
siRNA Scr treated counterparts. There is a significant reduction in pSMAD1,5,8 levels when Noggin is 
concomitantly added to BMI1 knock down cells. (E) Western blot confirming an increase in 
pSMAD1,5,8 expression (in relation to total SMAD1,5,8 expression) in protein extracts of shRNA 
BMI1 treated cells compared to shRNA Scr treated control. Tubulin expression is used for loading 
controls. (F) qRT-PCR showing no difference in BMI1 expression levels when Noggin is added to 
either shRNA Scr or shRNA BMI1 treated cells, excluding any non-specific actions of Noggin on BMI1 
expression. Scale bar in both (A) and (B) = 50 μm. Error bars in (C), (D) and (F) represent SD, n=3. *, 
p<0.05; **, p<0.01; ***, p<0.001.  
 
3.3.3 Primary human medulloblastoma cells isolated from a Group 4 tumour 
show high BMI1 expression and BMI1 knock down confirms activation of BMP 
signalling.  
   
Having observed BMP signalling pathway repression by BMI1  in MB cell lines, we 
wanted to validate the findings on primary human MB cells. We obtained different 
lines of primary cells from our collaborator Dr Xiao-Nan Li, Baylor College of 
Medicine, Texas Children’s Cancer Centre, USA. These primary short term cultures 
have previously been shown to give rise to MB mimicking the tumour of origin in 
murine xenografts (Shu, Wong et al. 2008; Zhao, Liu et al. 2012) .  Our Group have 
recently reported that BMI1 is most highly expressed in Group 4  MB (Behesti, 
Bhagat et al. 2013).  Among the cultures established by our collaborator, ICb-1299 
was derived from a group 4 MB and was shown to stably retain this expression 
profile (Zhao, Liu et al. 2012). Therefore we used short term cultures of ICb-1299 
cells for our experiments. First we checked BMI1 expression in these cells.  Total 
protein was extracted and Western blot was performed to assess BMI1 expression. 
We observed BMI1 protein expression (normalised to α-tubulin) in ICb-1299 at even 
higher levels compared to that in DAOY (Fig 3.6 A).  
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Next, we set out to check BMP signalling status upon BMI1 silencing in the primary 
cells. Due to the nature of growth of these cells as tumour spheres siRNA mediated 
knock down would be unsuitable. Therefore lentivirus shRNA mediated stable knock 
down method was used. The cells were infected with shRNA BMI1, and GFP 
positive cells were enriched for by FACS. Following short term cultures, the cells 
were collected to extract total RNA and protein. shRNA scrambled (Scr) lentivirus 
treated cells were used as controls. qRT-PCR analysis normalised to β–actin 
showed an approximately 4-5 fold reduction in BMI1 expression (Fig 3.6 B). Western 
Blot analysis normalised to α-tubulin demonstrated a significantly reduced BMI1 
protein expression in shRNA BMI1 treated cells (Fig 3.6 C).  
These findings demonstrated an effective BMI1 knock down achieved by lentiviral 
mediated BMI1 shRNA delivery in these cells (ICb-1299BMI1kd) as compared to 
scrambled shRNA treated cells (ICb-1299Scr).  
Prior to functional studies using the primary cells, it was essential to check for BMP 
pathway status following BMI1 silencing. Western blot analysis using total protein 
extracts from these short term cultures was performed. Negligible pSMAD1,5,8 
protein expression was noted in ICb-1299Scr as compared to SMAD1,5,8 expression, 
whereas a significant increase in its expression was detected in ICb-1299BMIkd (Fig 
3.6 D). This is indicative of increased phosphorylation of SMAD1,5,8 proteins and 
BMP pathway activation and  it is keeping with a  scenario where BMI1 represses 
BMP pathway in human MB cells.  
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Fig. 3.6 BMP pathway activation upon BMI1 knock down in primary Group 4 MB cells.   
 
(A) Western blot showing BMI1 expression in ICb-1299 to be even higher than that seen in the DAOY 
cell line. (B and C) Efficient BMI1 knock down is established in primary cells ICb-1299 following 
lentivirus shRNA-mediated transfection, as demonstrated by qRT-PCR analysis (B), and by Western 
blot analysis (C). (D) Western blot analysis shows an increase in pSMAD1,5,8 expression in relation 
to total SMAD1,5,8 (Tubulin as loading control) following BMI1 knock down in ICb-1299 cells. This is 
similar to the observation made in DAOY and D-458 cell lines and implies activation of BMP pathway. 
(E) qRT-PCR showing an increase in ID2 (a downstream target of BMP-SMAD pathway) expression 
in BMI1 silenced cells as compared to controls. Error bars in (B) and (E) represent SD of three 
technical replicas. *, p<0.05; ***, p<0.001.   
 
Having observed increased pSMAD1,5,8 levels upon BMI1 knock down, we asked if 
this could be confirmed by activation of known  downstream targets of BMP 
signalling.  To this end, we chose to check for ID (Inhibitors of DNA binding) mRNA 
transcript levels by qRT-PCR.   
Briefly, Id proteins are dominant negative helix-loop-helix (dnHLH)  transcription 
factors that do not have DNA binding capacity, but that can heterodimerize with 
basic helix-loop-helix (bHLH) proteins and inhibit transcriptional activity of the latter 
(Sun, Copeland et al. 1991). Four distinct members (Id1 – Id4) have been identified 
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in mammals and they are involved in control of cell growth, differentiation and 
tumorigenesis [Reviewed in (Ruzinova and Benezra 2003)]. ID genes are well 
established downstream targets of BMP – SMAD signalling pathway (Katagiri, Imada 
et al. 2002; Korchynskyi and ten Dijke 2002; Lopez-Rovira, Chalaux et al. 2002).  
Exogenous BMPs are shown to increase ID1 and ID2 expression in a time 
dependent fashion in human bone marrow stromal cells (Locklin, Riggs et al. 2001). 
Moreover, BMP-2 and BMP-4 treatment is shown to increase ID1 and ID2 protein 
levels along with pSMAD1,5,8 protein levels in primary medulloblastoma cells in vitro 
(Zhao, Ayrault et al. 2008). We optimised conditions for ID1 and ID2 and performed 
qRT-PCR, normalising the expression to GAPDH. There was no significant increase 
in ID1, but we noted an increase in ID2 expression in ICb-1299BMI1kd as compared to 
ICb-1299Scr (Fig. 3.6 E).        
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3.4 Discussion 
 
BMI1 overexpression is strongly associated with aggressive MB subtypes with poor 
prognosis (Wang, Venugopal et al. 2012). BMI1 is essential for self-renewal of 
haematopoietic and neural stem cells [reviewed in (Valk-Lingbeek, Bruggeman et al. 
2004)] and its targeted deletion in a mouse model (null mutant) causes severe 
neurological and haematopoietic defects (van der Lugt, Domen et al. 1994). As 
targeted deletion of BMI1 is incompatible with life, it is conceivable that its targeted 
suppression as a therapeutic option could be associated with important side effects. 
BMP-2 is shown to induce apoptosis in a dose and time dependent fashion in 
primary human MB cells (Hallahan, Pritchard et al. 2003). Moreover, BMP-2 and 
BMP-4 are shown to suppress primary murine MB cell growth in vitro and in vivo 
(Zhao, Ayrault et al. 2008), and BMP-2 inducing agents such as retinoic acid have 
been shown to reduce human MB cell growth in vitro and in vivo (Spiller, Ditzler et al. 
2008). Therefore BMPs or BMP agonists could be developed as therapeutic options 
for MB treatment. We hypothesise that, if repression of the BMP signalling pathway 
by BMI1 is an essential event in human medulloblastoma pathogenesis, then BMI1 
expression could be a potential bio-marker for MB which may respond to BMP 
analogues.  
In this chapter we demonstrate that in human MB cell lines DAOY and D-458, which 
are known to express BMI1, pSMAD1,5,8 expression is negligible. But upon BMI1 
silencing, pSMAD1,5,8 expression is increased - indicative of a derepression of the 
BMP signalling pathway. Moreover, we observe that pSMAD1,5,8 expression is 
increased following BMI1 silencing also in primary human MB cells, thereby 
validating our findings of cell lines. We have used two independent methods - 
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immunohistochemistry (for DAOY and D-458) and Western Blot (for primary cells 
Icb-1299 and DAOY) to demonstrate repression of BMP pathway by BMI1 in MB 
cells. Similar results were observed when BMI1 silencing was carried out using 
either transient siRNA technique (for DAOY and D-458) or protracted shRNA method 
(in primary cells Icb-1299 and in DAOY again), allowing us to exclude technical 
artefacts even more robustly.  The experiments carried out in DAOY and D-458 after 
concomitant inhibition of BMP signalling by noggin provided further support to the 
notion that the effect seen upon BMI1 knock down in human MB cells was BMP 
mediated.   
One of the downstream targets of BMP-SMAD signalling, ID2 gene expression was 
found to be increased following BMI1 silencing, providing additional support to the 
notion that BMI1 overexpression suppresses BMP signalling.  Id proteins are 
implicated in several cancers (Lasorella, Uo et al. 2001) and a recent study has 
shown that although Id expression in normal cerebellum is absent or minimal there is 
a differential expression of Id proteins observed in human medulloblastoma tumour 
cells and in the endothelial cells of the tumour (Snyder, Dulin-Smith et al. 2013). 
Therefore the association between BMI1 and Id genes could be further explored in 
future studies.  
In summary, we demonstrate here that BMI1 constitutively represses BMP signaling 
in both MB cell lines and in primary group 4 MB cells. To understand the relevance 
of BMI1 silencing on BMP signalling, we set out to investigate the BMP-dependency 
of the functional changes seen upon BMI1 knock down in MB cells.  
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CHAPTER 4 Cell migration of medulloblastoma cell lines is 
regulated by BMI1 in a BMP dependent fashion in vitro.  
 
4.1 Introduction 
 
The role of Bmi1 in human cancers has been primarily associated to the regulation of 
cell proliferation and senescence via suppression of p16Ink4a/p19Arf cell cycle 
inhibition pathways. (Jacobs, Kieboom et al. 1999; Jacobs, Scheijen et al. 1999; 
Meng, Luo et al. 2010). Studies investigating its role in cancer cell migration and 
invasive properties have also emerged. Bmi1 is shown to induce epithelial-
mesenchymal transition (EMT) in human nasopharyngeal carcinoma (Song, Li et al. 
2009). Suppression of endogenous Bmi1 has been shown to reduce cell motility and 
invasive properties in breast cancer cells (Guo, Feng et al. 2011) and in gliomas 
cells (Jiang, Wu et al. 2012). This is suggestive that Bmi1 regulates other cell 
signalling pathways, more relevantly, those regulating extracellular matrix and cell 
adhesion properties. BMP pathway is known to regulate EMT and hence cancer cell 
motility and invasion (Reviewed in (Yang and Weinberg 2008)). Furthermore, TGF-
β/BMP pathways are known to cross talk with other signalling pathway related to 
EMT such as Notch, Wnt and Shh pathways thereby influencing cancer invasion and 
metastasis (Reviewed in (Bailey, Singh et al. 2007) and (Guo and Wang 2009)).  
Using a genetically engineered mouse model, our team have  demonstrated that 
cell-cell interactions between granule and glial progenitors are critically affected by 
Bmi1 during cerebellar development, through specific inhibition of BMP signalling 
(Zhang, Santuccione et al. 2011). As BMP signalling is known to regulate cell-cell 
and/or cell-extracellular matrix (ECM) interactions, thereby controlling cell motility 
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(reviewed in (Guo and Wang 2009)), our team have also analysed whether Bmi1 
could regulate the expression of cell-cell and cell-matrix interaction genes in granule 
cell progenitors (GCPs). GCPs were isolated from P7 cerebella of Bmi1-/- mice and 
control littermates, total RNA was extracted at DIV1 and real time PCR expression 
arrays were used to analyse the expression of 84 genes related to cell adhesion 
(RT2 ProfilerTM PCR Array Mouse Extracellular Matrix and Adhesion Molecules). The 
analysis was performed on three independent preparations, fold changes were 
calculated and significance was analysed by Student’s t-test. 18 cell-cell/matrix 
interaction genes were expressed at significantly higher level in Bmi1-/- GCPs 
(p<0.05) (Table 4.1), of which 12 showed more than 2-fold increase in their 
expression level (range 2.11-5.68). These genes included Thrombospondin1, 2 and 
Fibronectin, Fibulin, Collagens -type I, IV, V and VI, Laminin 1 as well as CD44 and 
MMP 2, 8, 10.  
Next, it was assessed whether BMP pathway inhibition would affect the expression 
of Bmi1-regulated cell adhesion and extracellular matrix genes. Cultures were 
prepared from P7 cerebella of Bmi1-/- and control littermates in triplicates and were 
treated with Noggin prior to expression analysis. Noggin (Ng) is a well characterised 
inhibitor of BMP signalling which acts by competitively binding to the BMP cell 
surface receptors (Zimmerman, De Jesus-Escobar et al. 1996). We identified 4 
Bmi1-regulated cell adhesion genes whose expression was significantly (p<0.05) 
downregulated upon Noggin treatment are listed in Table 4.1. These genes were 
Thrombospondin 2, CD44, MMP10 and Collagen 6a1.  
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Table 4.1. Cell adhesion and extracellular matrix genes whose expression is significant 
upregulated in Bmi1-/- mCGC and expression profile after Noggin treatment* 
Genes Accession KO/WT-
Fold 
P value Ng-
KO/WT
-Fold 
P value 
Thrombospondin 1, mRNA NM_011580  4.72 0.0005 5.92 0.189343 
Elastin microfibril interfacer 
1, mRNA 
NM_133918  2.54 0.0012 2.8 0.303034 
Matrix metallopeptidase 2, 
mRNA  
NM_008610  2.97 0.0014 9.47 0.185114 
Thrombospondin 2, mRNA  NM_011581  1.65 0.0047 -1.15 4.98E-05 
Collagen, type IV, alpha 1, 
mRNA  
NM_009931  1.9 0.0058 2.59 0.057293 
Laminin, alpha 1  NM_008480  3.67 0.0062 2.83 0.168255 
A disintegrin-like and 
metallopeptidase (reprolysin 
type) with thrombospondin 
type 1 motif, 8, mRNA  
NM_013906  1.74 0.0071 3.08 0.182631 
Matrix metallopeptidase 10, 
mRNA  
NM_019471  4.32 0.0091 -1.22 0.007599 
Collagen, type VI, alpha 1  NM_009933  1.69 0.0115 1.02 0.028593 
Collagen, type I, alpha 1, 
mRNA  
NM_007742  2.61 0.0124 5.56 0.128066 
Collagen, type V, alpha 1, 
mRNA  
NM_015734  3.19 0.0133 1.01 0.158273 
CD44 antigen  NM_009851  1.73 0.0160 -1.13 0.037609 
Selectin, lymphocyte, mRNA  NM_011346  -2.36 0.0190 -2.5 0.49582 
Matrix metallopeptidase 8, 
mRNA  
NM_008611  5.68 0.0201 3.47 0.227461 
Tissue inhibitor of 
metalloproteinase 2, mRNA  
NM_011594  2.69 0.0289 1.96 0.106224 
Fibronectin 1  NM_010233  3.18 0.0310 4.08 0.331714 
Secreted acidic cysteine rich 
glycoprotein, mRNA  
NM_009242  2.11 0.0452 1.67 0.220898 
Fibulin 1  NM_010180  3.91 0.0495 1.51 0.109213 
* Statistically significant genes are highlighted in bold. 
 
These data suggest that a subset of cell adhesion genes may be regulated by Bmi1 
through BMP pathway repression during cerebellar development, which forms the 
basis for our further experiments described in this chapter. 
Having established that BMI1 represses BMP signalling in human MB cells (chapter 
3), we set out to assess whether Bmi1 could control cell adhesion and cell motility 
properties through suppression of BMP signalling. To this end we studied cell 
adhesion and cell motility of MB cells upon BMI1 knock down. To assess whether 
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BMI1 could regulate these properties of MB cells via BMP pathway, cells were 
concomitantly treated with Noggin and the results were analysed comparatively.  
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4.2 Experimental design and methodology:  
 
4.2.1 Assessment of multicellular aggregate formation:  
 
The cells treated with siRNA/shRNA BMI1 for knock down studies were cultured on 
PLL coated coverslips in 24 well plates (3 wells per group) and concomitantly treated 
with Noggin where appropriate to inhibit BMP signaling. Following incubation for 48 
hr they were fixed and immunohistochemistry was performed for BMI1 and 
pSMAD1,5,8 antibodies as described in the previous chapter. The coverslips were 
transferred to glass slides and mounted using DAPI medium. Five random 
fluorescent micrographs (20X magnification) were obtained using Leica Confocal 
microscope DFC350 set with Y3 (red), A4 (blue) and L5 (green) filters. The DAPI 
pictures were used to quantify the multicellular clusters using ImageJ software. 
Number of clusters of 10 cells or more were counted in five random fields in each 
well (3 wells per group) and averaged. The results were tabulated under scrambled 
and BMI1 siRNA group for both DAOY and D458. The experiment was conducted in 
triplicates. Student’s t-test was used to calculate the significance of differences.   
4.2.2 Cell migration assays 
 
To assess the effects of BMI1 silencing on MB cell migration/motility and cell 
invasion in vitro, Transwell® migration and wound healing assays were used.   
4.2.2.1 Wound healing assay using time lapse videomicroscopy 
 
Wound healing assay allows studying cell migration and cell interactions. The 
experiment was performed following published protocols (Hu and Verkman 2006; 
Kurayoshi, Oue et al. 2006). The procedure is detailed in M&M (chapter 2, section 
2.6.1).  
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Wound healing assay could not be conducted using D-458 cells as they grew as 
partial tumour spheres in suspension and showed minimal adhesion. Therefore 
wound healing assay was carried out using DAOY cells only.   
4.2.2.2 Time lapse videomicroscopy to assess cell motility (without wound) 
 
Time lapse videomicroscopy is used to track and study individual cell characteristics 
(Simpson, Selfors et al. 2008). This experiment was performed to confirm that the 
area of migration that was assessed by wound healing assay was not confounded by 
cell proliferation. Individual cells were each tracked and distance of motility was 
analysed in this experiment, to compliment wound healing assay. The procedure is 
described in M&M (chapter 2, section 2.6.2).   
 
4.2.2.3 Transwell® migration assay 
 
In contrast to cell motility assay, cell invasion assay requires cell to migrate through 
a basement membrane extract (BME) or extracellular matrix (ECM) barrier by 
enzymatic digestion of the barrier to migrate to the new location. Transwell® inserts 
(Corning); 24mm diameter wells with polycarbonate membrane of pore size 8 μm 
and base area of 4.5 cm2 were used for this assay. Transwell® migration assay is a 
well-established method to assess cancer cell invasion in vitro (Hu and Verkman 
2006; Moskovits, Kalinkovich et al. 2006). The procedure was performed according 
to the manufacturer’s protocol. The details of the procedure are mentioned in M&M 
(chapter 2, section 2.6.3).  
 
4.2.3 Proliferation assays 
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The effect of BMI1 silencing on cell proliferation was assessed by two independent 
methods – growth curve analysis and CyQuant NF assay.  
 
4.2.3.1 Growth curve analysis 
 
The proliferation of cells was assessed by time course experiment to produce a 
growth curve (Horiuchi, Huskey et al. 2012). The DAOY cells were quantified over a 
total of 7 passages, P1 to P7, corresponding to day 0, 3, 5, 7, 10, 12 and 14. The 
procedure is described in details in M&M (chapter 2, section 2.7.1).   
 
4.2.3.2 CyQuant NF assay 
 
The CyQUANT® NF assay (Hong, Jiang et al. 2007) was also used to assess 
proliferation. This assay is based on the measurement of cellular DNA content by 
fluorescent dye binding capacity. The procedure is detailed in M&M (chapter 2, 
section 2.7.2).  
 
4.2.4 Annexin V Apoptosis assay 
 
The effect of BMI1 silencing on apoptosis was assessed in DAOY cells by means of 
the Annexin V assay. Annexin V is a Ca2+ dependent phospholipid binding protein 
that has a high affinity for phospholipid phosphatidylserine (PS). PS is translocated 
from the inner to outer leaflet of the plasma membrane in early apoptotic cells. 
Annexin V conjugated with fluorochrome can be used to detect early apoptotic cells 
without compromising its affinity for PS (Vermes, Haanen et al. 1995). PE Annexin V 
Apoptosis Detection Kit I (BD Pharmingen™, BD Biosciences) was used with Alexa 
167 
 
Fluor 647 Annexin V conjugate (Invitrogen) as per manufacturer’s protocol. The 
complete procedure is described in M&M (chapter 2, section 2.8.1).    
 
4.2.5 Immunohistochemistry:  
 
The Formalin fixed paraffin embedded (FFPE) D-458 cell block sections were 
stained by avidin-biotinylated complex (ABC) method of immunohistochemistry for 
CD44, Thrombospondin, MMP8 and MMP10. The procedure is described in details 
in chapter 2 (section 2.11). The list of primary and secondary antibodies and 
blocking agents used is presented in Table 4.2.  
Table 4.2  List of primary antibodies, secondary antibodies used for ABC IHC. 
Primary antibodies 
 
For antigen to be 
detected 
 
Primary antibody 
used 
Company Concentration Positive 
control  
CD44 Rabbit polyclonal anti-
CD44 
Abcam 
(ab24504) 
20 μg/ml Glioblastoma 
Thrombospondin 
(THBS) 
Mouse monoclonal 
anti-thrombospondin 
Abcam 
(ab1823) 
1:25 Glioblastoma 
MMP8  Goat polyclonal anti-
MMP8 
Santa Cruz 
(sc-8848) 
1:50 Breast 
carcinoma 
MMP10 Rabbit polyclonal anti-
MMP10 
Abcam 
(ab59437) 
1:500 Breast 
carcinoma 
Biotinylated secondary antibody and blocking serum used 
 
For primary 
antibody source 
 
Secondary antibody used Blocking agent 
Rabbit or Mouse Universal biotinylated anti-mouse/anti-
rabbit IgG (Vector) raised from horse. 
2.5% Normal horse serum (Vector)  
 
 
Goat  1:400 Anti-goat IgG (Vector) raised from 
rabbit 
5% Normal rabbit serum    
 
4.2.6 Exogenous BMP treatment:    
 
Use of recombinant BMP-2 and/or BMP-4 for BMP pathway activation is well 
established (Iantosca, McPherson et al. 1999; Hallahan, Pritchard et al. 2003; 
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Piccirillo, Reynolds et al. 2006; Zhao, Ayrault et al. 2008). Use of BMP ligands is 
justified in DAOY cells as they are shown to express BMP receptors - BMPRI 
isoforms and BMPRII - which triggers phosphorylation of SMAD1,5,8 proteins 
(Iantosca, McPherson et al. 1999; Fiaschetti, Castelletti et al. 2011). To induce BMP 
signaling pathway in our study, we used recombinant human BMP-4 (R&D systems) 
on DAOY which was used at a concentration of 100 ng/ml for 24 – 36 hr. Further 
details of the procedure are described in M&M (chapter 2, section 2.3.1). The BMP-4 
treated cells were used in Transwell® migration and cell proliferation assays.     
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4.3 Results 
4.3.1 Increased multicellular cluster formation is observed upon BMI1 knock 
down in MB cell lines 
 
Having previously established that BMI1 silencing led to aberrant BMP pathway 
activation; we asked whether the cell adhesion properties of MB cells may be 
affected. DAOY and D-458 were plated in a density of 0.5 x 105 cells in 0.5 ml 
media/well in 3 wells of 24 well plates. The cells were transfected with BMI1 siRNA 
using lipid based transfection agent and incubated for 48 hr. Negative siRNA (Scr) 
treated cells were used as controls. Noggin was added to the relevant wells at 1 
μg/ml concentration. After 48 hr the cells were fixed and immunocytochemistry for 
pSMAD1,5,8 and BMI1 antibodies was performed. The cells were counterstained 
with DAPI nuclear stain. The pSMAD1,5,8 expression in BMI1 knock down and 
control cultures were quantified as described in chapter 3. While analysing these 
cultures we incidentally noticed a greater tendency to form multicellular aggregates 
in BMI1 knock down cultures. To quantify this observation, the number of 
multicellular aggregates as defined by cohesive clusters of 10 or more cells per 20x 
field was quantified in the DAPI staining. Five fields in each well were imaged and 
the experiments were conducted in triplicates.  
The average number of cell aggregates per high power field (hpf, 20x) was found to 
be increased in DAOYBMI1kd and D-458BMI1kd as compared to DAOYScr and D-458Scr 
respectively – 1.93 (+/- 0.31) vs. 0.07 (+/- 0.12) in DAOY (p=0.004), and 3 (+/- 0.6) 
vs. 1.2 (+/- 0.2) in D-458 (p=0.003) [Fig  4.1 A and B].      
To assess whether cluster formation was dependent on aberrant BMP pathway re-
activation after BMI1 knock down, DAOY and D-458 cultures were concomitantly 
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treated with Noggin. Previously we have demonstrated the efficacy of Noggin as 
BMP pathway inhibitor. Here we were interested to know if changes in adhesion 
seen upon BMI1 knock down are BMP pathway related. When Noggin was applied 
to DAOYScr or D-458Scr, there were no discernible change in the cellular aggregates 
noted (Fig 4.1 A and B). However  Noggin treated DAOYBMI1kd and D-458BMI1kd 
showed a reduced number of aggregates/hpf as compared to cultures without 
Noggin – 0.73 (+/- 0.30) vs. 1.93 (+/- 0.31) in DAOY (p=0.004), and 1.07 (+/- 0.30) 
vs. 3 (+/- 0.6) in D-458 (p=0.003) [Fig 4.1 A and B].    
 
Fig. 4.1 Deregulation of cell adhesion properties in MB cell lines following BMI1 knock down.  
 
(A) DAPI images demonstrating an increase in cell cluster formation upon BMI1 knock down in both 
DAOY (upper panel) and D-458 (lower panel) cells, which interestingly does not occur upon 
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concomitant addition of Noggin to BMI1 knock down cultures. The arrowheads show the cell clusters 
that were counted in each field, representing aggregates of 10 cells or more. There was no difference 
in cell cluster formation between Scr and Noggin treated Scr groups   (B) Quantification of average 
number (from three independent experiments) of cell clusters per 20x hpf shows an increase in 
siRNA-mediated BMI1 knock down cultures as compared to Scr cultures in both DAOY (left) and D-
458 (right). Furthermore, concomitant addition of Noggin to BMI1 knock down cultures shows a 
significant decrease in the number of cell clusters per field in both cell lines. Scale bar in (A) = 50 μm. 
Error bars in (B) represent SD (n=3). **,p<0.01. 
 
From the above findings we can infer that BMI1 knock down affects the cell adhesion 
properties of MB cell lines. Epithelial-Mesenchymal transition (EMT) and 
Mesenchymal-Epithelial transition (MET) are known  to be dependent upon change 
in the microenvironment and in stimulatory signals(reviewed in (Hugo, Ackland et al. 
2007)). As concomitant BMP inhibition by Noggin significantly reduced cluster 
formation induced by BMI1 knock down, it is likely that this phenomenon is mediated 
by BMP pathway activation. These results prompted us to further assess its 
functional relevance in in vitro experiments to assess cell motility and invasiveness 
of MB cell lines.      
 
4.3.2 BMI1 knock down affects MB cell migration in a BMP dependent fashion 
 
A well characterised method that mimics in vivo cell migration is the Wound healing 
assay which is based on cell-cell interaction and directional migration of cells 
(Rodriguez, Wu et al. 2005). Only DAOY cells (and not D-458) were used for this 
assay as they suitably grew as an adhesive monolayer. Each group of shRNA 
lentivirus infected cells were plated in 3 wells of a 24 well plate at a constant density. 
At this stage, Noggin was added at 1 μg/ml to the appropriate cultures and labelled. 
Following further 24 hr incubation when >90% confluence was seen, ~80 µm wide 
wounds (linear scratches) were incised in each well. The cells were then incubated 
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in time lapse chamber and the stage was set to acquire images from three areas 
from each well. Three phase contrast images (10x maginification) per well were 
intermittently acquired over 12 hr and movies were created using Metamorph 
software. Using the same software, area of migration of cells in to the incited wound 
(healed area) was determined. Then, relative area of migration in percentage to the 
original wound area was calculated. The experiments were conducted in triplicates. 
The schematic of the wound healing experiment is shown in Fig 4.2 A.  
We observed a significant reduction in the average relative wound area in the 
DAOYBMI1kd cultures as compared to DAOYScr cultures – 29.08% (+/- 5.19) vs. 
43.11% (+/- 6.47), p=0.0025 (Fig 4.3 B and C).  
The above reduction in area of migration in DAOYBMI1kd was observed to be reverted 
by concomitant treatment of with Noggin. The average area for DAOYBMI1kd with 
Noggin as compared to DAOYBMI1kd without Noggin were 40.18% (+/- 8.42) and 
29.08% (+/- 5.19) respectively, p=0.048 (Fig 4.2 B and C). There was however no 
significant difference in wound closure noted upon DAOYScr additionally treated with 
Noggin as compared to DAOYScr only – 45.79% (+/- 12.59) vs. 43.11% (+/- 6.47), 
p=0.12 (Fig 4.2 B and C). 
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Fig. 4.2 Wound healing assay demonstrating that cell migration of MB cell line DAOY is 
regulated by BMI1 in a BMP pathway dependent fashion.    
 
(A) Schematic diagram of the wound healing assay: Approximately 80 μm wound is incited in a 
confluent monolayer of cells and the cell migration is recorded on time lapse videomicroscopy to 
calculate relative area of wound or gap closure using Metamorph software at the end of 12 hr. (B) Top 
- representative picture of wound gap at 0 hr, Bottom row – representative pictures of wound gap 
closure (wound healing) following cell migration after 12 hr incubation, for shRNA Scr, shRNA Scr + 
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Ng, shRNA BMI1 and shRNA BMI1 + Ng treated cells, from left to right. There is a significant 
decrease in area of gap closure seen in shRNA BMI1 treated cells compared to shRNA Scr treated 
cells. Upon concomitant Ng addition, an increase (reversal) in the area of migration is noted. The red 
dotted lines mark the original gap at the start of the experiment at 0 hr. (C) Quantitation of average 
percentage of area of migration from three independent experiments. Scale bar in (B) = 20 μm. Error 
bars in (C) represent SD (n=3). *, p<0.05, **, p<0.01. Abbreviation: Ng, Noggin. 
 
BMI1 knock down in DAOY cells not only causes changes in cell adhesion as 
observed previously, but also causes changes in cell migration properties. 
Interestingly these changes appear to be dependent on BMP signalling as reversal 
of phenotype was observed upon concomitant Noggin treatment.  
 
4.3.3 BMI1 knock down affects individual cell motility. 
  
As it was possible that the changes in wound healing observed could be due to the 
effects of BMI1 on cell proliferation, we performed individual cell motility assay using 
time lapse microscopy. Similar to wound healing assay shRNA lentivirus treated 
DAOY cells were plated in 3 wells for each group at constant densities and 
incubated in time lapse chamber with stage set to acquire images from five random 
areas in each well. Phase contrast (20x magnification) images were acquired 
intermittently for 6 hr and compiled using Metamorph software. Using the same 
software, ten cells in each field were tracked and the distance of migration of each 
cell to its origin was determined. The experiments were conducted in triplicates. The 
average distances were calculated for both groups and compared.  
There was a significant reduction in the average distance travelled by the cells over 
6 hr observed in DAOYBMI1kd cultures as compared to DAOYScr cultures – 8.43 μm 
(+/- 1.61) vs. 11.41 μm (+/- 1.69), p=0.005 (Fig 4.3).   
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Fig. 4.3 Time lapse experiment tracing individual cells shows decreased cell motility following 
BMI1 knock down in DAOY.  
 
(A) Representative pictures of time lapse tracing of DAOY cell migration comparing shRNA Scr 
treated (left) and shRNA BMI1 treated (right) cells. Blue lines are tracings of movement of ten random 
cells recorded over 6 hr, representing the distance moved from their origin (red dot). (B) 
Quantification of average distance of cell migration, from three independent experiments, showing a 
significant reduction in individual cell motility following BMI1 knock down. This makes it unlikely that 
the effects of BMI1 on cell proliferation confound the results of the wound healing assay. Scale bar in 
(A) = 20 μm. Error bars in (B) represent SD (n=3). **, p<0.01.  
 
This reduction in individual cell migration upon BMI1 knock down support the 
conclusion that the reduction in the wound healing area observed is due to the 
effects of BMI1 on cell migration properties independently of its effects on cell 
proliferation.   
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4.3.4 BMI1 knock down reduced in vitro cell invasion in a BMP mediated 
fashion   
 
Having identified changes in cell-cell adhesion (multicellular aggregates/cluster 
formation) and cell motility (wound healing/migration) upon BMI1 knock down, we set 
out to investigate whether these could impact on the invasive properties of MB cells 
in vitro. As the above phenotypic changes were linked to BMP pathway, we also set 
out to investigate any dependency on BMP deregulation of the potential impact of 
BMI1 knock down on the invasive characteristics of MB cells. For this we used 
Transwell® migration assay – a method which to an extent simulates in vivo invasion, 
as it requires cells to migrate through a substrate barrier. MB are known to primarily 
metastasise via leptomeningel route (Chang, Housepian et al. 1969). The principal 
ECM components of the leptomeninges include laminin and collagens (Wikstrand, 
Friedman et al. 1991; Montagnani, Castaldo et al. 2000); including type I collagen 
(Hubert, Grimal et al. 2009). Therefore to mimic the leptomeningeal environment we 
used Matrigel™ (rich in laminin) and type I collagen as substrates barriers.   
The D-458 cells proved to be unsuitable for Transwell® assay as they failed to 
adhere to the basement membrane extracts used. Therefore the experiments were 
performed using DAOY cells alone. Porous Transwell® inserts were lined with 
Matrigel or collagen substrates. Serum starved shRNA lentivirus or siRNA treated 
cells (with or without Noggin addition) were seeded at a constant density in the 
substrate coated insert wells (3 wells per group) and serum containing media was 
used in the bottom wells.  The cells were incubated for 12 hr to allow migration 
through the substrate barrier.  The cells were then fixed and stained with 
Haematoxylin. The non-migrated cells from the top surface of the insert membrane 
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were scraped and the migrated cells on the bottom surface of the membrane were 
imaged. Five random images from each insert were acquired using light microscopy 
at 20X magnification. The number of cells migrated were counted using ImageJ 
software and the average number of cells per group were compared to controls. The 
experiments were conducted in triplicates. The schematic of the wound healing 
experiment is outlined in Fig 4.4 A.  
We observed a significant reduction in the number of migrating cells in DAOYBMI1kd 
cultures, compared to DAOYScr through collagen type I substrate after 12 hr – 80.67 
(+/- 55.51) vs. 176.07 (+/- 42.38), p=0.005 (Fig. 4.4 B,C).   
Importantly, the number of migrating cells significantly increased upon Noggin 
treatment of DAOYBMI1kd cultures as compared to DAOYBMI1kd alone – 147.23 (+/- 
46.63) vs. 80.67 (+/- 55.51), p=0.004 (Fig. 4.4 B,C). This reversal demonstrates that 
decreased migration of DAOYBMI1kd cells was dependent on aberrant activation of 
BMP pathway. No statistically significant difference in cell migration was noted upon 
Noggin treatment of DAOYScr as compared to DAOYScr alone – 129.58 (+/- 72.56) vs. 
176.07 (+/- 42.38), p=0.081 (Fig. 4.4 B,C).  
There was no statistically significant difference in the number of migrated cells 
between the DAOYBMI1kd and DAOYScr on Matrigel substrate – 87.22 (+/- 6.63) vs. 
118.61 (+/- 15.93), p=0.061(Fig 4.4 D), although a trend toward decrease migration 
similar to what observed in the experiments using collagen substrates was observed. 
The laminin contained in Matrigel substrate is known to be isolated from Engelbreth-
Holm-Swarm (EHS) mouse sarcoma cells (Kleinman, McGarvey et al. 1982), and 
hence Matrigel may not serve as an ideal physiological substrate for studies using 
MB cells. Furthermore, Collagen type 1 is shown to be expressed in leptomeninges 
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(Liang, Diehn et al. 2008), hence it could represent a more appropriate substrate for 
MB cell invasion as compared to Matrigel.     
 
 
 
Fig. 4.4 Transwell
®
 assay reveals a reduced DAOY cell invasion upon BMI1 knock down in 
vitro.  
 
(A) Schematic diagram of the Transwell
®
 assay: Constant number of cells was seeded in the upper 
chamber of substrate coated Transwell
®
 inserts, and allowed to migrate for 12 hr, followed by fixation, 
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staining and counting. (B) Pictures of the bottom surface after scraping the cells from top surface, 
representing only the migrated (invaded) cells at end of 12 hr. From left to right - shRNA Scr, shRNA 
Scr + Ng, shRNA BMI1 and shRNA BMI1 + Ng treated cells. There is a significant decrease in the 
number of cell invasion/migration through collagen seen in shRNA BMI1 treated cells compared to 
shRNA Scr treated cells. Upon concomitant Ng addition, an increased   invasion is noted. (C) 
Quantitation of the average number of migrated cells through collagen substrate. (D) Quantitation of 
average number of migrated/invaded cells through Matrigel substrate. Scale bar in (B) = 20μm.  Error 
bars in (C and D) represent SD (n=3). **, p<0.01. Abbreviation: Ng, Noggin. 
 
These results raise the possibility that BMI1 overexpression increases invasiveness 
of MB cells. These observations prompted us to perform further validation 
experiments taking advantage of ex vivo and in vivo models. Importantly, the 
changes we observed here could be reverted upon BMP pathway inhibition hence 
supporting the notion that BMI1 may contribute to MB aggressiveness via repression 
of the BMP pathway.   
 
4.3.5 BMI1 knock down leads to deregulation of cell adhesion/ECM molecules 
 
From previous experiments conducted by our team (experiments conducted by Dr 
Xinyu Zhang, results in press), which were discussed in this chapter’s introduction 
(section 4.1), four cell adhesion/ECM genes whose expression was significant 
upregulated in Bmi1-/- mCGC and reversed after Noggin treatment were identified 
(Table 4.1).  
Here we analysed whether BMI1 silencing would impact on the expression of these 
genes in MB cells. Immunohistochemistry for CD44, Thrombospondin 1&2 (THBS 
1/2), MMP10 and additionally for MMP8 was carried out on DAOY and D458 
cytoblocks that were previously generated in the Marino lab from cells treated with 
either BMI1 siRNA or with scrambled siRNA (controls). There was no interpretable 
staining noted in DAOY cell blocks. However, we observed a diffuse and intensely 
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increased staining for CD44 antibody in D-458BMI1kd cell blocks as compared to D-
458Scr (Fig 4.5 A,E). Conversely, THBS staining was seen to be uniformly reduced 
among D-458BMI1kd cell blocks as compared to D-458Scr (Fig 4.5 B,F). However there 
was no change in either intensity or extent of staining observed with MMP8 (Fig 4.5 
C,G) and MMP10 (Fig 4.5 D,H) antibodies.  
 
 
Fig. 4.5 Deregulation of certain cell adhesion/ECM molecules upon BMI1 silencing in D-458 
cells.  
 
D-458 cells were treated with siRNA BMI1 or siRNA Scr, fixed and embedded in paraffin blocks. 
Immunohistochemistry on the sections using CD44, Thrombospondin, MMP8 and MMP10 antibodies 
was performed. An increased (intensity) CD44 expression (A and E), and a decreased 
Thrombospondin (intensity and number) expression (B and F) was noted upon BMI1 knock down as 
compared to Scr controls. There was no change in expression present for MMP8 (C and G) and 
MMP10 (D and H). Scale bar in all = 20 μm. 
 
The changes in the expression of ECM proteins could be in keeping with the in vitro 
observation of changes in cell adhesion and cell migration/invasion after BMI1 
downregulation in medulloblastoma cells. However, a note of caution is warranted 
because the staining intensity could not be reliably quantified as the immunostaining 
was performed with the chromogenic method and the results were somewhat 
variable among the different replicas. Also, the lack of a reliable staining in the 
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DAOY cytoblock prevented us from comparing the results with existing datasets 
(Wiederschain, Chen et al. 2007) to further validate the findings.   
 
4.3.6 Decreased proliferation of MB cells upon BMI1 knock down is not BMP 
pathway dependent   
 
Next, we set out to assess whether the changes in cluster formation and in cell 
migration/invasion upon BMI1 downregulation could be influenced by the Ink4a/Arf-
mediated cell cycle control exerted by Bmi1 in various physiological and cancer-
related contexts. Bmi1 downregulation was shown to cause reduced proliferation and 
early senescence in various cancer cells such as oral carcinoma cells (Kang, Kim et 
al. 2007) and gliomas cells (Godlewski, Nowicki et al. 2008). Wiederschain et al., 
have shown that shRNA mediated BMI1 knock down in DAOY cells causes reduced 
proliferation (Wiederschain, Chen et al. 2007). Here we performed proliferation and 
apoptosis assays in MB cells to check the dependency of these effects on BMP 
pathway deregulation.   
We used two independent methods to quantify proliferation in MB cells in response 
to BMI1 downregulation – growth curve analysis and CyQuant assay. 
To produce a time course growth curve shRNA transfected DAOY cells were plated 
at a constant density of 1x105 cells per well in a 6 well plate and after 3 days 
incubation the cells were re-counted. Multiplication factor (f) was generated where f = 
no. newly counted cells/no. of originally plated cells. Estimated number of cells (e) 
was defined at each passage as e = f x previous e. During each passage, 1x105 cells 
were plated, for a total of 7 passages, P1 to P7, corresponding to day 0, 3, 5, 7, 10, 
12 and 14. Triplicates of each group of cells were prepared and counted. The 
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experiment was done in three biological replicas. Relevant DAOY cultures were 
supplemented with Noggin 1 μg/ml every 24 hr.  
There was a significant reduction in proliferation of DAOYBMI1kd cultures compared to 
DAOYScr for all passages (Fig 4.7 A,B). However there was no difference in 
proliferation in Noggin treated DAOYBMI1kd compared to DAOYBMI1kd only cultures (Fig 
4.7 A,B). The average estimated number of cells (e) calculated during each passage 
for each group is tabulated in Table 4.3, and the respective p values are listed in 
Table 4.4.   
Table 4.3 Growth curve assay with estimated number of DAOY cells ‘e’ at the end of each 
passage.   
 
Passage 
(days)  
 
Estimated cell number e with (std. dev.) 
sh Scr 
 
sh BMI1 
 
sh BMI1 + Ng 
 
P1 (0) 100000 100000 100000 
P2 (3) 
240333 
(+/- 1247) 
174333 
(+/- 1700) 
175000 
(+/- 17795) 
P3 (5) 
386917 
(+/- 6188) 
209763 
(+/- 1206) 
218483 
(+/- 34300) 
P4 (7) 
797090 
(+/- 22719) 
356499 
(+/- 15077) 
374355 
(+/- 54713) 
P5 (10) 
199189 
(+/- 110689) 
774266 
(+/- 76427) 
871283 
(+/- 113634) 
P6 (12) 
4648035 
(+/- 329337) 
1573638 
(+/- 170055) 
2023768 
(+/- 443809) 
P7 (14) 
9417207 
(+/- 352784) 
2782843 
(+/- 336752) 
3947720 
(+/- 771796) 
 
Table 4.4 Statistical significance (p value) calculated in DAOY growth curve analysis for 
different passages.   
Groups 
compared 
 
p values generated by Student’s t-test 
P2 (3) 
 
P3 (5) 
 
P4 (7) 
 
P5 (10) 
 
P6 (12) 
 
P7 (14) 
 
sh Scr vs. sh 
BMI1 0.000001 0.000028 0.002644 0.033383 0.016736 0.023710 
sh BMI1 vs. sh 
BMI1 + Ng 0.480233 0.305787 0.397628 0.075917 0.092425 0.092037 
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CyQUANT® NF proliferation assay, which is based on measurement of cellular DNA 
content by fluorescent dye binding capacity, was also performed using shRNA 
transfected DAOY cells. Each group of cells were plated in 3 wells in 96 well plates 
at a constant density and after 24 hr overnight incubation fluorescent dye binding 
solution was added to each wells and allowed equilibration for 30 min as per 
manufacturer’s instructions. The fluorescence intensity (excitation set at 480 ±10 nm, 
and emission detection at 530 ± 10 nm) of each sample was measured. The 
experiments were conducted in triplicates and average readings were obtained.    
The average fluorescence units (indicative of DNA content and hence proliferation, 
measured at a single time point) was significantly reduced among DAOYBMI1kd as 
compared to DAOYScr – 280.55 (+/- 43.60) vs. 532.44 (+/- 51.60), p=0.003 (Fig 4.6 
C). Importantly there was no significant difference in proliferation between Noggin 
treated DAOYBMI1kd cultures and DAOYBMI1kd alone – 203.56 (+/- 51.30) vs. 280.55 
(+/- 43.60), p=0.09 (Fig 4.6 C).   
 Proliferation assay on ICb-1299 primary cells showed similar results to that 
observed in DAOY. The average fluorescence units was significantly reduced among 
ICb-1299BMI1kd as compared to ICb-1299Scr – 37.11 (+/- 2.08) vs. 56.56 (+/- 3.28), 
p=0.001 (Fig 4.6 D).  
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Fig. 4.6 BMI1 controls MB cell proliferation in a BMP pathway independent fashion.  
 
(A) Representative pictures of DAOY cells in culture at P1 (day 3); demonstrating a reduced in vitro 
growth/proliferation in sh BMI1 treated cells (middle, inset – fluorescent channel of the same field 
showing GFP positive cells), compared to sh Scr treated cells (left), which does not change 
significantly upon concomitant addition of Ng (right). (B) Growth curve plotted against cell passages 
over seven passages (14 days), showing a significant reduction in proliferation among BMI1 knock 
down cells, with no significant difference upon addition of Ng. (C) CyQuant
®
 NF assay confirming the 
results observed with the growth curve analysis in DAOY. (D) CyQuant
®
 NF assay on ICb-1299 
primary cells, showing a reduced proliferation in shRNA BMI1 treated cells as compared to shRNA 
Scr treated controls. The values on X-axis are fluorescence units corresponding to rate of proliferation 
(based on new DNA content). Scale bar in (A) = 50 μm. Error bars in (C and D) represent SD (n=3). *, 
p<0.05; **, p<0.01; ****, p<0.0001; *****, p<0.00001. Abbreviation: BF, bright field; Ng, Noggin; P, 
passage number with corresponding day in ().  
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The above results confirm the literature findings (Wiederschain, Chen et al. 2007) 
that BMI1 downregulation leads to reduced cell proliferation in both MB cell lines and 
primary cultures. However, concomitant treatment of DAOYBMI1kd with Noggin did not 
affect proliferation as demonstrated by two independent methods. This is compatible 
with a model whereby BMI1-mediated regulation of proliferation is independent of 
BMP pathway, thus is not involved in the migration/invasion phenotype.   
 
4.3.7 BMI1 knock down does not significantly affect apoptosis and remains 
uninfluenced by inhibition of the BMP pathway  
 
Next, we set out to study if BMI1 knock down has any effects on apoptosis in MB 
cells. For this we used Annexin V assay with Alexa Fluor 647 conjugate as per 
manufacturer’s protocol. 1x105 lentivirus sh RNA transfected DAOY cells (with or 
without Noggin treatment) were collected in 100 μl of 1X binding buffer per group in 
FACS tube. 5 μl of Annexin V conjugate was added to each tube along with 10 μl of 
1:1000 DAPI. The samples were gently mixed and incubated at room temperature in 
the dark for 15 min. 400 μl of 1X binding buffer was then added to each tube and the 
samples were run in a flow cytometer machine according to protocols  optimised for 
DAPI, GFP and Annexin V channel detection. The percentage of total GFP positive 
cells was detected first. Then the gates were set to detect early apoptosis (Annexin 
V positive, DAPI negative), dead cells (DAPI positive, Annexin V positive) and live 
cells (Annexin V negative, DAPI negative) from the GFP only positive population 
(representing lentivirus infected cells only). The percentage of early apoptotic cells 
was determined using FACS Diva™ v6.1.3 software. Average percentage of four 
independent experiments was used for analysis.  
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11-23% of cells were detected to be viable cells for analysis (Fig 4.7 A), among 
them, 59-61% of the cells were GFP positive (Fig 4.7 B). Among the GFP positive 
cells, the average percentages of Annexin V only positive cells indicative of early 
apoptosis for DAOYBMI1kd as compared to DAOYScr were 80.13% (+/- 11.15) vs. 
85.65% (+/- 8.02), p=0.257 (Fig 4.7 C, 3rd and 1st pic from left). This difference for 
Noggin treated DAOYScr as compared to DAOYScr only were 81.50% (+/- 6.35) vs. 
85.65% (+/- 8.02), p=0.254 (Fig 4.7 B, 2nd and 1st pics from left). The counts for 
concomitant Noggin treated DAOYBMI1kd as compared to DAOYBMI1kd only were 
78.58% (+/- 10.77) vs. 80.13% (+/- 11.15), p=0.434 (Fig 4.7 B, 4th and 3rd pics). To 
summarise, there was no significant changes in apoptosis seen upon BMI1 knock 
down whether or not the BMP pathway was concomitantly inhibited (Fig 4.7 D). 
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Fig. 4.7 BMI1 knock down does not affect apoptosis, and remain uninfluenced upon BMP 
pathway inhibition.  
 
(A) Fluorescent activated cell sorting (FACS) flow cytometry, selecting suitable fluorescent labelled 
cells (11-23%) from the total cells. (B) Among the selected cells, approximately 59-61% of the cells 
were GFP positive representing efficiently infected with GFP-lentivirus. This population is selected for 
Annexin V apoptosis assay. (C) FACS analysis indicating the fractions of dead (DAPI only positive), 
early apoptotic (Annexin V only positive) and alive (DAPI and Annexin V negative) cells. There is no 
significant difference in early apoptosis between shRNA BMI1 or shRNA Scr treated cells. 
Furthermore, there is no difference in early apoptosis between shRNA BMI + Ng or shRNA BMI1 only 
treated cells. (D) Average of percentage of early apoptosis cells (Annexin V positive fraction) from 
three independent experiments, showing no significant difference in different cell groups as above. 
Error bars in (D) represent SD (n≥3). Abbreviation: Ng, Noggin; SSC, side scatter; FSC, forward 
scatter; FITC, green fluorochrome (480 nm) in flow cytometry; GFP, green fluorescent protein; DAPI, 
4’,6’-Diamindino-2-Phenylindole, staining nuclei of dead cells.    
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4.3.8 Exogenous BMP-4 treatment of MB cell lines affects in vitro cell invasion 
in a BMI1-dependent fashion 
 
Next, we reasoned that if Bmi1 represses BMP pathway in MB cells, its expression 
could be an indicator of potential responsiveness of the cells to BMP treatment.   
Hence we set out to investigate whether changes in cell invasion could be exerted by 
treatment with exogenous BMP treatment and whether they were dependent on 
Bmi1 expression. .  
First, we wanted to confirm BMP pathway activation upon treatment of DAOY cells 
with exogenous BMP. 1 x 105 DAOY cells were plated in 2 ml medium in each well of 
a 6 well and treated with BMP-4 at 100 ng/ml concentration for 24 – 72 hr. Protein 
expression analysis for pSMAD1,5,8 and SMAD1,5,8 was performed by Western 
blot. This demonstrated BMP pathway activation 24h and 48h after BMP-4 treatment 
(Fig.4.8).      
 
 
Fig. 4.8 BMP-4 activates BMP pathway in DAOY cells.  
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Western blot analysis showing an increase in phosphorylated SMAD1,5,8 (pSMAD1,5,8) protein  in 
relation to SMAD1,5,8 expression in DAOY cells upon treatment with human recombinant BMP-4 100 
ng/ml, indicative of BMP pathway activation. The pSMAD1,5,8 levels are increased at 24 - 48 hr time 
points. Tubulin expression is used as loading control. Abbreviation: BMP, Bone Morphogenetic 
Protein.  
 
4.3.8.1 BMI1 expression is essential for BMP-4 mediated reduction of DAOY in 
vitro cell invasion 
 
There is conflicting evidence in the literature on the effects of BMPs on cancer cells. 
BMP-2 is shown to enhance in vitro migration and invasiveness in a time and dose 
dependent fashion in gastric carcinoma cells (Kang, Kim et al. 2010) and breast 
carcinoma cells (Katsuno, Hanyu et al. 2008). Contrarily, BMP-4 treatment has been 
shown to effectively inhibit tumour growth in in vivo glioblastoma tumour transplants 
(Piccirillo, Reynolds et al. 2006). Here we investigate the effects of exogenous BMP 
on cell invasion in DAOY cells. For this we used previously established Transwell® 
migration assay (discussed previously in this chapter, section 4.3.4 and Fig 4.4 A.).  
The timeline of BMP pathway activation observed in DAOY upon treatment with 
exogenous BMP4 was well within the requirements for the Transwell migration 
assay. Hence the assay was performed as previously described (section 4.2.2.3).  
There was a significant reduction in the average number of cell migration/20X field 
noted in DAOYScr treated with BMP-4 as compared to untreated DAOYScr cells – 75.8 
(+/- 14.78) vs. 142.85 (+/- 24.26), p=0.003 (Fig 4.9 A,B). As observed previously, 
reduction in migration was reproducible in DAOYBMI1kd as compared to DAOYScr 
cultures – 65 (+/- 8.85) vs. 142.85 (+/- 24.26), p=0.001 (Fig 4.9 A,B). Notably there 
was no additional reduction of cell migration seen in DAOYBMI1kd cultures treated with 
BMP-4 as compared to DAOYBMI1kd without BMP4 treatment – 61.84 (+/- 9.07) vs. 65 
(+/- 8.85), p=0.160 (Fig.4.9 A,B).  
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Fig. 4.9 BMP treatment reduces in vitro invasion in DAOY.  
 
(A) Pictures (20x magnification) of the bottom surface of the Transwell
®
 inserts coated with collagen 
substrate, after scraping the cells from top surface, representing only the migrated (invaded) cells at 
end of 12 hr. From left to right - shRNA Scr, shRNA Scr + BMP-4, shRNA BMI1 and shRNA BMI1 + 
BMP-4 treated cells. There is a significant decrease in number of cell invasion/migration through 
collagen seen in shRNA Scr + BMP-4 treated cells compared to shRNA Scr only treated cells. This 
decrease is comparable to and similar to that seen upon shRNA BMI1 treated cells. There is no 
further change in invasion with concomitant shRNA BMI1 + BMP-4 treatment. (B) Quantitation of 
average number of migrated/invaded cells (from four replicas) through collagen substrate. Scale bar 
in (A) = 20 μm. Error bars in (B) represent SD (n=4). **, p<0.01. Abbreviation: BMP, Bone 
Morphogenetic Protein.  
 
These results show that the effects of exogenous BMP-4 treatment on in vitro cell 
migration/invasion in MB cell lines are similar to those obtained upon BMI1 knock 
down and the lack of additional changes seen upon concomitant BMP-4 treatment in 
BMI1 silenced cells raise the possibility that BMI1 expression is essential for BMP 
mediated effect on the cells 
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4.4 Discussion  
  
The events leading to metastasis such as detachment of the cells, dissemination, 
attachment and growth at the secondary site occur as result of epithelial cells 
temporarily acquiring mesenchymal features (Meng and Wu 2012). Collectively 
these changes are termed as epithelial-mesenchymal transition (EMT, originally 
described in embryogenesis) which include changes in cell-cell/ cell-extracellular 
matrix adhesion, cell motility and cell cytoskeleton, which are orchestrated by 
complex molecular changes (Yilmaz and Christofori 2009). As discussed above, 
BMPs are implicated in induction of EMT and metastasis of several cancers (Bailey, 
Singh et al. 2007). They are known to have contradictory roles depending on the 
cancer tissue type and their effects must be interpreted individually. Here we 
observe changes in cell adhesion, cell motility and invasion phenotypes in MB cells 
in response to BMI1 silencing. Interestingly all of these changes were reversible 
upon concomitant inhibition of BMP signalling by Noggin, suggesting that the above 
cellular effects of BMI1 are mediated by BMP pathway. 
Differential expression of selected cell adhesion/ECM molecules observed among 
BMI1 silenced MB cells supports the notion that BMI1 regulates MB dissemination or 
metastasis. To briefly discuss the relevance of cell adhesion/ECM molecules that we 
studied – (1) Thrombospondins are adhesive glycoprotein that mediates cell-to-cell 
and cell-to-matrix interactions, and they bind to fibrinogen, fibronectin and collagens. 
Thrombospondin 1&2 (THBS 1/2) are overexpressed in medulloblastoma 
(MacDonald, Brown et al. 2001; Wiederschain, Chen et al. 2007). (2) CD44 is a cell-
surface glycoprotein receptor for hyaluronic acid and is known to be expressed in 
primitive neuroectodermal tumours (Parker and Pilkington 2005). (3) Matrix 
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metalloproteinase (MMP) are zinc dependent enzyme family involved in breakdown 
of extracellular matrix, mainly degrading type I, II and III collagens. They are known 
to be expressed in medulloblastoma albeit with variability in different subtypes 
(Vince, Herbold et al. 2001; Ozen, Krebs et al. 2004). All of these molecules are 
shown to be modulated by TGF-β/BMP – SMAD signalling pathway in EMT and 
metastasis of various malignancies (reviewed in (Ikushima and Miyazono 2010)). It is 
therefore possible that the differential expression of THSB and CD44 seen in BMI1 
silenced D-458 cells could be secondary to BMP pathway activation.  
Bmi1 has been shown to control cell proliferation and senescence in physiological 
conditions and in the cancer related context by regulating the ink4a/arf locus 
(Jacobs, Kieboom et al. 1999). Bmi1 is shown to be overexpressed in proliferating 
precursor cells during cerebellar development (Leung, Lingbeek et al. 2004). In our 
study we observed a decrease in proliferation of DAOY cells upon BMI1 knock down. 
This is in keeping with the published literature (Wiederschain, Chen et al. 2007; 
Wang, Venugopal et al. 2012). Interestingly we did not observe a difference when 
BMP pathway was concomitantly suppressed, supporting the view that the effects of 
proliferation is independent of BMP pathway.  
In our study we did not detect any significant changes in apoptosis (using Annexin V 
assay) in DAOY cell lines in response to BMI1 downregulation. This is in contrast to 
published literature (Wiederschain, Chen et al. 2007) where BMI1 knock down was 
shown to increase apoptosis (cells in subG1 phase, using Propidium idodide assay) 
in DAOY cells.  Although the reason of this discrepancy is at present unknown, it is 
possible that the effect on apoptosis could depend on level of BMI1 knock down 
achieved.  
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Although different BMPs are known to have contradictory roles in different cancers 
(reviewed in (Thawani, Wang et al. 2010)), in the  MB context, BMP-2 and BMP-4 
have been shown to prevent cerebellar granule cell precursor cell proliferation (Rios, 
Alvarez-Rodriguez et al. 2004). BMP-4 is reported to have inhibitory role in glioma 
tumour growth (Piccirillo, Reynolds et al. 2006; Liu, Tian et al. 2010). Furthermore, 
there is evidence to suggest that BMP-2 and BMP-4 inhibit tumour growth in vitro 
and in vivo (Hallahan, Pritchard et al. 2003; Zhao, Ayrault et al. 2008). Therefore 
BMPs are potential therapeutic targets for MB treatment. In fact, BMP-2 inducing 
agent 13-cis retinoic acid, either alone or in combination with other chemotherapeutic 
agents has been shown to effectively reduce in vivo MB tumour growth in a pre-
clinical study (Spiller, Ditzler et al. 2008). Vrijens et al., have described small 
molecule BMP activators which could potentially be developed as a medulloblastoma 
treatment (Vrijens, Lin et al. 2013).           
Here we observe reduced invasion upon BMP-4 treatment in DAOY cell lines, in a 
similar fashion as observed upon BMI1 downregulation. Interestingly, exogenous 
BMP-4 treatment did not exert an additional effect when applied after BMI1 knock 
down. These findings raise the possibility that expression of BMI1 could represent a 
biomarker for MB which could benefit from treatment with small molecules acting as 
BMP agonists. However further validation studies using primary human 
medulloblastoma tissue samples and pre-clinical studies using genetically 
engineered mouse models are necessary to confirm these preliminary data.  
Having established that BMI1 regulates cell adhesion, migration and invasion 
properties of MB cell lines in vitro via suppression of BMP signalling, we further 
studied their effects on primary cell growth and invasion using ex vivo and in vivo 
models.    
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CHAPTER 5 Ex vivo organotypic co-culture assay reveals 
effects of BMI1 on cell migration properties in MB cells.  
 
5.1 Introduction 
 
Our results so far have shown that i) BMI1 silencing causes aberrant activation of 
BMP signalling in primary human MB cells and in MB cell lines, and ii) BMI1 
regulates cell adhesion, migration and invasion properties of MB cell lines in vitro via 
suppression of BMP signalling in MB cell lines. Here, we set out to further 
characterise the effects of BMI1 knock down on growth and migration of primary 
human MB cells using an ex vivo model – the organotypic cerebellar slice (OCS) co-
culture. We decided to use this model because in vitro models such as the Transwell 
migration assay (or Boyden chamber assay) and the wound healing assay would not 
be suitable for the primary cells which grow as tumour spheres in culture.  In parallel, 
the experiments were conducted also on DAOY cells to compare the results of the 
ex vivo assay with those obtained in cell culture.  
The OCS assay was originally developed to study neuron-specific interactions and 
neuronal development of the cerebellum because it retains some aspects of the 
anatomical complexity of the developing cerebellum (Tanaka, Tomita et al. 1994). 
Organotypic brain slice cultures have been successfully used to study glioma cell 
invasion (de Bouard, Christov et al. 2002; Jung, Kim et al. 2002; Palfi, Swanson et 
al. 2004) and to quantify proliferation and angiogenesis of glioma cell lines (De 
Bouard, Guillamo et al. 2003; Guillamo, de Bouard et al. 2009). In brief, the brain 
explants are placed on a porous membrane to form an interface between medium 
and air, and co-cultured with fluorescence tagged tumour cell spheres for relevant 
assessments. The main advantage of this method is that the cytoarchitectural and 
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morphological characteristics of the tissue are maintained for a few days to a couple 
of weeks (Stoppini, Buchs et al. 1991). Moreover, this method recapitulates the 
cellular and extracellular matrix conditions in vivo, thus allowing us to assess their 
invasion and motility in an environment closely mimicking in vivo conditions.     
5.2 Experimental design and methodology:  
 
5.2.1 Organotypic cerebellar slice (OCS) preparation:   
 
The OCS was prepared in accordance to previously published literature (Guillamo, 
de Bouard et al. 2009; Farioli-Vecchioli, Cina et al. 2012). The brains were isolated 
from P4-P6 C57BL/6 pups after decapitation by carefully separating and peeling the 
skull, and then collected in ice cold dissection buffer. The dissection buffer was 
prepared by supplementing 200 ml of Hank’s Balanced Solution (HBSS) with 2 ml of 
45% glucose (Sigma) and 3 ml of Amphotericin B (Sigma). The cerebellum was 
dissected from the brain and the attached meninges were removed. The cerebellum 
was sectioned sagittally at 420 µm thickness using McIlwain tissue chopper (The 
Mickle Lab. Engineering Co. Ltd.). The chopped slices were then transferred on to a 
Teflon disk (Fischer), containing dissection buffer, and individual slices were gently 
separated. The slices were kept cold for 1 hour to prevent overt gliosis.  
Millicell-CM insert (Millipore), a porous membrane, was placed in each well of a 6-
well plate, and 1.3 ml of culture media was added to the bottom of each well. The 
plate was incubated at 370C for at least 1 hour. The culture media is prepared by 
supplementing 50 ml of MEM (Sigma) with 25 ml of HBSS, 25 ml of horse serum 
(GIBCO), 0.5 ml of 200 mM glutamine (GIBCO), 1 ml of 45% glucose and 1.5 ml of 
Amphotericin B.  Then, under stereomicroscopy (Zeiss, KL1500 LCD) 3 - 5 viable 
cerebellar slices were selected and plated on each Millicell-CM insert. The slices 
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were incubated at 370C for 24 hr before co-culturing with the tumour spheres and the 
co-culture was continued for 8 days. The culture media was replaced every 3 days.  
5.2.2 Generation of tumour cell spheres:  
 
In order to perform co-culture assay, it was necessary to culture MB cells as tumor 
spheres. For DAOY cells, the spheres were generated as per previously published 
protocol (Meng, Kallinteri et al. 2007). 0.5-1 x 106 DAOY cells which were previously 
labelled with GFP as described in M&M (chapter 2, section 2.2.3.1) and in chapter 3, 
were harvested from monolayer culture and cultured in a 25 cm2 screw-top culture 
flasks (Falcon) with 10 ml complete media. These flasks were maintained at 37oC on 
an orbital incubator (Stuart Scientific) at a constant rotation of 70 rev/min. Following 
24 hr incubation, tumour spheres were obtained (Fig. 5.1A).  
ICb-1299 cells were cultured at 370C in ultra-low attachment 6-well plate (Costar) to 
ensure tumour sphere of adequate size were obtained (Wang, Wang et al. 2008). 
The cells were cultured in Dulbecco’s MEM medium containing F12 (Invitrogen) 
supplemented with EGF 20 ng/ml (Peprotech), FGF 20 ng/ml (Peprotech), 1% B27 
(Invitrogen) and 1% penicillin-streptomycin (Sigma). After 3 days incubation, 
satisfactory tumour spheres were obtained (Fig 5.1 B), which were used to co-culture 
with organotypic cerebellar slice culture to assess cell migration.  
 .   
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Fig. 5.1 Generation of tumour spheres for the co-culture assay. 
 
(A) Tumour sphere from DAOY cells generated as a result of culturing them in a flask and incubating 
on an orbital rotator for 24 hr. (B) Tumour spheres from ICb-1299 cells generated as a result of 
culturing them in ultra-low attachment plates with culture media supplemented with growth factors. 
Generation of tumour spheres enabled co-culturing with the ex vivo OCS. Scale bars in A and B = 200 
μm.  
 
5.2.3 Organotypic cerebellar slice (OCS) and tumour cell sphere co-culture:  
 
The tumour spheres were then seeded on the cerebellar slice cultures under a 
dissecting microscope (Leica M165C) and incubated for 8 days. The co-cultures 
were then fixed with cold 4% PFA for 15-20 min and the membrane of the insert was 
carefully cut to include the co-culture slices, which were transferred on to glass 
slides with the co-culture side facing up. The co-cultures were stained with DAPI 
nuclear stain and mounted with a glass coverslip. The tumour cells could be 
identified by their GFP positivity induced by the lentiviral infection. The schematic of 
the method of the OCS co-culture is shown in Fig 5.2.  
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Fig. 5.2 Schematic of Organotypic Cerebellar Slice (OCS) – tumour sphere co-culture assay.  
 
The cerebellum harvested from C57/BL6 pups was sliced at 420 µm thickness, and the slices were 
cultured on semi-porous membrane placed in a plate containing culture media. GFP lentivirus infected 
MB tumour spheres from DAOY or ICb-1299 cells were seeded on the slices, co-cultured for 8 days 
and fixed. The area of migration and distance of migration after 8 days was analysed using confocal 
microscopy.    
 
 5.2.4 Imaging and analysis:   
 
Tumour cells could be identified because of their GFP positivity against the other 
DAPI positive cerebellar cells. The images were captured with Confocal 710 
microscope (Zeiss) at a magnification of 10X (for DAOY), 20X (for ICb1299) and 20X 
(for DAOY), 40X oil (for ICb1299) for area and distance assessment respectively. 
Lower magnification was suitable to capture the entire area of migration whereas 
more precise individual distance of migration could be assessed more accurately by 
using higher magnification images. The difference in magnification used for the 
measurements of DAOY and ICb1299 is because DAOY are considerably larger in 
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size as compared to ICb1299. Cell migration was assessed using three  parameters 
– i) percentage of invasion area (total area – tumour area/ total area x 100) and ii) 
maximum distance of migration (distance in μm from the periphery of the initial 
tumour sphere to the most distally migrated tumour cell), and iii) The depth of 
invasion in μm using Zen 2011 software (Zeiss). Three areas were assessed on 
each slice and a total of three slices were analysed for each experimental group. The 
experiments were conducted in technical and biological triplicates. The depth of 
invasion from the surface was measured by using Z-stack analysis (Froeling, Mirza 
et al. 2009).   
 
5.3 Results 
5.3.1 BMI1 silencing causes a reduction in the migration area of primary MB 
cells ICb-1299 and of the MB cell line DAOY.  
 
We prepared organotypic cerebellar slices of 420 µm nominal thickness from the 
cerebellum of C57BL/6 P4-6 pups and cultured them on porous membranes in a 
chamber containing medium for a minimum of 24 hours. Primary cells ICb-1299 
transfected with shRNA were maintained as tumour spheres as short term cultures. 
For better comparison, shRNA transfected DAOY were also cultured as tumour 
spheres for this specific experiment. Tumour spheres (at least 3-5 spheres/slice) 
were then transferred onto the surface of viable OCS slices and co-cultured for 8 
days.  
After 8 days of co-culture, we observed a reduced migration area in both DAOYBMI1kd 
and ICb1299BMI1kd as compared to DAOYScr and ICb-1299Scr respectively – 43.63% 
(± 6.06) vs 64.23% (± 7.83) in DAOY (p=0.021) [Fig 5.3 A,C,E] and 35.34% (± 2.64) 
vs 48.19% (± 3.74) in ICb1299 (p=0.008) [Fig 5.3 B,D,E].   
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Fig. 5.3 BMI1 silenced tumour spheres show reduced migration area in an ex vivo OCS co-
culture.   
 
(A) A reduction in the migration area is noted in DAOY
BMI1kd
 tumour sphere (right), compared to 
DAOY
Scr
 (left). The white dotted line is drawn to represent total the area of migration at the end of 8 
days, and the red dotted line represents the area of initial tumour sphere. (B) A reduction of migration 
area is noted also for ICb-1299
BMI1kd
, tumour spheres (right) as compared to ICb-1299
Scr 
(left). (C and 
D) Schematic representation of the area of migration for DAOY (C) and ICb-1299 (D). The inner white 
spheres, TS, represent the initially seeded tumour spheres, corresponding to the red dotted lines from 
(A and B). The outer circle represents the area of migration at the end of 8 days of co-culture; The 
blue area, AoM, is the representation of the area of migration, corresponding to white dotted lines in 
(A and B). AoM is calculated by subtracting TS from the total area. (E) Quantification of average area 
of migration (%) from three independent experiments for both DAOY and ICb-1299 co-cultures. Three 
areas were assessed on each slice and a total of three slices were analysed in each group. Error bars 
represent SD (n=3). *, p<0.05; **, p<0.01. Scale bar in (A) = 100 μm, and in (B) = 20 μm. 
Abbreviation: AoM, Area of Migration; TS, Tumour Sphere (initially seeded).    
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These results raised the possibility that cell migration was affected also in primary 
MB cells in an ex vivo co-culture assay. However, as we had established that BMI1 
knock down reduced the proliferative capacity of MB cells, it was essential to exclude 
that the reduction in migration area was not due to passive distribution secondary to 
the reduced proliferation caused by BMI1 knock down. To address this point, the 
maximum distance of migration of individual cells was also analysed.    
 
5.3.2 MB cells show a reduced distance of migration upon BMI1 knock down 
 
Three fluorescent high magnification images were acquired per slice from the 
periphery of the original tumour sphere where individual tumour cell were seen to 
migrate away. The distance between the farthest migrated cell and the edge of the 
original tumour sphere was measured in μm using Zen software. The experiment 
was conducted in triplicates. The average distance of migration was determined 
between BMI1 knock down and control groups.  
After 8 days of co-culture, we observed a significantly reduced average distance of 
migration in both DAOYBMI1kd and ICb1299BMI1kd as compared to DAOYScr and ICb-
1299Scr respectively – 157.40 μm (± 23.38) vs 250.03 μm (± 34.71) in DAOY 
(p=0.017) [Fig 5.4 A,C], and 80.50 μ (± 23.37) vs 115.28 μm (± 34.71) in ICb1299 
(p=0.041) [Fig 5.4 B, C].   
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Fig. 5.4 BMI1 silenced tumour spheres show reduced distance of migration in an ex vivo OCS 
co-culture.   
 
(A) A reduction in the maximum distance of migration is noted in shRNA BMI1 treated DAOY tumour 
sphere (right), compared to shRNA Scr treated sphere (left). The white dotted drawn represents the 
distance of the farthest cell to the edge of the initial tumour sphere (marked with red dotted line). (B) A 
reduction in the maximum distance of migration is noted also in ICb-1299, shRNA BMI1 treated 
tumour sphere (right) as compared to shRNA Scr treated sphere (left). (C) Quantification of average 
distance of migration (μm) from three independent experiments for both DAOY and ICb-1299. (D) 
Quantification of average depth of invasion (μm) using Z stack analysis from three independent 
experiments for both DAOY and ICb-1299. Three areas were assessed on each slice and a total of 
three slices were analysed in each group. Error bars represent SD (n=3). *, p<0.05. Scale bar in (A) = 
40 μm, and in (B) = 20 μm.  
 
In keeping with the results of the in vitro experiments, the ex vivo experiment show 
reduction in cell motility and migration of DAOY cells upon BMI1 knock down. 
Moreover, reduction in migration was observed also in short term cultures of the 
primary MB cells ICb1299 upon BMI1 knock down. This validates the notion that 
BMI1 plays a role in regulating the migratory properties of MB cells.  
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The depth of tumour cell invasion from the surface of the slice to the deepest 
invasive cell within the slice parenchyma was assessed from the areas adjacent to 
the original tumour sphere. This was done using Z stack series imaging by confocal 
microscopy and the distance (in μm) of depth of invasion was assessed using Zen 
software. There was a significantly reduced average depth of invasion observed in 
DAOYBMI1kd as compared to DAOYScr 22.48 μm (± 1.57) vs 28.52 μm (± 2.30), 
p=0.018 [Fig 5.4 D]. Although there was a trend towards decreased depth of invasion 
observed in ICb-1299BMI1kd as compared to ICb-1299Scr, the results were not 
statistically significant – 23.39 μm (± 7.02) vs 31.22 μm (± 8.03) p=0.178 [Fig 5.4 D]. 
 
5.4 Discussion  
 
In this part of the study we have taken advantage of organotypic cerebellar slices 
isolated from neonatal mice and co-cultured them with human MB tumour cell sphere 
as an ex vivo model to investigate MB tumour cell migration. With this model, we 
have 1) validated the in vitro findings in a model closer to physiological in vivo 
conditions, and 2) confirmed the in vitro findings of the DAOY cell lines using the 
primary MB cells ICb-1299.  
Studying the invasive and metastatic characteristics of the tumour cells would be 
provide more precise assessment of the tumour cell behaviour and would have 
better translational value. Meng et al., describe the suitability of cerebellar slice and 
MB cell tumour sphere co-culture model to study invasion (Meng, Kallinteri et al. 
2007). They demonstrate that the DAOY tumour aggregate first attached to the 
organotypic cerebellar slice and then invaded into the slice parenchyma replacing 
the normal tissue. By studying the invasion pattern by confocal and electron 
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microscopy, they also suggest that cerebellar slices are more conducive to study MB 
invasion as compared to cerebral slices. Here we observe a trend of reduced slice 
invasion in ICb-1299BMI1kd cell and a significantly reduced invasion of DAOYBMI1kd into 
the cerebellar slice parenchyma. This is in keeping with the reduced in vitro invasion 
observed in Transwell assay and is supportive of our notion that Bmi1 plays a role in 
modulating the invasive properties of the MB tumour cells.  
In order to examine whether BMI1-mediated repression of the BMP pathway remains 
intact in MB, in collaboration with Michael Taylor group from The Hospital for Sick 
Children, University of Toronto, we re-examined a publicly available transcriptome-
wide analysis of DAOY MB cell line (Wiederschain, Chen et al. 2007). We identified 
1483 genes differentially expressed between DAOYBMI1kd and control DAOY cells. A 
Gene Set Enrichment Analysis (GSEA) identified over-represented canonical 
pathways that included genes related to ECM-receptor interactions as well as the 
TGF-β pathway. Importantly among the deregulated cell adhesion molecules 
(ITGA3, LAMB3, LAMC1, COL7A1, Thrombospondin 1 and CD44), several genes 
either represented the human homologue of the genes identified in BMI1-/- granule 
cell progenitors (Chapter 4, Table 4.1) or belong to the same protein family.  
To further strengthen the connection between BMI1 and TGF-β-regulated cell 
adhesion molecules identified in murine cells and MB cell lines with human primary 
MB samples, we examined 282 non-WNT primary MBs, previously profiled using 
Affymetrix Human Gene 1.1ST arrays. Using unsupervised hierarchical clustering 
(HCL) we demonstrate that two Group 4 molecular variants existed - BMI1-high, 
TP53-low and BMI1-low, TP53-low, which largely cluster apart suggesting that a 
distinct transcriptome-wide gene signature associate with the expression of BMI1. To 
elucidate the specific pathways associated with these two sets of Group 4 tumours, a 
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transcriptome-wide supervised Significance Analysis of Microarrays (SAM) was 
performed. Interestingly, only 190 unique genes demonstrate statistically differential 
gene expression changes in BMI1 high subset as compared to BMI1 low subset of 
Group 4 MBs.  Overrepresented Gene Ontologies (GO) include: regulation of 
secretion, oxidoreductase activity and, extracellular matrix structural constituents. In 
the latter category, statistically significant downregulation of Laminin B1 (LAMB1, -
1.93) and upregulation of EFEMP2 (+1.71), FBN2 (+2.21), SMC3 (1.53), 
Thrombospondin 4 (THBS4, +2.12) were detected. The above bioinformatics 
analysis was performed with the help of Adrian Dubuc and Marc Remke from 
Michael Taylor group (unpublished data). These data suggest that BMI1 exerts its 
role in human MB pathogenesis at least in part through modulation of the expression 
of cell adhesion genes, potentially via BMP pathway repression.  
 
Invasion is a complex process by itself which in addition to  cell-cell and cell-ECM 
interaction, would also depend on other host tissue factors such as angiogenesis 
(Pilkington 1994). The rate of tumour cell proliferation may also influence the 
assessment of the depth of the tumour. Furthermore, certain factors such as 
necrosis of the core of the slices over time (Lossi, Alasia et al. 2009), limits accurate 
assessment of depth of migration and hence the true invasion. While OCS co-
cultured was a good model to validate our in vitro observations related to cell 
migration, we next set out to validate the growth and invasion of MB cells using an in 
vivo mouse model. 
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CHAPTER 6 Tumour volume and parenchymal invasion but 
not leptomeningeal spreading is controlled by BMI1 in an 
orthotopic MB xenograft model.  
 
6.1 Introduction 
 
Medulloblastoma are aggressive tumours with approximately one-third of cases 
presenting with metastatic disease at diagnosis and up to two-third of cases 
relapsing  to treatment presenting with leptomeningeal disease (Reviewed in (Packer 
1999)). Medulloblastoma is defined by its proclivity to disseminate via CSF route to 
brain and spinal cord (Mumert, Dubuc et al. 2012), and presence of metastasis at the 
time of diagnosis is considered a powerful independent prognostic factor (Zeltzer, 
Boyett et al. 1999). The mechanism for leptomeningeal spread vary to that of local 
tumour invasion (Laerum 1997), albeit, local invasion is also an important factor 
determining the treatment response and survival outcome (Riffaud, Saikali et al. 
2009; Sikkema, den Dunnen et al. 2012). Chang et al. classified MBs with presence 
of local invasion and brain stem invasion into a higher tumour stage – T3 from T1 or 
T2, reflective of poorer outcome (Chang, Housepian et al. 1969). It was therefore 
relevant to study the invasive characteristics of our MB cells using a suitable in vivo 
model. Genetically engineered mouse (GEM) model would be an ideal tool for this. 
But prior to embarking on sophisticated GEM model, which is relatively expensive 
and has longer latency, we chose to perform our validation experiments on an 
alternative suitable, in vivo xenograft (transplant from a different species) model. 
This model provides the advantage of being able to study the characteristics of cells 
from human origin as opposed to those from murine origin in GEM model. Orthotopic 
(normal or usual position) xenograft transplants in immune-deficient mouse is a well-
established model to study tumour invasion and metastasis in several cancers (Tan 
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and Chu 1985) including brain cancers (Giannini, Sarkaria et al. 2005).Furthermore, 
the use of GFP labelling to study tumour invasion and metastasis of  individual cell 
by fluorescent imaging monitoring is also well established (MacDonald, Tabrizi et al. 
1998; Zhang, Li et al. 2002).               
So far, our in vitro experiments have shown that BMI1 controls MB cell adhesion, cell 
migration and invasion in a BMP dependent manner. We have also observed effects 
of BMI1 on MB cell migration in an organotypic ex vivo experiment. Here we set out 
to determine the contribution of BMI1 to in vivo tumour growth and invasive 
characteristics. Short term cultures of lentiviral shRNA BMI1 infected primary MB 
cells ICb-1299, and their control counterpart were orthotopically transplanted in 
NOD-SCID mice. To be able to compare the results obtained in vivo with the 
experiments carried out in vitro, DAOY cells were also xenografted  Following 
transplantation, we first assessed if an effective BMI1 knock down was maintained in 
the xenograft tumours at the end of the termination of the experiment. Then we 
performed immunohistochemistry to assess whether BMP pathway activation 
observed in vitro upon BMI1 knock down would be occurring also in vivo. Four 
independent functional parameters were compared between BMI1 silenced 
xenografts and controls – i) tumour volume, ii) intraparenchymal invasion, iii) spread 
along the Virchow-Robin spaces, and iv) tumour burden within the spinal cord.   
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6.2 Experimental design and methodology 
 
6.2.1 Intra-cerebellar transplantation in NOD-SCID mice  
 
The animal procedures were carried out as per the Animals Scientific Procedures 
Act 1986 as described in M&M (Chapter 2, section 2.9). Briefly, the neonatal (P4 – 
P6) NOD-SCID mice were first anaesthetised and a constant quantity of 1x105 cells 
shRNA lentivirus transfected MB tumour cells in 3-5 μl sterile PBS were transplanted 
in to right cerebellar hemisphere. The cells were injected using a stereotaxic frame 
(coordinates: 1-2 mm lateral and 1-2 mm posterior to lambda suture, and 2-3 mm 
deep) with a 25 μl Hamilton syringe/26 gauge needle. A total of 19 mice were 
injected with ICb-1299 cells (10 scrambled, 9 BMI1 knock down) and 18 mice with 
DAOY cells (9 scrambled, 9 BMI1 knock down). The mice were culled if they 
developed neurological signs or at the end of the experiment which was 12 weeks 
after transplantation. The brain was harvested from these animals, the cerebellum 
and the brain stem were dissected from the rest of the forebrain and they were fixed 
in 4% PFA, followed by treatment with 30% sucrose and cryopreservation in OCT 
compound. The spinal cord was also isolated from these animals as described below 
in section 6.2.6.  
6.2.2 Cryostat tissue sectioning 
 
The OCT embedded cerebellum and brain stem samples were sectioned in their 
entirety at 20 μm thickness interval. The sections from each sample were transferred 
to twelve glass slides serially (ie. 1-12 sections to slides 1-12 and 13 – 24 sections to 
slide 1 – 12 again etc.) to  ensure that each slide would represent the entire sample. 
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The slides were labelled and left to dry overnight. The dried sections were stored at -
800C until stereology and confocal microscopy analysis was performed.  
6.2.3 Immunohistochemistry 
 
Immunohistochemistry was used to i) test the efficiency of BMI1 knock down and ii) 
to test pSMAD1,5,8 expression in MB tumour cells following xenograft 
transplantation. The procedure was performed as described in M&M (chapter  2, 
section 2.10.3). Briefly, the sections were first incubated with blocking solution (NDS 
or NGS) for 1 hr and treated with either BMI1 or pSMAD1,5,8 primary antibody  
overnight. Appropriate fluorescent secondary antibody (red, either 568 or 546 nm) 
was then added for 2 hr. The primary and secondary antibodies used along with their 
concentrations are listed in Table 6.1. The sections were mounted with DAPI 
containing mounting medium and coverslipped. The GFP positive tumour regions 
were identified under confocal microscope and five random high power images (63X 
oil for BMI1 and 100X oil for pSMAD1,5,8 assessment) were acquired per each 
case. The experiment was done in triplicates (three different cases were used for 
each group). The number of pSMAD1,5,8 positive (red) cells were counted and 
average counts were compared between shRNA BMI1 knock down and control 
groups in both DAOY and ICb-1299 xenografts. The statistical significance was 
calculated using student’s t test.  
Table 6.1 Details of primary antibodies used for immunofluorescence.  
For antigen to 
be detected 
Primary antibody used Company Concen
tration 
Alexa Fluor® 
secondary 
antibody 
(Invitrogen) 
BMI1 Goat polyclonal anti-
Bmi1 
Santa Cruz 
Biotechnology (sc-
8906) 
1:200 donkey anti-goat 
IgG 568 (red)  
A11057 
pSMAD1,5,8 Rabbit polyclonal anti-
phosphoSmad1/5/8 
Cell signalling  
(9511) 
1:100 Goat anti-rabbit 
546 (red) IgG  
A11035 
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6.2.4 Tumour volume estimation by stereomicroscopy using Cavalieri probe 
 
As each of the 12 slides prepared above are a true representation of the entire 
xenograft, one slides for each sample was chosen for this assessment. The slide 
was mounted using DAPI containing medium and covered with a glass coverslip. 
Every section on the slide was screened for tumour GFP positivity under 
fluorescence stereomicroscope (Nikon Eclipse 80i) using 10X (aperture 0.45) 
objective. The tumour volume was estimated by Cavalieri probe using Stereo 
Investigator 10 software (MicroBrightField, Inc.) in accordance with previously 
published literature (Villeneuve, Tremblay et al. 2005; Ghulam Muhammad, Candolfi 
et al. 2009). The GFP positive tumour regions recognised under stereomicroscope 
were marked using grid points, set at 20 μm grid spacing. The tumour regions were 
marked on multiple sections by driving the LEP motorised stage along X and Y axes. 
The grids overlapping the tumour areas were counted by the software and were 
converted into volume estimates after accounting for the non-consecutive section 
interval (which was constant at 12) and section thickness (which was constant at 20 
μm). The results generated were collated in excel spread sheet and averaged for all 
samples. The average tumour volume estimates were compared between shRNA 
BMI1 silenced xenografts with scrambled controls for both ICb-1299 and DAOY 
groups. The statistical significance was calculated by student’s t test.  
6.2.5 Depth of tumour invasion measurement by confocal microscopy 
 
One of the twelve slides prepared (section 6.2.2) which is representative of the entire 
xenograft was mounted using DAPI containing medium and covered with a glass 
coverslip. As for stereomicroscopy, all sections on the slide were screened for GFP 
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positive tumour. On each slide three tumour regions with intraparenchymal 
(cerebellum or brain stem) invasion or spread along Virchow Robin space were 
imaged at 20X magnification using Confocal microscope. The maximum depth of 
invasion - distance in μm from the pial surface to the farthest invading/spreading 
tumour cell was measured in each region using ImageJ 1.43u software (National 
Institutes of Health, USA). The distances were averaged for each case and 
compared between shRNA BMI1 silenced and scrambled groups for both ICb-1299 
and DAOY xenografts. The statistical significance was calculated by student’s t test.  
6.2.6 Spinal cord dissection and tumour burden analysis  
 
The spinal cords of the engrafted animals were harvested to assess tumour burden 
as an evidence of metastatic spread, as described in M&M (chapter 2, section 
2.9.4.3). The harvested cords were fixed in 10% formalin and longitudinally divided in 
to 5-7 segments approximately corresponding to their anatomic levels and 
embedded in paraffin blocks. The blocks were sectioned at 4-5 μm thickness and 
were stained with H&E for morphological analysis of tumour burden. The sections 
from all the samples were screened for presence of tumour deposits in the spinal 
cord, identified by histological characteristics of medulloblastoma. The rate of tumour 
positivity in shRNA BMI1 silenced xenografts were compared with controls.    
The schematic of in vivo xenograft generation and analysis is represented in Fig 6.1. 
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Fig. 6.1 Schematic of orthotopic xenograft generation and analysis. 
 
Lentivirus infected, GFP labelled, DAOY or ICb-1299 cells were injected into right cerebellar 
hemisphere of NOD-SCID pups. The cerebellum and brain stem were isolated 12 weeks later at the 
latest, fixed and cryopreserved. The entire cerebellum and brain stem were serially sectioned and 
screened for the presence of tumour by histology and immunohistochemistry. The volume estimates 
of xenografts were compared between shRNA BMI1 and shRNA Scr treated cells by 
stereomicroscopy using Cavalieri method. The depth of tumour cell invasion was analysed and 
compared using confocal microscopy. In addition, spinal cords of all primary tumour positive cases 
were collected, sectioned and screened for the presence of tumour deposits.      
 
  
213 
 
6.3 Results:  
6.3.1 Intracerebellar injection of MB cells yields tumour xenografts 
 
A constant number (1x105 in 3-5 μl) of shRNA transfected ICb-1299 or DAOY cells 
were injected in to right cerebellar hemisphere of each NOD-SCID mouse. A total of 
19 mice (9 males, 10 females) were injected with ICb-1299 cells (10 scrambled, 9 
BMI1 knock down) and 18 mice (7 males, 11 females) with DAOY cells (9 
scrambled, 9 BMI1 knock down) [Fig 6.2A]. Unless they developed symptoms, they 
were sacrificed at twelve weeks after transplantation.  
Among DAOY engrafted mice, two of nine mice (22.2%) with DAOYScr and one of ten 
mice (10%) with ICb-1299Scr developed neurological symptoms related to tumour 
growth at 8 weeks and 10 weeks respectively and hence had to be terminated at 
those time points. The rest of the DAOYScr / ICb-1299Scr and all of DAOYBMI1kd / ICb-
1299BMI1kd xenografted mice were asymptomatic and were terminated at 12 weeks 
(Fig 6.2 B). Kaplan-Meier survival plot comparing the BMI1 knock down xenografts 
with controls did not show statistically significant difference in the survival estimation 
(using Log Rank test) between the groups  Fig 6.2 C and D).  
All DAOY engrafted mice (18/18, 100%) developed a tumour and no significant 
difference in tumour take was found also between ICb-1299Scr (6 of 10, 60%) and 
ICb-1299BMI1kd (6 of 9, 66%) engrafted mice (Fig 6.2 E).  
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Fig. 6.2 Statistics of MB xenografts generated.  
 
(A) Tabulation of number and gender of mice injected with DAOY or ICb-1299 cells. (B) Graph 
representing number of mice that were symptomatic (terminated) before 12 weeks in each group. No 
mice with shRNA BMI1 transplants were symptomatic while a minor fraction of shRNA Scr 
transplanted mice developed symptoms prior to 12 weeks. (C and D) Kaplan-Meier curve comparing 
survival estimates of shRNA BMI1 transplants against shRNA Scr transplants in DAOY (C) and ICb-
1299 (D). There was no significant difference in survival estimates in either group on Log-Rank 
analysis. (E) Graph depicting fraction of tumour-take in DAOY and ICb-1299 transplants. All of DAOY 
transplanted mice developed tumour, while the tumour uptake among ICb-1299 transplants was 60-
66%.  
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Histological and immunohistochemical analysis was carried out to confirm the 
diagnosis. Histologically the DAOY xenografts consist of multifocal tumour growth in 
the cerebellum and the brain stem composed of poorly differentiated densely packed 
round to oval neoplastic cells with hyperchromatic nuclei surrounded by scanty 
cytoplasm. Occasional tumour cell rosettes and nodules were present, reminiscent of 
both classic and desmoplastic medulloblastoma morphology (Giangaspero, Binger et 
al. 2000) [Fig 6.3 A and B]. ICb-1299 xenografts also showed similar features to that 
of DAOY xenografts. However, the tumour cells showed more abundant cytoplasm, 
prominent nuclear moulding and there were areas of necrosis. The features were 
reminiscent of anaplastic medulloblastoma (Shu, Wong et al. 2008) [Fig 6.3 C and 
D]. Immunohistochemistry revealed ICb-1299 generated tumours to be diffusely 
positive  for synaptophysin (Fig 6.3 E), and negative for GFAP (Fig 6.3 F), in keeping 
with that seen in medulloblastoma (Giangaspero, Binger et al. 2000).  
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Fig. 6.3 Histology and immunohistochemisty of xenograft tumours confirming features of MB.  
 
(A) H&E section showing medulloblastoma ( black arrow),  upon  DAOY (shRNA Scr treated) cells 
xenograft.  In this case, the tumour is present in the brain stem, abutting cerebellum, and tumour 
infiltration to parenchyma is seen. (B) High power view of area corresponding to arrow head in (A), 
showing  poorly differentiated densely packed round to oval neoplastic cells with hyperchromatic 
nuclei surrounded by scanty cytoplasm. (C) H&E section showing medulloblastoma ( white arrow),  
upon ICb-1299 (shRNA Scr treated) primary cells xenograft . In this case, the tumour is present in the 
cerebellum and extends into the brain stem. (D) High power view of area corresponding to arrow head 
in (C), showing histological features resembling DAOY xenograft, but in addition the tumour cells 
showed more abundant cytoplasm and prominent nuclear moulding. Furthermore, 
immunohistochemistry reveals ICb-1299 xenograft to be Synaptophysin (membrane) positive (E), and 
GFAP negative (F), in keeping with the expression pattern that is seen in human medulloblastoma. 
The lower part of (F) shows GFAP positivity in reactive astrocytes of the  surrounding brain tissue. 
Scale bar in (A) and (C) = 50 μm, and in (B), (D), (E) and (F) = 20 μm.  
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Having confirmed the histological identity of the xenografts, we set out to investigate 
if protracted BMI1 knock down was maintained in the xenografted tumour cells.   
6.3.2 BMI1 knock down is confirmed in the xenografts.  
 
Prior to functional analysis of the xenografts, it was important to confirm stable BMI1 
knock down induced by lentiviral shRNA transfection of MB cells pre-injection in the 
xenografts 12 weeks after engraftment. Previous studies in which tumour xenografts 
were generated following shRNA lentivirus based BMI1 knock down in hepatocellular 
carcinoma cells (Chiba, Miyagi et al. 2008) and in medulloblastoma cells (Wang, 
Venugopal et al. 2012) have shown stable knock down 14 weeks and 8 weeks after 
engraftment respectively. Here we performed immunohistochemical analysis on 
three xenografts from each cell type to assess BMI1 expression. The cryosections 
were treated with anti-Bmi1 antibody and stained with fluorescent secondary 
antibody (Alexa Fluor 568, red), counterstained with DAPI nuclear stain and 
examined by confocal microscopy. Five regions from each tumour sample, three 
samples from each group, were examined.   
There was prominent reduction of BMI1 expression noted in xenograft tumours 
arising from DAOYBMI1kd and ICb-1299BMI1kd transplants as compared to those arising 
from the respective scrambled treated control cells (Fig 6.4). This confirmed an 
efficient protracted BMI1 knock down which was maintained 12 weeks after injection. 
.    
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Fig. 6.4 GFP positivity and efficient BMI1 knock down is maintained in the xenografts.   
 
(A and B) BMI1 immunohistochemistry on xenografts reveals an effective knock down in shRNA 
BMI1 treated cells (lower panel) as compared to shRNA Scr treated cells (upper panel) in both DAOY 
(A) and ICb-1299 (B). Five fields in each sample and three samples from each group were screened, 
in which similar difference in BMI1 expression was noted. Left – GFP (green) channel, middle – BMI1 
(red) channel, right – merge. A strong GFP signal is retained in the xenograft cells, which makes it 
suitable for further fluorescent microscopy tracing of the cells. Scale bar in (A) and (B) = 20 μm.  
 
6.3.3 An increased phosphorylation of SMAD 1,5,8 is seen  in BMI1 silenced 
xenografts 
 
Our in vitro results have shown that BMI1 silencing causes de-repression of BMP 
signalling in primary human MB cells ICb-1299 and in MB cell lines DAOY (chapter 
3, Figs 3.6 and Fig 3.5). Having established that an efficient protracted BMI1 knock 
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down was maintained in the medulloblastoma xenografts, we set out to determine 
the BMP pathway status in these tumours.  
We performed pSMAD1,5,8 immunohistochemical labelling on DAOYBMI1kd, DAOYScr, 
ICb-1299BMI1kd and ICb-1299Scr tumours, as previously described. Briefly, the 
cryosections were treated with anti-pSmad1,5,8 antibody and stained with 
fluorescent secondary antibody (Alexa Fluor 546, red), counterstained with DAPI 
nuclear stain and examined by confocal microscopy. Five regions from each tumour 
sample were imaged at high power (100X oil) and the percentage of pSMAD1,5,8 
positive (red) cells per field (pSMAD1,5,8 positive/total DAPI positive cells x 100) 
were counted. Average counts were compared between shRNA BMI1 knock down 
and control groups in both DAOY and ICb-1299 xenografts. The statistical 
significance was calculated using student’s t test 
The average number of xenograft tumour cells expressing pSMAD1,5,8 was 
increased in BMI1 silenced group as compared to scrambled group – 38.27% 
(±6.16) vs 16.02% (± 3.51) in DAOY (p=0.005) [Fig 6.5 A and C], and 32.77% (±6.0) 
vs 12.33% (±1.50) in ICb-1299 (p<0.01) [Fig. 6.5 B and C], in keeping with the notion 
that BMP pathway de-repression is induced by  BMI1 silencing also in vivo.      
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Fig. 6.5 pSMAD1,5,8 expression is increased in BMI1 silenced xenografts. 
(A and B) pSMAD1,5,8 immunohistochemistry on xenografts reveals an increased expression in 
shRNA BMI1 treated cells (lower panel) as compared to shRNA Scr treated cells (upper panel) in both 
DAOY (A) and ICb-1299 (B). Left – GFP (green) channel, middle – pSMAD1,5,8 (red) channel, right – 
merge. (C) Quantitation of the number of pSMAD1,5,8 positive cells per field shows a significant 
increase in the average percentage, in both DAOY and ICb-1299. Five fields in each sample and 
three samples from each group were analysed. Scale bar in (A) and (B) = 10 μm. Error bars in (C) 
represent SD (n=3). **, p<0.01.  
221 
 
 
6.3.4 BMI1 silenced xenografts show reduced tumour volume estimates. 
 
In line with other studies, we previously observed reduced proliferation in DAOYBMI1kd 
in comparison to DAOYScr (Chapter 4, Fig 4.7). We also noted a reduced area of 
migration in DAOYBMI1kd and ICb-1299BMI1kd cells in organotypic cerebellar slice co-
culture assay in comparison to their scrambled counterparts (Chapter 5, Fig 5.3). 
Here, we tested the effects of BMI1 knock down in these cells on the in vivo tumour 
growth by means of analysis of the tumour volume estimates of the xenografts. 
Briefly, representative sections of each xenograft were stained with DAPI and 
analysed using stereomicroscope (under fluorescence filter). The overlapping GFP 
positive tumour regions were grid-marked using Stereo Investigator software and the 
tumour volume was estimated using Cavalieri probe (Villeneuve, Tremblay et al. 
2005; Ghulam Muhammad, Candolfi et al. 2009) after accounting for non-
consecutive section interval and section thickness. The average tumour volume 
estimates (in mm3) were compared between shRNA BMI1 silenced xenografts with 
scrambled controls for both ICb-1299 and DAOY groups. The statistical significance 
was calculated by student’s t test.  
The average total tumour volume estimates for DAOYBMI1kd (n=9) and ICb-1299BMI1kd 
(n=6) were reduced as compared to that of DAOYScr (n=9) and ICb-1299Scr (n=6) 
xenografts respectively - 2.39 mm3 (± 1.63) vs 5.18 mm3 (± 2.57) for DAOY 
(p=0.009) [Fig. 6.6 C] and 3.35 mm3 (± 1.05) vs 9.24 mm3 (± 3.09) for ICb-1299 
(p=0.001) [Fig 6.6 A-C].  
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Fig. 6.6 Xenograft tumour volume estimates.  
 
(A and B) A 2-D representation of tumour volume estimates using Cavalieri probe by Stereo 
Investigator software. The overlapping tumour areas marked during Stereomicroscopic evaluation are 
represented in red (20 μ grid spacing used).The total tumour volume was estimated after accounting 
for the non-consecutive section interval (which was constant at 12) and section thickness (which was 
constant at 20 μm). The total tumour volume estimate in xenograft arising from shRNA BMI1 treated 
cells (B) was lower than that of shRNA Scr treated cells (A).  (C) The average tumour volume 
estimate from all the xenografts analysed show a reduction in BMI1 knock down tumours as 
compared to controls, in both DAOY and ICb-1299. Error bars in (C) represent SD (n≥6). **, p<0.01.  
 
 
Although we cannot exclude that an effect of BMI1 knock down on BMP mediated 
cell adhesion/migration/invasion could have contributed to the phenotype, the most 
likely scenario is that it is mainly attributable to the BMI1 mediated impact on 
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proliferation. To further decipher the role of BMI1 in MB tumour cell invasion in vivo, 
we investigated the parenchymal invasion of the xenografts.   
 
6.3.5 BMI1 silenced xenografts show reduced intraparenchymal tumour 
invasion 
 
The extent of local (cerebellar) and brain stem invasion is prognostically highly 
significant (Chang, Housepian et al. 1969; Riffaud, Saikali et al. 2009; Sikkema, den 
Dunnen et al. 2012). In our study, we have previously observed reduced in vitro 
invasion of DAOYBMI1kd cells in a BMP dependent fashion (Chapter 4, Fig 4.5). We 
have also observed reduced distance of migration in DAOYBMI1kd and ICb-1299BMI1kd 
in an ex vivo experiment (Chapter 5, Fig 5.4). Wang et al. have demonstrated 
reduced in vivo tumour infiltration upon BMI1 knock down in DAOY cells grown as 
tumour spheres (Wang, Venugopal et al. 2012). Here we analysed our xenografts for 
cerebellar and brain stem invasion, at single cell level, taking advantage of the GFP 
labelling induced by lentiviral infection. Briefly, representative sections were stained 
with DAPI and examined by confocal microscopy. Three regions with 
intraparencymal (cerebellum or brain stem) invasion were imaged at 20X 
magnification. The images were analysed with ImageJ software and the maximum 
depth of invasion, which was the distance in μm from the pial surface to the farthest 
invading tumour cell was assessed. The measurements were averaged for each 
case and compared between shRNA BMI1 silenced and scrambled groups for both 
ICb-1299 and DAOY xenografts. The statistical significance was calculated by 
student’s t test.  
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Interestingly, the average depth of invasion into the cerebellar parenchyma from the 
pial surface revealed a significant reduction for both DAOYBMI1kd and ICb-1299BMI1kd 
xenografts as compared to DAOYScr and ICb-1299Scr respectively - 141.35 µm (± 
51.51) vs 216.61 µm (± 61.24) for DAOY (p0.008) [Fig 6.7 B], and 159.74 μm (± 
34.96) vs 239.49 μm (± 25.75) for ICb-1299 (p=0.001) [Fig. 6.7 A and B].  
 
 
Fig. 6.7 Reduced cerebellar intraparenchymal infiltration in BMI1 silenced MB xenografts.  
 
The depth of invasion (marked with white dotted line) was measured as the distance in μm from the 
pial surface of the cerebellum (marked with red dotted line) to the deepest GFP positive cell within the 
cerebellar parenchyma. (A) The maximum depth of tumour cell infiltration in xenograft arising from 
shRNA BMI1 treated cells (right) was lower than that of shRNA Scr treated cells (left). (B) The 
average distance of tumour cell infiltration from all the xenografts analysed show a reduction in BMI1 
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knock down tumours as compared to controls, in both DAOY and ICb-1299. Three different regions 
from each sample group were analysed. Scale bar in (A) = 50 μm. Error bars in (B) represent SD 
(n≥6). **, p<0.01. 
 
Similar findings were also recorded when measuring the depth of tumour cell 
invasion into the brain stem – 401.78 μm (± 126.41) in DAOYBMI1kd vs 575.83 µm (± 
175.91) in DAOYScr (p=0.018) [Fig 6.8 B], and 332.78 μm (± 39.23) in ICb-1299BMI1kd 
vs 459.09 μm (± 62.06) in ICb-1299Scr (p=0.001) [Fig.6.8 A and B]. Additionally, there 
were more prominent necrotic areas noted in the brain stem as compared to the 
cerebellum in ICb-1299 xenografts, although this finding was not quantified. The 
infiltration of the tumour cells into the brain stem was deeper as compared to the 
cerebellum.    
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Fig. 6.8 Reduced brain stem intraparenchymal infiltration in BMI1 silenced MB xenografts.   
 
The depth of invasion (marked with white dotted line) was measured as the distance in μm from the 
pial surface of the brain stem (marked with red dotted line) to the deepest GFP positive cell within the 
brain stem parenchyma. (A) The maximum depth of tumour cell infiltration in xenograft arising from 
shRNA BMI1 treated cells (right) was lower than that of shRNA Scr treated cells (left). The white 
arrow indicates tumour mass superficial to the brain stem pial surface. (B) The average distance of 
tumour cell infiltration from all the xenografts analysed show a reduction in BMI1 knock down tumours 
as compared to controls, in both DAOY and ICb-1299. Three different regions from each sample 
group were analysed. Scale bar in (A) = 50 μm. Error bars in (B) represent SD (n≥6). *, p<0.05; **, 
p<0.01. 
 
In summary, reduced intraparenchymal invasion was observed in both DAOYBMI1kd 
and ICb-1299BMI1kd xenografts as compared to their control counterparts. These 
observations are in agreement with our in vitro results where reduced invasion was 
noted in a Transwell® assay in DAOYBMI1kd in comparison to DAOYScr.    
6.3.6 BMI1 silenced xenografts show no change in the spreading along the 
Virchow Robin spaces or in the tumour burden in the spinal cord. 
 
Primary CNS malignancies may also disseminate via certain minor routes such as 
subpial, perineuronal (satellitosis), intravascular and Virchow Robin spaces. Virchow 
Robin spaces are microscopic channels that follow along the arterioles which 
penetrate into the brain substance from the subarachnoid space (Patankar, Mitra et 
al. 2005). In addition to CSF and leptomeningel routes, medulloblastoma 
disseminate locally in the brain via Virchow Robin spaces (Roger E McLendon 
2006).  Therefore we chose to investigate spread along Virchow Robin space in our 
in vivo study. Similar to depth of invasion analysis described above, representative 
sections of each xenograft was stained with DAPI and examined by confocal 
microscopy. Three regions of tumour spread along the Virchow Robin spaces were 
imaged for each case. The maximum depth of spread in μm from the surface was 
measured in each region, averaged and compared between shRNA BMI1 silenced 
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and scrambled groups for both ICb-1299 and DAOY xenografts. The statistical 
significance was calculated by student’s t test.  
There was no statistically significant differences noted in the average distance of 
spreading along the Virchow Robin spaces between BMI1 knock down and 
scrambled groups of xenografts - 448.80 μm (± 98.03) in DAOYBMI1kd vs 553.95 µm 
(± 231.05) in DAOYScr (p=0.126) [Fig 6.9 B], and 482.33 μm (± 56.46) in ICb-
1299BMI1kd vs 481.04 μm (± 94.64) in ICb-1299Scr (p=0.489) [Fig.6.9 A and B].  
Fig. 6.9 There is no change in the spreading along Virchow-Robin space in BMI1 silenced MB 
xenografts.   
The spread/migration (marked with white dotted line) of MB cell along the Virchow-Robin (VR) spaces 
(which are the channels along the arterioles) was measured as the distance in μm from the pial 
surface of the cerebellum/brain stem (marked with red dotted line) to the deepest GFP positive cell 
along the VR space. (A) There is no notable difference in maximum depth of tumour cell 
spread/migration along the VR space in xenograft arising from shRNA BMI1 treated cells (lower), 
compared to that of shRNA Scr treated cells (top). (B) The average distance of tumour cell 
spread/migration from all the xenografts analysed show no difference in BMI1 knock down tumours as 
compared to controls, in either DAOY or ICb-1299. Three different regions from each sample group 
were analysed. Scale bar in (A) = 50 μm. Error bars in (B) represent SD (n≥6).   
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Dissemination of medulloblastoma to the spinal cord via CSF and leptomeningeal 
remains paramount in determining tumour prognosis (Zeltzer, Boyett et al. 1999; 
Mumert, Dubuc et al. 2012). Even the presence of microscopic local leptomeningeal 
tumour spread has been suggested to bear prognostic significance in 
medulloblastoma (Ayan, Kebudi et al. 1997). Therefore, we determined the tumour 
burden in the spinal cord in the MB engrafted animals. The spinal cords were fixed in 
formalin, sectioned into multiple segments and examined histologically for any 
presence of tumour deposits. The rate of tumour positivity in shRNA BMI1 silenced 
transplants were compared with control transplants.    
None of the twelve ICb-1299 xenografts had associated spinal deposits. However, 
microscopic MB tumour deposits (Fig 6.10 A), with features similar to those seen at 
the primary implantation site, were seen in approximately two third of DAOY 
transplanted cases. Importantly, there was no difference in the incidence or rate of 
tumour burden between DAOYScr (6 of 9, 66%) and DAOYBMI1kd (6 of 9, 66%) 
transplants (Fig 6.10 B).      
In conclusion, contrary to the intraparenchymal invasion results, BMI1 knock down 
did not seem to influence the spreading along the Virchow Robin spaces or the rate 
of spinal cord seeding in our xenograft model.      
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Fig. 6.10 Spinal cord tumour burden in DAOY xenografts.  
 
(A) H&E section of spinal cord from DAOY engrafted animals showing leptomeningeal tumour deposit 
(black arrow) with histological features similar to that of the primary implant. Left – low power, right – 
high power image. (B) Quantitation of incidence of tumour burden between sh Scr and sh BMI1 
treated DAOY transplants shows no difference. Abbreviation: L-M, leptomeningeal. Scale bar in (A) = 
20 μm. 
 
6.4 Discussion  
 
In this part of the study we demonstrate that xenografts originating from BMI1 knock 
down MB cells are smaller and show reduced intraparenchymal invasion as 
compared to their scrambled counterpart. Increased pSMAD1,5,8 expression was 
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found also within BMI1 silenced xenografts. These observations suggest that i) BMI1 
controls both tumour growth and parenchymal invasion in MB xenografts, although 
this may be achieved through different mechanisms and ii) confirms that BMI1 knock 
down in MB cells reactivates BMP signalling pathway also in vivo, consistent with our 
in vitro  results.  
Several genes and pathways are known which confer aggressiveness in 
medulloblastoma. Genetic profiling of metastatic medulloblastoma by Mumert et al. 
demonstrate that Shh-induced MBs tend to be localised, while ERAS, LHX1, and 
CCRK are metastasis-inducing which are overexpressed in aggressive subgroups of 
human MBs (Mumert, Dubuc et al. 2012). Expression profiling of metastatic and non-
metastatic primary human MB by MacDonald et al. show several dysregulated genes 
associated with PDGFRA and RAS/MAPK signaling pathway (MacDonald, Brown et 
al. 2001). Furthermore, MB with molecular profiling of group 3 (mainly MYC 
amplification associated) and group 4 (mainly isochromosome 17q associated) are 
known to be more aggressive (higher metastasis and poorer prognosis) compared to 
Shh or Wnt groups (Kool, Korshunov et al. 2012; Taylor, Northcott et al. 2012).  
In chapter 4, we discussed the differential expression of certain cell adhesion/ECM 
molecules that was observed in relation to BMI1 expression in developing granule 
neurones in mouse cerebella (Xinyu Zhang, unpublished data), and our current  
observation of  dysregulated expression of CD44 and THSB in BMI1 knock down MB 
cells. In chapter 5, we identified deregulated cell adhesion/ECM genes namely 
LAMB1, EFEMP2, FBN2, SMC3, and THBS4 in relation to BMI1 expression in 
primary MB (Adrian Dubuc, Mark Remke; unpublished data). Impairment of the 
Cadherin family of transmembrane glycoproteins, in particular downregulation of E-
cadherin, and switch from E-cadherin to N-cadherin, has a strong affiliation to EMT 
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and cancer invasiveness (Shiozaki, Oka et al. 1996). BMI1 overexpression has been 
shown to repress E-cadherin, and induce EMT (Yang, Hsu et al. 2010).  
Integrins are transmembrane glycoproteins, which are physiologically expressed. 
However certain cancers can be associated with high integrin expression, which 
could be a marker of aggressive phenotypes (Shirakihara, Kawasaki et al. 2013; 
Tome, Kimura et al. 2013). There is evidence that Bmi1 modulates integrin-mediated 
cell adhesion in murine neural stem cells in a novel Ink4a/Arf-independent manner 
(Bruggeman, Hulsman et al. 2009). TGF-β/BMP - SMAD pathways cross talk with 
other pathways which regulate cadherin and integrins and trigger EMT (reviewed in 
(Huber, Kraut et al. 2005; Thiery and Sleeman 2006)). Therefore it is plausible that 
changes in cell adhesion, cell motility and invasion phenotypes observed in response 
to BMI1 silencing of MB cells in our study can also be due to deregulation of 
cadherin or integrin family of proteins, probably mediated by BMP signalling. 
However this is speculative at this stage and would need validation. We plan to 
undertake a genome-wide analysis of Group 4 primary MB cells to understand the 
BMI1 associated molecular mechanisms more comprehensively (discussed in  
chapter 8).  
 
In Wang et al. study, mice implanted with DAOY spheres with BMI1 knock down 
showed better survival, with corresponding tumours showing reduced local tumour 
infiltration as compared to controls, but they did not observe difference in tumour 
volumes between the two groups (Wang, Venugopal et al. 2012). Although, there 
was no difference in survival projection or tumour take between BMI1 knock down 
and control groups in our study, the difference in parenchymal invasion that we 
observed correlates to Wang et al. study. In line with our results, there is evidence 
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that xenografts generated from BMI1 knock down cells resulted in reduced tumour 
volume in various cancer including breast cancer (Hoenerhoff, Chu et al. 2009), 
pancreatic cancer (Yin, Wei et al. 2011) and laryngeal cancer (Yao, Wang et al. 
2013). Interestingly we did not see increased spreading of MB cells along VR spaces 
in our xenograft model and tumours expressing high levels of BMI1 were not 
associated with higher incidence of spinal metastasis, therefore implying that the 
molecular mechanisms regulating intraparenchymal invasion and leptomeningeal 
spread may be different. In support of this, Wu et al. have shown that in both mouse 
and human medulloblastoma, metastatic tumour was genetically divergent from the 
matched primary tumour, suggesting that only certain cells from the primary tumour 
have the ability to metastasise (Wu, Northcott et al. 2012).  
In order to validate the phenotypes observed upon BMI1 knock down in our study, 
we set out to investigate if an inverse relationship between BMI1 expression and 
BMP pathway activation exists in the primary human MB tissue. To do this, we 
studied the expression pattern of BMI1 and pSMAD1,5,8 in primary human MB 
tissue micro array.    
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CHAPTER 7 Preliminary pSMAD expression analysis in 
primary MB tissue demonstrate weak correlations 
warranting further evaluation  
7.1 Introduction 
  
Medulloblastoma develops as a result of deregulated developmental mechanisms, 
and in the context of cerebellar development, BMI1 is thought to be a downstream 
target of SHH pathway (reviewed in (Marino 2005)). Shh and BMP pathways 
antagonise each other to regulate granule cell progenitor proliferation during 
cerebellar development (reviewed in (Rodini, Suzuki et al. 2010; Roussel and Hatten 
2011). Our group have recently demonstrated that during cerebellar development 
Bmi1 critically influences cell-cell interactions via specific inhibition of BMP signalling 
(Zhang, Santuccione et al. 2011). However, to our knowledge there is no previous 
literature linking BMI1 and BMP signalling to medulloblastoma pathogenesis. BMPs 
(BMP-2 and/or BMP-4) have been shown to prevent cerebellar granule cell precursor 
cell (putative cell of origin for MB) proliferation (Rios, Alvarez-Rodriguez et al. 2004) 
and shown to have inhibitory role in medulloblastoma growth (Hallahan, Pritchard et 
al. 2003; Zhao, Ayrault et al. 2008). Therefore BMPs may be potential therapeutic 
targets for MB treatment, and furthermore, BMI1 expression could be potential 
biomarker for those MB which may benefit from small molecule BMP agonist 
treatment. With this in view we attempted to validate the notion that BMI1 represses 
BMP pathway, i.e., an inverse relationship existed between BMI1 and BMP pathway 
status, using primary human MB tissue samples   
Tissue Micro Arrays (TMAs) are arrays of several different tissue samples 
represented as cylindrical cores on a single slide which enable rapid and 
simultaneous immunohistochemical analysis of multiple samples. They were first 
234 
 
described in 1987 (Wan, Fortuna et al. 1987) and popularised as high throughput 
method for molecular analysis in 1998 (Kononen, Bubendorf et al. 1998). We have 
taken advantage of two TMAs containing a total of 362 MB samples to conduct 
preliminary expression correlation analysis following immunohistochemistry for BMI1 
and pSMAD1,5,8 to test the feasibility of their use to validate our findings in MB cells.  
7.2 Experimental Design and methodology 
 
7.2.1 Primary human medulloblastoma TMA  
 
For validation on human primary MB tissue, we used two different TMA sets. The 
first TMA set (referred to as TMA I) comprised one slide containing 64 MB tumour 
cores which was prepared at Institute of Clinical Pathology, Department of 
Pathology, University of Zürich, Switzerland. The second set (referred to as TMA II) 
comprised two slides containing a total of 298 MB tumour cores which was prepared 
by our collaborator Dr Stefan Pfister from German Cancer Research Centre DKFZ, 
Heidelberg, Germany. Supplementary information available with TMAs included 
histological types for the former set and molecular subgroups for the latter set. 
Immunohistochemistry using pSMAD1,5,8 and/or BMI1 antibody was performed on 
the paraffin sections of the TMAs as described in M&M (chapter 2, section 2.10). The 
primary and secondary antibodies used along with the staining conditions are listed 
in Table 7.1. 
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Table 7.1 Antibodies and the conditions used for TMA immunohistochemistry by ABC method 
For antigen to be 
detected 
 
Primary antibody used Secondary 
antibody used 
Blocking agent 
used 
BMI1  Rabbit polyclonal anti-Bmi1 
(Abcam ab38295), 1:100, 
overnight incubation at RT. 
 
 
Universal 
biotinylated anti-
mouse/anti-rabbit 
IgG (Vector) raised 
from horse, 1 hr at 
RT. 
 
2.5% Normal 
horse serum 
(Vector), 1 hr RT 
 
 
pSMAD1,5,8 Rabbit polyclonal anti-
phosphoSmad1/5/8 (Millipore 
AB3848), 1:100, overnight 
incubation at RT. 
 
7.2.2 Assessment and analysis of expression 
 
The protein expression was assessed by myself and Prof. Marino with >90% 
concordance. The expression pattern was scored as 0 = negative, 1 = mildly 
positive, 2 = strongly positive for both markers (Fig 7.1). In addition, for BMI1 staining 
the positive scores were suffixed with ‘f’ of ‘d’ corresponding to focal or diffuse 
staining pattern respectively (Fig 7.1 B,C). There was no focal/diffuse criteria for 
pSMAD1,5,8 as the tumour either stained diffusely for this marker or not at all (Fig 
7.1 D,E,F). 
Non-parametric correlation analysis was carried out on the immunohistochemical 
assessment data using SPSS® statistical package version 20 (IBM®). Spearman 
correlation (Spearman rank correlation) coefficient (de Siqueira Santos, Takahashi et 
al. 2013) was computed to identify significant association between the two 
biomarkers or between the biomarker and the molecular subgroup. A coefficient 
value of 0.2 or more was considered as an indicator of strong correlation 
(McDonnell, Chari et al. 2008), and p<0.05 was considered as statistically significant. 
Coefficient value with a minus sign is indicative of an inverse or negative correlation, 
and that with at plus sign is indicative of a positive or direct correlation.   
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7.3 Results 
7.3.1 There is a weak inverse correlation between BMI1 and pSMAD1,5,8 
expression in MBs.  
 
First we examined the TMA I set, containing 64 MBs. TMA I was treated with both 
pSMAD1,5,8 and BMI1 antibodies. An expression score was assigned to each 
tumour contained within the TMAs as described above (section 7.2.2) [Fig 7.1].  .  
 
Fig. 7.1 Immunohistochemistry scoring of Tissue Micro Array. 
 
(A-C) Representative sections of primary human medulloblastoma tumour samples showing variable 
intensity of BMI1 (nuclear) staining, where score 0 = negative, 1 = mild and 2 = strong expression. 
BMI1 expression was in addition further classified as focal ‘f’ (B) or diffuse‘d’ (C) depending on the 
extent of staining observed.  (D-F) Representative sections of primary human medulloblastoma 
tumour samples showing variable intensity of pSMAD1,5,8 staining (predominantly nuclear). All 
pSMAD1,5,8 positive cases showed  diffuse staining pattern. Scale bar in all = 10μm.  
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Expression correlation analysis was performed using SPSS statistical package. The 
expression analysis data were cross tabulated and Spearman correlation co-efficient 
value was generated.  
Analysis of correlation between BMI1 and pSMAD1,5,8 expression  among tumours 
of TMA I subset showed a weak negative (indirect) correlation score of -0.038 with 
no statistical significance (p=0.764, n=64) [Fig 7.2].  
 
Fig. 7.2 Correlation analysis of BMI1 and pSMAD1,5,8 expression in TMA I. 
 
(A) There is a trend of negative expression correlation between BMI1 and pSMAD1,5,8 expression. 
But the correlation in this small cohort is weak and has no statistical significance. Bar graph on the left 
showing case distribution according to their expression scores, with breakdown of the cases in the 
table on the right.   
 
The trend of negative or indirect correlation observed in this small cohort analysed 
could be in keeping with our findings on the cell lines where we observe an inverse 
relationship between BMI1 expression and pSMAD1,5,8 expression in two MB cell 
lines and primary MB cells of Group 4. However it is necessary that the power of the 
study is strengthened by increasing the number of tumour cases. We plan to achieve 
this by analyzing BMI1 expression from TMA II subset, further adding 298 cases. We 
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will obtain BMI1 expression data for TMA II set from our collaborators and further 
validate them with immunohistochemistry.    
While we are in the process of obtaining BMI1 expression data on TMA II, we 
performed an interim correlation analysis on TMA II dataset, comparing pSMAD1,5,8 
expression with MB Groups. 
7.3.2 There is a significant correlation of pSMAD1,5,8 expression in certain 
subgroups of MB.  
 
Here TMA II set, with 298 MB tumours were used for immunohistochemical analysis 
using pSMAD1,5,8 only. The pSMAD1,5,8 expression (indicating an activated BMP 
signalling pathway) analysis between Group 4 and non-Group 4, had a  significant 
positive or direct correlation between Group 4 and non-Group 4 MBs (correlation 
coefficient  of + 0.169, p=0.037, n=152) [Fig 7.3 A]. This means that among the 152 
inclusion cases (tissue cores with measurable immunohistochemical staining) 
analysed, Group 4 MBs were likely to have higher expression of pSMAD1,5,8 as 
compared to non-Group 4 MBs. This relationship is contrary to observation from our 
current in vitro/in vivo study, where we see a low pSMAD1,5,8 expression in Group 4 
primary cells, which was increased upon BMI1 knock down. However correlation of 
these results with data on the expression of BMI1 is essential to draw any firm 
conclusion.    
There was a significant negative (indirect) pSMAD1,5,8 expression correlation 
among Group WNT as compared to non-Group WNT cases (correlation coefficient  -
0.185, p=0.023, n=152) [Fig 7.3 B]. This means that among the 152 inclusion cases 
analysed, WNT Group cases were likely to have lower or no pSMAD1,5,8 expression 
as compared to non-WNT Group cases. However, there was no significant 
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pSMAD1,5,8 expression correlation among Group SHH vs non-Group SHH and 
Group C vs non-Group C cases.  
 
Fig. 7.3 Correlation analysis of pSMAD1,5,8 expression and MB subgroups in TMA II. 
 
(A) pSMAD1,5,8 expression correlation between Group 4 vs non-Group 4 cases, showing a positive 
correlation. (B) pSMAD1,5,8 expression correlation between Group WNT vs non-Group WNT cases, 
showing a significant negative correlation. The bar graphs on the left show case distribution according 
to their expression scores or Group distribution. Group distribution is on X-axis, where, 1 = cases 
belonging to that Group, 0 = cases from other Groups. The tables on the right contain the breakdown 
of number of cases. For pSMAD1, 5,8, 0 = negative, 1 = mild positive, 2 = strong positive staining. 
p<0.05 was considered as statistically significant.  
 
7.3.2 There is a significant direct correlation of pSMAD2 expression in MB 
Group SHH.  
 
The SMAD2 and SMAD3 proteins are activated by a closely related, but different leg 
of the TGF-β pathway, induced by TGF-β1, and phosphorylation of SMAD2 and 
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SMAD3 are a reliable indicator of activation of TGF-β signalling pathway (Nakao, 
Imamura et al. 1997). SMAD2 and SMAD3 are phosphorylated via TGF-β (TβRI) and 
activin (ActRIB) receptors, whereas SMAD1, SMAD5 and SMAD8 are activated by 
BMP (ALK-1, ALK-2, BMP-RIA/ALK-3 and BMP-RIB/ALK-6) receptors in response to 
BMP ligands (Derynck and Zhang 2003). Nevertheless, both phosphorylated 
pSMAD2,3 and pSMAD1,5,8 have a common downstream target, SMAD4, where 
phosphorylated pSMAD4 translocate into the nucleus and regulates transcription 
(chapter 1, Fig 1.7). This convergence of pathways on SMAD4 caught our interest, 
and therefore we analysed the expression pattern of already known pSMAD2 in TMA 
II set. 
First, comparison of pSMAD2 staining scores with pSMAD1,5,8 scores was done, 
which showed a significant positive (direct) correlation (correlation coefficient  of 
+0.187, p=0.026, n=142) [Fig 7.4 A]. This means that activation of TGF-β pathway 
and closely related BMP pathway are directly related in the MB cases analysed 
across all the subgroups.  
The expression pattern of pSMAD2 was further analysed in different MB subgroups. 
There was a significant positive (direct) pSMAD2 expression correlation among 
Group SHH vs non-Group SHH cases (correlation value of +0.292, p<0.001, n = 
272) [Fig 7.4 B]. This means that the Group SHH MBs are more likely to have TGF-β 
pathway activation in comparison to non-SHH MBs. There was no significant 
pSMAD2 expression correlation among Group WNT vs non-Group WNT, Group C vs 
non-Group C or Group D vs non-Group D cases.  
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Fig. 7.4 Correlation analysis of pSMAD2 expression and MB subgroups in TMA II 
 
(A) Expression correlation between pSMAD1,5,8 vs pSMAD2, showing a significant positive 
correlation among the 142 cases included. (B) pSMAD2 expression correlation between Group SHH 
vs non-Group SHH cases, showing a significant positive correlation. The bar graphs on the left show 
case distribution according to their expression scores or Group distribution. Expression score 
distribution is on X-axis in (A). In (B), the X-axis has the Group distribution, where 1 = cases 
belonging to that Group, 0 = cases from other Groups. The tables on the right contain the breakdown 
of number of cases. For pSMAD2, 0 = negative, 1 = positive staining. For pSMAD1, 5,8, 0 = negative, 
1 = mild positive, 2 = strong positive staining. p<0.05 was considered as statistically significant.  
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7.4 Discussion  
 
Here we observed a trend of inverse correlation between BMI1 and pSMAD1,5,8 
expression in TMA I (n=64), but the correlation was not statistically significant. 
However we are keen to further analyse this expression pattern also in TMA II (n = 
298) thereby increasing the power of the study.  
BMI1 expression is reported to be expressed across all molecular subgroups of MB, 
but its expression is shown to be enriched in non-SHH/non-WNT groups, particularly 
in Group 4 MBs (Behesti, Bhagat et al. 2013). In this current study we detected an 
increased BMI1 in the primary cells of Group 4, with a low pSMAD1,5,8 expression. 
Upon BMI1 knock down these cells showed an increased pSMAD1,5,8 expression 
indicative of derepression of BMP pathway (chapter 3, section 3.3.3, Fig 3.6). These 
findings made us curious to study the pSMAD1,5,8 expression pattern in different 
subgroups (subgroups specification was already known) of primary human MBs.  We 
observed a positive (direct) pSMAD1,5,8  expression correlation in Group 4 as 
compared to non-Group 4 MBs. But we felt that the correlation value is too weak 
(correlation coefficient of +0.169, p=0.037) to confidently interpret these results. A 
strong correlation is indicated with correlation coefficient is  ≥0.2. Similar analysis 
with other subgroups showed no significant correlation for Group SHH vs non-Group 
SHH or Group 3 vs non-Group 3, but a negative correlation in Group WNT vs non-
Group WNT MBs (correlation coefficient -0.185, p=0.023). Again this correlation was 
rather weak. Therefore we felt that there is a need to analyse more primary cases to 
establish a better pSMAD1,5,8 expression correlation in different subgroups, in 
particular that of Group 4, which would be of relevance to our current study. To this 
end, we are currently optimising conditions to stain TMA I with KCNA1 antibody, 
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which has been suggested as a marker of Group 4 (Northcott, Korshunov et al. 
2011).  
Similar to BMPs, members of the TGF-β signalling pathway, including SMAD2/3 
have been shown regulate EMT differently in different physiological conditions and in 
different cancers (reviewed in (Zavadil and Bottinger 2005; Leivonen and Kahari 
2007)). This complex role of TGF-β signalling in cancer invasion and metastasis is 
exemplified by its dual role reported in pathogenesis of certain cancers such as 
breast carcinoma (Kang, Siegel et al. 2003; Deckers, van Dinther et al. 2006). Here 
we observed a weak but positive or direct correlation between pSMAD2 (TGF-β1 
induced) and pSMAD1,5,8 expression (BMP induced) [correlation coefficient of 
+0.187, p=0.026, n=142]. This is in keeping with a study where both pSMAD2 and 
pSMAD1,5,8 are shown to be expressed or repressed in the same direction in 
primary breast cancer tissue (Katsuno, Hanyu et al. 2008), but analysis of higher 
number of cases is indicated to confirm this. However, interestingly, a strong positive 
correlation (correlation coefficient of +0.292) with high statistical significance 
(p<0.001) was noted for pSMAD2 expression in Group SHH as compared to non-
Group SHH. Evidently larger number of inclusion cases (n=272) makes this 
association stronger. This reiterates the need to include further cases and to re-
analyse expression correlation between BMI1 and pSMAD1,5,8 in order to validate 
our current findings in  primary MB tumour samples. It would be certainly interesting 
to further investigate pSMAD2-Group SHH and pSMAD2-pSMAD1,5,8 connection 
we have observed. But prior to embarking on SMAD2/TGF-β pathway, we would like 
to focus on BMP pathway, which is more relevant to our current project 
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The future plan for TMA analysis is to obtain BMI1 expression data for TMA II which 
would enable us to add them to the data obtained with TMA I to increase the power 
of the study. Depending on the initial results, we will then extend the study to 
investigate the expression of other relevant cell adhesion/ECM markers such as 
CD44, THSB and MMP 10 which would help us validate the differential expression of 
these genes/molecules noted in murine GCPs of developing cerebella and in the 
human MB cell line, in relation to Bmi1 expression, as described in chapter 4.   
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CHAPTER 8 Discussion   
 
8.1 Summary of principal findings   
 
In this study we have demonstrated a novel connection between the Polycomb gene 
BMI1 and the BMP pathway in the pathogenesis of human MB. BMI1 represses BMP 
signalling pathway, as assessed by increased phosphorylation of SMAD1,5,8 
proteins, indicative of derepression of the BMP pathway, upon BMI1 knock down in 
MB cell lines and in primary MB cells of Group 4. We have shown that BMI1 controls 
MB cell adhesion, cell migration and invasion in a BMP dependent manner in vitro. 
The effects of BMI1 on MB cell migration and invasion was observed also in an ex 
vivo assay.  Using an in vivo xenograft model of primary Group 4 MB cells we have 
demonstrated that BMI1 controls parenchymal invasion. Furthermore, we observed 
that BMP-4 treatment reduced in vitro invasion in a MB cell line, in a similar fashion 
as seen upon BMI1 downregulation.  
Our preliminary findings on primary human MB tumours shows a trend toward an 
inverse  correlation between BMI1 expression and pSMAD1,5,8 in keeping with our 
findings on the cell lines and the primary MB cells, although further validation with 
more cases will be required to enhance statistical power and validate these results.   
In summary, the data so far raise the possibility that expression of BMI1 could 
represent a biomarker for MB which could benefit from treatment with small 
molecules acting as BMP agonists. 
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8.2 Discussion and outlook 
 
MB is the commonest intracranial paediatric malignancy and despite advances in 
treatment, it is still associated with high mortality and serious treatment related 
morbidities (Polkinghorn and Tarbell 2007). With the advent of integrated genomics 
platforms to classify MBs into molecular subgroups, our understanding of the 
pathogenesis and basic biology of these tumours has advanced in recent years 
(Kool, Koster et al. 2008; Cho, Tsherniak et al. 2011; Northcott, Korshunov et al. 
2011). Patient risk stratification is evolving to include a combination of clinico-
pathological and molecular factors that reflect the clinical relevance (Ellison 2010). 
However further understanding of the molecular pathogenesis involved in this 
heterogeneous disease is needed to be able to effectively risk-stratify the patients 
and to develop targeted individualised therapy, thereby avoiding undesirable side 
effects. In this study we explore the role of the Polycomb gene BMI1 in MB cell 
invasion and its connection to the BMP signalling pathway.    
The best characterised role of BMI1 in human cancers is related to the regulation of 
cell proliferation and senescence via suppression of p16Ink4a/p19Arf cell cycle 
inhibition pathways (Jacobs, Kieboom et al. 1999; Jacobs, Scheijen et al. 1999; 
Meng, Luo et al. 2010) which in turn regulates the activity of cyclin D, Cdk4/Cdk6 
and p53 (reviewed in (Kim and Sharpless 2006)). BMI1 is overexpressed in a 
significant proportion of human MB and its best characterised role is a pro-
proliferative one in the context of SHH driven tumorigenesis (Leung, Lingbeek et al. 
2004; Michael, Westerman et al. 2008). However, recently our team have reported 
that Bmi1 regulates cell adhesion and migration of cerebellar progenitors through 
repression of the BMP pathway (Zhang, Santuccione et al. 2011). In this study we 
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demonstrate that BMI1 represses BMP pathway in human MB cells, and in fact BMI1 
knock down caused an aberrant activation of BMP pathway. These findings are in 
keeping with the  study of Bracken and co-authors in which they show by gene 
expression profiling of human embryonic fibroblasts in combination with ChIP-on-
chip experiments, that BMPs are direct targets of BMI1 (Bracken, Dietrich et al. 
2006). Similarly, by combining ChIP-seq with in vivo RNAi screening, Gargiulo et al. 
have demonstrated a role for Bmi1 in adult neural progenitor and glioma cells via 
transcriptional repression of genes responsive to TGF-β/BMP signalling pathway, 
such as Atf3 (activating transcription factor 3), highlighting p16INK4a/p19ARF-
independent functions for BMI1 in development and cancer (Gargiulo, Cesaroni et al. 
2013).  
BMPs are members of the TGF-β family of proteins, and their role during cerebellar 
development and in MB pathogenesis is well characterized [reviewed in (Behesti and 
Marino 2009)]. BMPs are known to antagonize Shh-dependent proliferation and 
induce differentiation of GNPs (Zhao, Ayrault et al. 2008). BMP-mediated regulation 
of cell adhesion and of the cellular interactions with the extracellular matrix have 
been demonstrated also in soft tissues (Wang, Kim et al. 2012). Here, we show that 
BMI1 controls tumour volume and intraparenchymal invasion in an orthotopic 
xenograft model of MB, and that BMI1 silencing causes a reduced in vivo 
pSMAD1,5,8 expression indicative of BMP pathway activation. While the reduced 
tumour volume observed in BMI1-silenced cells is in keeping with previous reports 
where reduced tumour growth was seen in subcutaneous DAOY xenografts upon 
shRNA BMI1 knock down (Wiederschain, Chen et al. 2007), the effect on brain 
invasion is novel. Our data together with the results of the in vitro migration assays 
which show that cell adhesion and motility are controlled by BMI1 through BMP 
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pathway inhibition raise the possibility that this mechanism also underpins the in vivo 
phenotype. We observed reduced individual cell motility among DAOYBMI1kd, hence 
supporting the notion that BMI1 influences cell invasion phenotype (those observed 
in vitro and in vivo), independent to its effects on cell proliferation.  
Reanalysis of a previously published dataset of DAOYBMI1kd (Wiederschain, Chen et 
al. 2007), revealed deregulation of TGF-β pathway and differential expression of 
several cell adhesion molecules such as Integrins, Laminins, Collagens, 
Thrombospondin and CD44 (analysis done by Adrian Dubuc and Mark Remke from 
Michael Taylor group, unpublished data). Several of these genes either represented 
the human homologue of the genes identified in Bmi1-/- granule cell progenitors in a 
BMP dependent fashion (experiments performed by Xinyu Zhang, Marino Lab) or 
belong to the same protein family. Furthermore, differential expression of 
Thrombosponin1/2 and CD44 was seen in this study in BMI1 silenced MB cell lines 
D-458.  
Expression of BMI1 is enriched preferentially in Group 4 human MB and 
overexpression of Bmi1 in the granule cell lineage in the mouse induces MB, albeit, 
only in the context of p53 deletion (Behesti, Bhagat et al. 2013). A biostatistical 
analysis of human Group 4 MB overexpressing BMI1 while concomitantly expressing 
low levels of p53 revealed a set of differentially expressed genes, which affected 
extracellular matrix structural constituents (Adrian Dubuc and Mark Remke, 
unpublished data). Among these genes, again members of the Thrombospondin and 
Laminin families were detected. Thrombospondins are strongly expressed in 
postmitotic premigratory GNPs (O'Shea, Liu et al. 1990) where they bind to Integrins, 
which are involved in the control of GNPs proliferation in cooperation with SHH, as 
shown in mice lacking Integrin β1 (Blaess, Graus-Porta et al. 2004). Interestingly 
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type IV collagens induce expression of Thrombospondins and the role of these 
matrix proteins in regulation of differentiation of CNS progenitors has been 
demonstrated (Lu and Kipnis 2010). Members of both the Thrombospondin and 
(Zhou, Picard et al. 2010) and collagen families (Pomeroy, Tamayo et al. 2002) are 
deregulated in human MB with an aggressive phenotype. Together these data raise 
the possibility that invasion of MB cells is regulated by BMI1 through BMP-mediated 
control of cell adhesion. Interestingly we did not see increased spreading of MB cells 
along VR spaces in our xenograft model and tumours expressing high levels of BMI1 
were not associated with higher incidence of spinal deposits, therefore implying that 
the molecular mechanisms regulating intraparenchymal invasion and leptomeningeal 
spread may be different 
 
In keeping with the published literature (Wiederschain, Chen et al. 2007; Wang, 
Venugopal et al. 2012), we observed a decreased proliferation of DAOY cells in a 
BMP pathway-independent fashion in vitro, which  is likely to contribute to the 
reduced tumour volume observed in our xenografts of DAOYBMI1kd cells. Insulin like 
growth factor I receptor (IGF-IR) and members of TAM (Tyro3, Axl and Mer) receptor 
tyrosine kinases are shown to be overexpressed in primary human schwannomas 
and promote tumour cell proliferation, cell to matrix adhesion and tumour cell survival 
(Ammoun, Schmid et al. 2012; Ammoun, Provenzano et al. 2013). BMI1 is shown to 
mediate repression of IGF-IR transcription in prostate cancer (Goel, Chang et al. 
2012), and another PcG gene EZH2 is shown to control transcription of AXL receptor 
kinase in human glioblastoma (Ott, Litzenburger et al. 2012). Therefore it would be 
interesting to study the relationship between BMI1 and IGF-IR and the members of 
TAM receptor kinases in context of MB cell proliferation.    
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Contrary to a previous study (Wiederschain, Chen et al. 2007), we did not observe 
an impact of BMI1 silencing on apoptosis in DAOY MB cells. Although the reason of 
this discrepancy is at present unknown, it is possible that the effect on apoptosis 
could depend on the level of BMI1 knock down achieved. Watson and Eilers et al. 
have shown the role of certain proto-oncogenes such as c-Jun in regulation of 
apoptosis of developing neurons including that of cerebellar granule neurons 
(Watson, Eilers et al. 1998; Eilers, Whitfield et al. 1999). It would be of interest to 
study if there is any association of c-Jun with BMI1 in apoptotic mechanisms of 
human MB. 
Due to the essential role of BMI1 in maintenance of haematopoietic and neural stem 
cells (Valk-Lingbeek, Bruggeman et al. 2004), targeted inhibition of BMI1 could 
potentially cause serious side effects. For similar reasons small molecule drugs that 
reduce BMI1 protein levels may not be safe in cancer treatment (Cao, Bombard et al. 
2011). Glioblastoma tumour stem cells treated with BMPs, in particular BMP-4, 
showed a reduced tumorigenicity  due to reduced proliferation and induction of 
differentiation (Piccirillo, Reynolds et al. 2006). Proliferation arrest and induction of 
differentiation following BMP treatment (BMP-2/BMP-4) has been shown also in MBs 
(Zhao, Ayrault et al. 2008), raising the possibility that small molecules acting as BMP 
agonists could be implemented in the treatment of patients with MB. Importantly, we 
show that the impact of BMP treatment on the invasive and proliferative properties of 
MB cells is most effective when BMI1 is expressed at high levels; raising the 
possibility that BMI1 could be used as a biomarker to identify groups of patients who 
can benefit from a treatment with BMP agonists. 
MB, in particular those of SHH Group are thought to arise from GNPs and cerebellar 
neural stem cells (Goodrich, Milenkovic et al. 1997; Sutter, Shakhova et al. 2010). 
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The cell of origin of Group 4 MB is not well understood. Our data raise the possibility 
that these MB may also originate from GNPs but may have lost SHH dependency 
during their oncogenic transformation pathway. Alternatively, BMI1-mediated 
repression of BMP could be a molecular feature of MB overexpressing BMI1 
independently of the molecular group they belong to.  
Genetically engineered mouse (GEM) models are a valuable tool for deciphering the 
molecular and cellular mechanisms of human diseases including cancer, and they 
can be  useful preclinical models for testing targeted drug treatments (Wu, Northcott 
et al. 2011). GEM model with Shh pathway aberrations have been extensively 
developed (Lau, Schmidt et al. 2012) while models of  non-SHH tumours are rare. It 
would be important to validate the potential use of BMP agonists in GEM models of 
MBs overexpressing BMI1.  An example of such a GEM model with BMI1 
overexpression is NeuroD2:SmoA1 model, which expresses the constitutively active 
mutant of Smoothened, SmoA1 in cerebellar GNPs, and it is  known to yield MB at 
94% penetrance at an average age of 2 months (Hatton, Villavicencio et al. 2008). A 
further development of this model, the Math1-Cre:SmoM2, have been shown to 
develop MB an earlier age and at full penetrance with 100% tumour rate (Schuller, 
Heine et al. 2008). Importantly, the incidence of tumours arising from GNPs 
expressing oncogenic Smo is known to drop dramatically in Bmi1-/- background 
(Michael, Westerman et al. 2008). It would therefore be interesting to study BMP 
pathway activation in these mice to further validate our findings in a genetically 
engineered model. Furthermore, the response to BMP treatment could be studied in 
cells isolated from these tumours to test their effects in a pre-clinical model. 
However, recent evidences suggest that BMI1 expression is enriched in non-SHH 
(and non-WNT) human MBs, especially in Group 4 tumours, hence a SHH MB model 
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may not represent the best choice. As the molecular classification and sub-
classification of MBs is advancing rapidly, we feel that validation of our current 
findings in a subgroup specific manner would enhance the translational value of our 
study.    
Furthermore it would be interesting to carry out a genome wide screening to 
elucidate more comprehensively the molecular mechanisms underpinning the 
phenotype observed upon BMI1 downregulation in primary MB cells of Group 4.  
In the context of the current project, we have established conditions to stably knock 
down BMI1 with lentiviral mediated shRNA technique in primary MB cells, including 
those of Group 4. To assess direct and indirect effects on transcription of targets and 
to obtain an in-depth view of the transcriptome, including potentially novel 
transcripts, effects on splicing and very sensitive assessment of transcriptional 
levels, we plan to take advantage of the RNA-Seq techniques. Whole genome 
analysis of small RNA, including miRNA will also be carried out, as their crosstalk 
with PcG genes is well established in both normal and neoplastic cells (Cao, Mani et 
al. 2011). It would be interesting to focus in particular on genes and pathways that 
can extend our understanding of the phenotype observed such as for example, ECM 
interaction/cell adhesion/BMP pathway.  
Understanding the diverse molecular mechanisms underpinning the heterogeneity of 
MB is the essential first step toward the design of novel more tailored therapies for 
this disease. BMI1 plays an essential role in the pathogenesis of MB, particularly 
those of Group 4. A comprehensive analysis of the direct and indirect effects on 
transcription of target genes downstream of BMI1 is essential to better understand 
the molecular basis of this highly aggressive subgroup of MB. The results obtained 
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from this study have the potential not only to benefit the scientific community but also 
to significantly contribute to improve the diagnosis, disease stratification and 
treatment of patients with MB. 
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